WO2023134764A1 - 含吡啶多环类衍生物、其制备方法和应用 - Google Patents

含吡啶多环类衍生物、其制备方法和应用 Download PDF

Info

Publication number
WO2023134764A1
WO2023134764A1 PCT/CN2023/072370 CN2023072370W WO2023134764A1 WO 2023134764 A1 WO2023134764 A1 WO 2023134764A1 CN 2023072370 W CN2023072370 W CN 2023072370W WO 2023134764 A1 WO2023134764 A1 WO 2023134764A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkoxy
cycloalkyl
deuterated
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/072370
Other languages
English (en)
French (fr)
Inventor
董加强
邓欣贤
俞文胜
金芳芳
龚珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority to KR1020247027246A priority Critical patent/KR20240134978A/ko
Priority to JP2024540616A priority patent/JP2025503581A/ja
Priority to CA3242679A priority patent/CA3242679A1/en
Priority to EP23740105.4A priority patent/EP4464694A4/en
Priority to US18/728,864 priority patent/US20250066360A1/en
Priority to AU2023207395A priority patent/AU2023207395A1/en
Priority to CN202380016406.6A priority patent/CN118525005A/zh
Priority to MX2024008704A priority patent/MX2024008704A/es
Priority to IL314247A priority patent/IL314247A/en
Publication of WO2023134764A1 publication Critical patent/WO2023134764A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Definitions

  • the invention belongs to the field of biomedicine, and specifically relates to a pyridine-containing polycyclic derivative and a preparation method and application thereof.
  • MK2 MAPK activated protein kinase 2, MAPK activated protein kinase 2
  • MAPK MAPK activated protein kinase 2
  • MAPK a protein kinase, as an important downstream molecule of the classic inflammatory signal transduction pathway MAPK, it regulates the expression of inflammatory factors.
  • the activated p38 MAPK protein phosphorylates and activates MK2, leading to the phosphorylation of MK2 substrate TTP, promoting the stability of pro-inflammatory cytokine mRNA, thereby increasing the protein expression level of inflammatory cytokines.
  • MK2 is activated. Inhibition of the p38-MK2 pathway through genetic or pharmacological means can inhibit the expression of inflammatory factors, indicating that MK2 is involved in mediating the development of arthritis. Inflammation regulation. Inhibitors of p38-MK2 hold promise for the treatment of patients with relapsed, refractory rheumatoid arthritis who have poor response to existing therapies.
  • ATI-450 of Aclaris Therapeutics has entered the clinical phase IIb of rheumatoid arthritis.
  • Other clinical MK2 inhibitors include CC-99677 from BMS and MMI-0100 from Moerae Matrix, both of which can directly inhibit the activity of MK2, which is different from ATI-450.
  • the published patent applications for p38-MK2 (or MK2) inhibitors include: Aclaris Therapeutics patents (WO-2012078684, WO-2013086208, WO-2014197846, WO-2021022186, WO-2012078687, WO2012078673, WO2012078674) ; BMS patent (WO -2020236636, WO-2018170199, WO-2016044463, WO-2018170201, WO-2018170200, WO-2018170203, US20210198276, US20210139501, US20200148701, US20200 102326); Moerae Matrix patents (WO-2016112292, WO-2016145234, US-10336788, WO- 2014040074, WO-2018231722, WO-2012142320, WO-2016033432, WO-2013134636, WO-2011149964) etc.
  • the p38-MK2 inhibitor has a good application prospect as a drug in the pharmaceutical industry.
  • p38-MK2 inhibitors provide a safer and more effective treatment for rheumatoid arthritis patients with relapsed, refractory, and poor responses to existing therapies;
  • p38-MK2 inhibitors have broad-spectrum anti-inflammatory effects (TNF/IL- 6/IL-1), theoretically can be used to treat a variety of inflammatory diseases and autoimmune diseases;
  • p38-MK2 inhibitors are small molecule inhibitors, compared with macromolecular drugs such as TNF monoclonal antibodies, they have oral convenience and patient compliance good advantage, and at the same time
  • JAK inhibitors such as infection, tumor, thrombus, and cardiotoxicity
  • the object of the present invention is to provide a compound represented by general formula (I), its stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound structure represented by general formula (I) is as follows:
  • Ring A is selected from cycloalkyl, heterocyclyl, aryl or heteroaryl;
  • Ring B is selected from cycloalkyl, heterocyclyl, aryl or heteroaryl;
  • L 1 is selected from a bond, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, -(CH 2 ) n -, -(CH 2 ) n C(O)(CR aa R bb ) n1 - , -(CH 2 ) n C(O)NR cc (CH 2 ) n1 -, -(CH 2 ) n (CR aa R bb ) n1 -, -(CR aa R bb ) n O(CH 2 ) n1 - , -(CH 2 ) n O(CR aa R bb ) n1 -, -(CR aa R bb ) n S(CH 2 ) n1 -, -(CH 2 ) n S(CR aa R bb ) n1 -, - (CR aa R b
  • R aa , R bb and R cc are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, alkyl, deuterated alkyl, haloalkane radical, hydroxyalkyl, alkoxy, deuterated alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, the amino, alkyl, deuterium Alkylkyl, haloalkyl, hydroxyalkyl, alkoxy, deuterated alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, optionally can be further superseded;
  • any two of R aa , R bb and R cc are linked to form a cycloalkyl, heterocyclyl, aryl or heteroaryl, and the cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally can be further replaced;
  • L 2 and L 3 are each independently selected from a bond, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -(CH 2 ) n2 -, -(CH 2 ) n2 C(O)(CR a1 R b1 ) n3 -, -(CH 2 ) n2 C(O)NR c1 (CH 2 ) n3 -, -(CH 2 ) n2 (CR a1 R b1 ) n3 -, -(CR a1 R b1 ) n2 O(CH 2 ) n3 -, -(CH 2 ) n2 O(CR a1 R b1 ) n3 -, -(CR a1 R b1 ) n2 S(CH 2 ) n3 -, -(CH 2 ) n2 S(CR a1 R b1 ) n3 -
  • R a1 , R b1 and R c1 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, alkyl, deuterated alkyl, haloalkane group, hydroxyalkyl group, alkoxy group, deuterated alkoxy group, haloalkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclyl group, aryl group or heteroaryl group, the amino group, alkyl group, deuterium group Alkylkyl, haloalkyl, hydroxyalkyl, alkoxy, deuterated alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, optionally can be further superseded;
  • R a is each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, Alkoxy, deuterated alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, the amino, alkyl, deuterated alkyl, haloalkyl , alkoxy, haloalkoxy, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, optionally may be further substituted;
  • R b are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, Alkoxy, deuterated alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, the amino, alkyl, deuterated alkyl, haloalkyl , alkoxy, haloalkoxy, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, optionally may be further substituted;
  • R c are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, Alkoxy, deuterated alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, the amino, alkyl, deuterated alkyl, haloalkyl , alkoxy, haloalkoxy, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, optionally may be further substituted;
  • R b is linked with R c to form cycloalkyl, heterocyclyl, aryl or heteroaryl, and the cycloalkyl, heterocyclyl, aryl and heteroaryl can optionally be further substituted;
  • Each R d is independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, alkyl, bridged cycloalkyl, deuterated alkyl, haloalkyl , hydroxyalkyl, alkoxy, deuterated alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or -(CR ee R ff ) n4 C( O)R gg , -(CR ee R ff ) n4 NR hh C(O)R gg , -(CR ee R ff ) n4 S(O) 2 R gg , -(CR ee R ff ) n4 C(O) NR hh R gg or -(CR ee R ff
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-8 alkyl, C 1-8 deuterated alkanes C 1-8 haloalkyl, C 1-8 hydroxyalkyl, C 1-8 alkoxy, C 1-8 deuterated alkoxy, C 1-8 haloalkoxy , C 2-8 alkenyl, C 2-8 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl or 5-14 membered heteroaryl;
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-6 alkyl, C 1-6 Deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3- 8-membered heterocyclic group, C 6-10 aryl group or 5-10 membered heteroaryl group;
  • n4 is 0, 1, 2, 3 or 4;
  • R d each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, alkyl, deuterated alkyl, haloalkyl, hydroxyalkyl, Alkoxy, deuterated alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, the amino, alkyl, deuterated alkyl, haloalkyl , alkoxy, haloalkoxy, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, optionally may be further substituted;
  • L and R are linked to form cycloalkyl, heterocyclyl, aryl or heteroaryl, which may optionally be further substituted;
  • R c is linked with R d to form cycloalkyl, heterocyclyl, aryl or heteroaryl, which may be further substituted optionally;
  • x is an integer from 0 to 6;
  • y is an integer from 0 to 6;
  • z is an integer from 0 to 6;
  • e is an integer from 0 to 6;
  • n 0, 1, 2 or 3;
  • n1 0, 1, 2 or 3;
  • n2 is 0, 1, 2 or 3;
  • n3 is 0, 1, 2 or 3;
  • n 0, 1, 2 or 3;
  • p 0, 1, 2 or 3;
  • n1 0, 1, 2 or 3;
  • p1 is 0, 1, 2 or 3.
  • Ring D is selected from cycloalkyl, heterocyclyl, aryl or heteroaryl;
  • Ring E is selected from heterocyclyl
  • Ring B is selected from cycloalkyl, heterocyclyl, aryl or heteroaryl;
  • X 3 is selected from N or CR b1 ;
  • L 1 is selected from a bond, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, -(CH 2 ) n -, -(CH 2 ) n C(O)(CR aa R bb ) n1 - , -(CH 2 ) n C(O)NR cc (CH 2 ) n1 -, -(CH 2 ) n (CR aa R bb ) n1 -, -(CR aa R bb ) n O(CH 2 ) n1 - , -(CH 2 ) n O(CR aa R bb ) n1 -, -(CR aa R bb ) n S(CH 2 ) n1 -, -(CH 2 ) n S(CR aa R bb ) n1 -, - (CR aa R b
  • R aa , R bb and R cc are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1 -6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1 -6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkene Base, C 2-6 alkynyl, C
  • L 3 is selected from bond, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -(CH 2 ) n2 -, -(CH 2 ) n2 C(O)(CR a1 R b1 ) n3 -, - (CH 2 ) n2 C(O)NR c1 (CH 2 ) n3 -, -(CH 2 ) n2 (CR a1 R b1 ) n3 -, -(CR a1 R b1 ) n2 O(CH 2 ) n3 -, - (CH 2 ) n2 O(CR a1 R b1 ) n3 -, -(CR a1 R b1 ) n2 S(CH 2 ) n3 -, -(CH 2 ) n2 S(CR a1 R b1 ) n3 -, -(CR a
  • R a1 , R b1 and R c1 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1 -6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1 -6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkene Base, C 2-6 alkynyl, C
  • R a is each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl , C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 Alkynyl, C 3-12 cycloalkyl, 3-12 membered
  • any two adjacent or non-adjacent R a links to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5-14 membered heteroaryl group, and the C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino , oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -14
  • L 1 is linked with R a to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5-14 membered heteroaryl group
  • the C 3-12 cycloalkyl group, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio group, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkane Oxygen, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-
  • R b1 or R b3 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene Base, C 2-6 alkynyl, C 3-12 cycloalkane group, 3-12 membered heterocyclic group, C 6-14 aryl group or 5-14 membered heteroaryl group, the amino group, C 1-6 alkyl group, C 1-6 deuterated alkyl group, C 1-6 Haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl , C 2-6 alkenyl, C 2-6 alkynyl
  • R c2 or R c3 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene radical, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkane C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy , C 1-6 haloalkoxy, C 1-6 hydroxyalkyl , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12
  • R d each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 bridged cycloalkane C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl, 5-14 membered heteroaryl, -(CR ee R ff ) n4 C(O) R gg , -(CR ee R ff ) n4 NR hh C(O)R gg , -(CR ee R ff ) n4 NR hh OR gg , -(CR e
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkanes C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl or 5-14 membered heteroaryl;
  • said C 3-12 cycloalkyl, 3 -12 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl can optionally be Further deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl , C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C Substituted by one or more substituents in 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl and 5-14 membere
  • x is an integer from 0 to 6;
  • e is an integer from 0 to 6;
  • n 0, 1, 2 or 3;
  • n1 0, 1, 2 or 3;
  • n2 is 0, 1, 2 or 3;
  • n3 is 0, 1, 2 or 3;
  • n4 is 0, 1, 2, 3 or 4;
  • n6 is 0, 1, 2, 3 or 4;
  • n 0, 1, 2 or 3;
  • p 0, 1, 2 or 3;
  • n1 0, 1, 2 or 3;
  • p1 is 0, 1, 2 or 3.
  • ring D described in the present invention is selected from C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl;
  • ring D is selected from C 6-10 aryl, 5-6 membered monocyclic heteroaryl or 7-10 membered bicyclic heteroaryl; more preferably, ring D is selected from pyrazolyl, thienyl, thiazolyl , oxazolyl, pyrimidinyl, pyridyl, phenyl,
  • ring E described in the present invention is selected from 6-12 membered heterocyclic groups; preferably, ring E is selected from
  • M is selected from C, CH, N or does not exist
  • M is selected from C, CH, N or does not exist
  • M is selected from C, CH, N or does not exist
  • X 3 is selected from N or CR b1 ;
  • Ring B is selected from cycloalkyl, heterocyclyl, aryl or heteroaryl;
  • L 1 is selected from a bond, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, -(CH 2 ) n -, -(CH 2 ) n C(O)(CR aa R bb ) n1 - , -(CH 2 ) n C(O)NR cc (CH 2 ) n1 -, -(CH 2 ) n (CR aa R bb ) n1 -, -(CR aa R bb ) n O(CH 2 ) n1 - , -(CH 2 ) n O(CR aa R bb ) n1 -, -(CR aa R bb ) n S(CH 2 ) n1 -, -(CH 2 ) n S(CR aa R bb ) n1 -, - (CR aa R b
  • R aa , R bb and R cc are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1 -6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1 -6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkene Base, C 2-6 alkynyl, C
  • L 3 is selected from bond, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -(CH 2 ) n2 -, -(CH 2 ) n2 C(O)(CR a1 R b1 ) n3 -, - (CH 2 ) n2 C(O)NR c1 (CH 2 ) n3 -, -(CH 2 ) n2 (CR a1 R b1 ) n3 -, -(CR a1 R b1 ) n2 O(CH 2 ) n3 -, - (CH 2 ) n2 O(CR a1 R b1 ) n3 -, -(CR a1 R b1 ) n2 S(CH 2 ) n3 -, -(CH 2 ) n2 S(CR a1 R b1 ) n3 -, -(CR a
  • R a1 , R b1 and R c1 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1 -6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1 -6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkene Base, C 2-6 alkynyl, C
  • R a is each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl , C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 Alkynyl, C 3-12 cycloalkyl, 3-12 membered
  • any two adjacent or non-adjacent R a links to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5-14 membered heteroaryl group, and the C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino , oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6 -14
  • L 1 is linked with R a to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5-14 membered heteroaryl group
  • the C 3-12 cycloalkyl group, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio group, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkane Oxygen, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-
  • R b1 or R b3 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene radical, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkane C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 3-12 cycl
  • R c2 or R c3 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene radical, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkane C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 3-12 cycl
  • R d each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 bridged cycloalkane C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl, 5-14 membered heteroaryl, -(CR ee R ff ) n4 C(O) R gg , -(CR ee R ff ) n4 NR hh C(O)R gg , -(CR ee R ff ) n4 NR hh OR gg , -(CR e
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkanes C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl or 5-14 membered heteroaryl;
  • x is an integer from 0 to 6;
  • e is an integer from 0 to 6;
  • n 0, 1, 2 or 3;
  • n1 0, 1, 2 or 3;
  • n2 is 0, 1, 2 or 3;
  • n3 is 0, 1, 2 or 3;
  • n4 is 0, 1, 2, 3 or 4;
  • n6 is 0, 1, 2, 3 or 4;
  • n 0, 1, 2 or 3;
  • p 0, 1, 2 or 3;
  • n1 0, 1, 2 or 3;
  • p1 is 0, 1, 2 or 3.
  • ring A described in the present invention is selected from C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl;
  • ring A is selected from 6-12 membered bicyclic heterocyclic group, 5-6 membered monocyclic heteroaryl group or 7-10 membered bicyclic heteroaryl group;
  • Ring A is selected from pyrazolyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl, pyridyl, phenyl, tetrahydroquinolinyl, benzocyclopentyl, pyrrolopyrimidinyl, pyrrolo Pyridyl, pyrazolopyridine or imidazopyridine.
  • ring B described in the present invention is selected from C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl;
  • ring B is selected from 3-7 membered monocyclic heterocyclyl, 6-12 membered bicyclic heterocyclyl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl or 7-14 membered heteroaryl and ring;
  • ring B is selected from 5-membered monocyclic nitrogen-containing heteroaryl, 6-membered monocyclic nitrogen-containing heteroaryl, 5-6-membered heteroaryl, 5-6-membered cycloalkyl, 5-6-membered heteroaryl Base and 5-6 membered heteroaryl or 5-6 membered heteroaryl aphenyl;
  • ring B is selected from pyrimidine, pyridocyclohexyl, pyridocyclopentyl, pyrrolotriazinyl, pyrrolopyrimidinyl, pyridocyclopentenyl, pyridine, thiazole, pyrazole, pyridopyrrolone , pyridofuranone, pyridosulfolane,
  • ring B is selected from thiazolyl, oxazolyl, pyrazolyl, imidazolyl, 1,2,4-thiadiazolyl, 1,3,4-oxadiazolyl, pyrimidinyl, pyrido Cyclohexyl, pyridopentyl, pyrrolotriazinyl, pyrrolopyrimidinyl, pyridopentenyl, pyridyl, pyridopyrrolone, pyridofuranone or pyridoxolane.
  • L 1 described in the present invention is selected from bond, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, -(CH 2 ) n -, -(CH 2 ) n C(O)(CR aa R bb ) n1 -, -(CH 2 ) n C(O)NR cc (CH 2 ) n1 -, -(CH 2 ) n (CR aa R bb ) n1 -, -(CR aa R bb ) n O(CH 2 ) n1 -, -(CH 2 ) n O(CR aa R bb ) n1 -, -(CR aa R bb ) n S(CH 2 ) n1 -, -( CH 2 ) n S(CR aa R bb ) n1 -
  • L 1 is selected from a bond, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, -(CH 2 ) n -, -(CH 2 ) n C(O)-, -(CR aa R bb ) n O-, -O(CR aa R bb ) n1 -, -(CR aa R bb ) n S-, -S(CR aa R bb ) n1 -, -(CH 2 ) n1 NR cc - , -NR cc (CR aa R bb ) n1 -or -NR cc C(O)-;
  • L 1 is selected from a bond, -CH 2 -, -OCH 2 -, -OCD 2 -, -NH-, -C(O)NH-, -OCH(CH 3 )-, -OC(CH 3 ) 2 -, -NH-CH 2 - or
  • R aa , R bb and R cc are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1 -6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1 -6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkene Base, C 2-6 alkynyl, C
  • R aa , R bb and R cc are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-3 alkyl , C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy , C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, the amino , C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, C 1-3 hydroxyalkyl, C 2 -4 alkenyl, C 2-4 alkyn
  • any two of R aa , R bb and R cc are linked to form C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, said C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, Amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy , C 1-6 deuterated alkoxy and C 1-6 haloalkoxy replaced by one or more substituents;
  • any two of R aa , R bb and R cc are linked to form C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, so
  • the C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-10 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano , amino, oxo, thio, carboxyl, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy
  • X 1 is selected from N or CR a5 ;
  • X 3 is selected from N or CR b1 ;
  • R a1 , R a2 , R a3 , R a4 or R a5 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1- 6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, all Amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl , C 2-6 alkenyl
  • R aa or R bb are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene radical, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkane C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 3-12 cycl
  • R aa and R bb are linked to form C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, said C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl, optionally can be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, sulfur Substitute, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated Alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5 -One or more substituents in the
  • R b1 , R b2 or R b3 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1 -6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1 -6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkene Base, C 2-6 alkynyl, C
  • R b1 and R b2 substituents are linked to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5-14 membered heteroaryl group, and the C 3-12 cycloalkane Base
  • 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, Thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterium Substituted alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 3
  • R c1 , R c2 or R c3 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1 -6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1 -6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkene Base, C 2-6 alkynyl, C
  • R c1 and R c2 substituents are linked to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5-14 membered heteroaryl group, and the C 3-12 cycloalkane Base
  • 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, Thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterium Substituted alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 3
  • the R c1 and R b2 substituents are linked to form a 3-12 membered heterocyclic group or a 5-14 membered heteroaryl group, and the 3-12 membered heterocyclic group and the 5-14 membered heteroaryl group can optionally be further Deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3- Substituted by one or more substituents in 12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl;
  • R is selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1 -6 bridged cycloalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl, 5-14 membered heteroaryl, -(CR ee R ff ) n4 C(O)R gg , -(CR ee R ff ) n4 NR hh C(O)R gg , -(CR ee R ff ) n4 NR hh OR gg
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkanes C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl or 5-14 membered heteroaryl;
  • said C 3-12 cycloalkyl, 3 -12 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio , carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14
  • One or more substituents in the heteroaryl group
  • R 2 , R 3 or R 4 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1 -6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1 -6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkene Base, C 2-6 alkynyl, C 3-12 cycloal
  • any two adjacent or non-adjacent R 1 , R 2 , R 3 and R 4 are linked to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5- 14 membered heteroaryl
  • the C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro , hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl , C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkyne
  • n4 is 0, 1, 2, 3 or 4;
  • said compound is further shown in general formula (XIV-A) (XIV-B) or (XIV-C):
  • X 1 is selected from N or CR a5 ;
  • X 2 is selected from N or CR 2 ;
  • X 3 is selected from N or CR b1 ;
  • R a1 , R a2 , R a3 , R a4 or R a5 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1- 6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 Haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, all Amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl , C 2-6 alkenyl
  • R aa or R bb are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene radical, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkane C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy , C 1-6 haloalkoxy, C 1-6 hydroxyalkyl , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12
  • R aa and R bb are linked to form C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, said C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl, optionally can be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, sulfur Substitute, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated Alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5 -One or more substituents in the
  • R b1 or R b3 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene radical, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkane C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 3-12 cycl
  • R c2 or R c3 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene radical, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkane C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy , C 1-6 haloalkoxy, C 1-6 hydroxyalkyl , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12
  • R da , R db or R' da are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 Alkenyl, C 2-6 alkynyl, C 3-12 cycloal
  • R da and R db are linked to form C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, said C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl, optionally can be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, sulfur Substitute, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated Alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5 -One or more substituents in the 14-
  • Rdc or Rdd are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thiol, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene radical, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkane C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 3-12 cyclo
  • R dc and R dd are linked to form C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, said C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl, optionally can be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, sulfur Substitute, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated Alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5 -One or more substituents in the
  • R is selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1 -6 bridged cycloalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl, 5-14 membered heteroaryl, -(CR ee R ff ) n4 C(O)R gg , -(CR ee R ff ) n4 NR hh C(O)R gg , -(CR ee R ff ) n4 NR hh OR gg
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkanes C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl or 5-14 membered heteroaryl;
  • R 2 , R 3 or R 4 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1 -6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1 -6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 Alkenyl, C 2-6 alkynyl, C 3-12 cycloal
  • any two adjacent or non-adjacent R 1 , R 2 , R 3 and R 4 are linked to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5- 14 membered heteroaryl
  • the C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro , hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl , C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3 -One or
  • R is selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1 -6 bridged cycloalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2 -6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl, 5-14 membered heteroaryl, -(CR ee R ff ) n4 C(O)R gg , -(CR ee R ff ) n4 NR hh C(O)R gg , -(CR ee R ff ) n4 NR hh OR gg
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkanes C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy , C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl or 5-14 membered heteroaryl;
  • said C 3-12 cycloalkyl, 3 -12 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio , carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14
  • One or more substituents in the heteroaryl group
  • R 6 or R 8 are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterium Substituted alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkene radical, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkane C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl , C 2-6 alkynyl, C 3-12 cycloalkyl
  • any two adjacent or non-adjacent R 6 , R 7 and R 8 are linked to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5-14 membered heterocyclic group Aryl, the C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl can optionally be further replaced by deuterium, halogen, nitro, hydroxyl, Mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1 -6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 members
  • n4 is 0, 1, 2, 3 or 4;
  • n5 is 0, 1 or 2;
  • n5' is 0, 1 or 2;
  • n5 and n5' are not 0 at the same time
  • n6 is 0, 1, 2, 3 or 4.
  • said compound is further such as general formula (I'-1-1), (I'-1-2), (XIV-1), (XIV-2), (XIV- A-1), (XIV-A-2), (XIV-B-1), (XIV-B-2), (XIV-C-1), (XIV-C-2), (XV-1) or (XV-2):
  • R a described in the present invention is each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl base, the amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 Hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl,
  • each R a is independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-3 alkyl, C 1-3 deuterium Substituted alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 2-4 alkene radical, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, the amino, C 1-3 alkane C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy , C 1-3 haloalkoxy, C 1-3 hydroxyalkyl , C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloal
  • R b described in the present invention are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl group, the amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl,
  • each R b is independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-3 alkyl, C 1-3 deuterium Substituted alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 2-4 alkene radical, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, the amino, C 1-3 alkane C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy , C 1-3 haloalkoxy, C 1-3 hydroxyalkyl , C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloal
  • R c described in the present invention are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl base, the amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 Hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl,
  • each Rc is independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-3 alkyl, C 1-3 deuterium Substituted alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 2-4 alkene radical, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, the amino, C 1-3 alkane C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy , C 1-3 haloalkoxy, C 1-3 hydroxyalkyl , C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, the
  • R b is linked with R c to form a C 3-12 cycloalkyl group, a 3-12 membered heterocyclic group, a C 6-14 aryl group or a 5-14 membered heteroaryl group, the C 3-12 cycloalkyl group, 3-12 membered heterocyclyl, C 6-14 aryl and 5-14 membered heteroaryl, optionally can be further replaced by deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, sulfur Substitute, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated Alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl and 5
  • R d described in the present invention is each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, 5-10 member bridged cycloalkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1 -6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Aryl or 5-14 membered heteroaryl or -(CR ee R ff ) n4 C(O)R gg , -(CR ee R ff ) n4 NR hh C(O)R gg , -(CR ee
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-8 alkyl, C 1-8 deuterated alkanes C 1-8 haloalkyl, C 1-8 hydroxyalkyl, C 1-8 alkoxy, C 1-8 deuterated alkoxy, C 1-8 haloalkoxy , C 2-8 alkenyl, C 2-8 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclyl, C 6-14 aryl or 5-14 membered heteroaryl;
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-6 alkyl, C 1-6 Deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 Alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
  • R ee , R ff links to form cycloalkyl, heterocyclyl, aryl or heteroaryl, said cycloalkyl, heterocyclyl, aryl and heteroaryl, optionally can be further replaced by deuterium, halogen, Nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxy Alkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl , 3-12 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl are substituted by one or more substituents;
  • n4 is 0, 1, 2, 3 or 4.
  • R d are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl , C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 Alkynyl, C 3-12 cycloalkyl, 3-12 membered
  • each R d is independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-3 alkyl, C 1-3 deuterium Substituted alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 2-4 alkene radical, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, the amino, C 1-3 alkane C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy , C 1-3 haloalkoxy, C 1-3 hydroxyalkyl , C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloal
  • each R d is independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-3 alkyl, C 1-3 Deuterated alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 2-4 Alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl or -(CR ee R ff ) n4 C (O)R gg , -(CR ee R ff ) n4 NR hh C(O)R gg , -(CR ee R ff ) n4 S(O) 2 R gg , -(CR ee R
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-3 alkyl, C 1-3 deuterated alkanes C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy , C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
  • n4 is 0, 1, 2, 3 or 4.
  • R a1 , R a2 , R a3 , R a4 , R a5 , R b1 , R b2 , R b3 , R c1 , R c2 and R c3 described in the present invention are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 Haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, the amino, C 1-3 alkyl, C 1-3 deuter
  • R da , R db , R' da , R dc and R dd described in the present invention are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano , amino, oxo, thio, carboxyl, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy Base, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl, the amino, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy , C 1-3 haloalkoxy, C 1-3
  • R and R described in the present invention are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio , carboxyl, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy C 1-3 haloalkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-10 Member heteroaryl or -(CR ee R ff ) n4 C(O)R gg , -(CR ee R ff ) n4 NR hh C(O)R gg , -(CR ee R ff ) n4 S(O) 2
  • R ee , R ff , R gg and Rhh are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, amino, carboxyl, C 1-3 alkyl, C 1-3 deuterated alkanes C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy , C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl;
  • n4 is 0, 1, 2, 3 or 4.
  • R 2 , R 3 , R 4 , R 6 and R 8 described in the present invention are each independently selected from hydrogen, deuterium, halogen, nitro, hydroxyl, mercapto, cyano, Amino, oxo, thio, carboxyl, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 hydroxyalkyl, C 1-3 alkoxy , C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 3-8 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl, the amino, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, C 1-3 hydroxyalkyl, C
  • R in the present invention is selected from halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2- 6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12
  • R is selected from halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl or C 2-6 alkyne base;
  • R2 is selected from fluorine.
  • R in the present invention is selected from halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl , C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3-12 membered heterocyclic group, C 6-14 aryl or 5-14 membered heteroaryl, the amino, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 2- 6 alkenyl, C 2-6 alkynyl, C 3-12 cycloalkyl, 3
  • R is selected from halogen, nitro, hydroxyl, mercapto, cyano, amino, oxo, thio, carboxyl, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 2-6 alkenyl or C 2-6 alkyne base;
  • R6 is selected from fluorine.
  • the present invention further provides compounds represented by general formula (M-1) or (M-2), stereoisomers thereof or pharmaceutically acceptable salts thereof:
  • X is selected from halogen, preferably from chlorine or bromine
  • Ring D and ring E, M 1 , M 2 , M 3 , n6, L 1 , R a , R b3 , R c2 , R c3 , X 3 and x are as described above.
  • the present invention further provides a method for preparing the aforementioned compound of general formula (I'-1) or its stereoisomer and a pharmaceutically acceptable salt thereof, comprising the following steps:
  • the compound shown in general formula (M-1) obtains the target compound shown in general formula (I'-1) by reaction;
  • X is selected from halogen, preferably from chlorine or bromine
  • Ring D, ring E, ring B, L 1 , L 3 , R a , R b3 , R c2 , R c3 , X 3 , R d , x and e are as described above.
  • the present invention further provides a method for preparing the aforementioned compound of general formula (XIV) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, comprising the following steps:
  • X is selected from halogen, preferably from chlorine or bromine
  • M 1 , M 2 , M 3 , L 1 , L 3 , R a , R b3 , R c2 , R c3 , X 3 , R d , x, e and n6 are as described above.
  • the present invention further provides a method for preparing the aforementioned compound of general formula (XV) or a stereoisomer thereof and a pharmaceutically acceptable salt thereof, comprising the following steps:
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective dose of the compound, its stereoisomer or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients Forming agent; further the compound, its stereoisomer or its pharmaceutically acceptable salt, the percentage by weight in the composition is 0.1% ⁇ 95%, preferably 0.5% ⁇ 85%, more preferably 1% ⁇ 60%, more preferably 10%-50%, even more preferably 15-40%, even more preferably 20-30%, even more preferably 20-25% (based on the total weight of the pharmaceutical composition).
  • the present invention further relates to the application of the compound, its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the preparation of medicines for treating diseases mediated by p38 kinase.
  • the present invention further relates to the application of said compound, its stereoisomer or pharmaceutically acceptable salt thereof, or its pharmaceutical composition in the preparation of medicines for treating autoimmune diseases, metabolic diseases and tumors, etc.
  • Autoimmune diseases are selected from Selected from chronic inflammatory diseases, acute inflammatory diseases, autoinflammatory diseases and atherosclerosis; metabolic diseases selected from diabetes and fibrotic diseases; tumors selected from leukemia and lymphoma.
  • the present invention also relates to a method for preventing and/or treating autoimmune diseases, metabolic diseases and tumors, etc., which comprises administering to patients a therapeutically effective dose of the compound of the present invention or its stereoisomer or its pharmaceutically acceptable salt, or a pharmaceutical composition thereof; wherein the autoimmune disease is selected from chronic inflammatory diseases, acute inflammatory diseases, autoinflammatory diseases, and atherosclerosis; metabolic diseases are selected from diabetes and fibrotic diseases; tumors are selected from Leukemia and Lymphoma etc.
  • the invention also provides methods of using the compounds or pharmaceutical compositions of the invention to treat disease conditions including, but not limited to, conditions associated with p38 kinase-mediated diseases.
  • alkyl refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably 1 to 8 carbon atoms atom, more preferably an alkyl group of 1 to 6 carbon atoms, most preferably an alkyl group of 1 to 3 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-Dimethylpropyl, 2,2-Dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 4 -Heptyl, 1-propylbutyl, 2-methylhexyl
  • lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl Base, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, 4-heptyl, 1-propylbutyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-Dimethylbutyl, 1,2-Dimethylbutyl, 2,2-Dimethylbutyl, 1,3-Dimethylbutyl, 2-Ethylbutyl, 2-Methylbutyl pentyl, 3-methylpentyl, 4-methylpentyl,
  • Alkyl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, said substituents being preferably one or more of the following groups independently selected from alkyl radical, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane Oxygen, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate, preferably methyl, ethyl, isopropyl, tert-butyl, haloalkyl in the present invention , deuterated alkyl, alkoxy substituted alkyl and hydroxy substituted alkyl.
  • alkylene refers to a divalent alkyl group formed by further substituting one hydrogen atom of the alkyl group, wherein the alkyl group is as defined above.
  • methylene refers to -CH 2 -
  • ethylene refers to -(CH 2 ) 2 -
  • propylene refers to -(CH 2 ) 3 -
  • butylene refers to -(CH 2 ) 4 -etc.
  • the point of attachment of the alkylene chain to the rest of the molecule and to the group can be through one carbon or any two carbons within the chain.
  • Alkylene groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, preferably one or more of the following groups independently selected from Alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cyclo Alkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate, preferably methyl, ethyl, isopropyl, tert-butyl, haloalkane in the present invention radical, deuterated alkyl, alkoxy-substituted alkyl, and hydroxy-substituted alkyl.
  • alkenyl refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, which is a straight or branched chain group containing 2 to 20 carbon atoms, preferably containing 2 An alkenyl group having to 12 carbon atoms, more preferably an alkenyl group having 2 to 8 carbon atoms, further preferably an alkenyl group having 2 to 6 carbon atoms, and most preferably an alkenyl group having 2 to 4 carbon atoms.
  • Alkenyl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio.
  • alkenylene refers to a divalent alkenyl group in which one hydrogen atom of the alkenyl group is further substituted, wherein the alkenyl group is as defined above, for example: vinylene, propenylene, butenylene, etc.
  • Alkenylene may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio , alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, hetero Cycloalkylthio.
  • alkynyl refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, which is a straight or branched chain group containing 2 to 20 carbon atoms, preferably containing 2 to 20 carbon atoms.
  • ethynyl, propynyl, 1-butynyl, 2-butynyl or 3-butynyl and the like are examples of the alkynyl group having 2 to 4 carbon atoms.
  • Alkynyl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio.
  • alkynylene refers to a divalent alkynyl group in which one hydrogen atom of an alkynyl group is further substituted, wherein alkynyl is as defined above. For example, ethynylene, propynylene, butynylene and the like.
  • Alkynylene may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio , alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, hetero Cycloalkylthio.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably containing 3 to 12 carbon atoms, more preferably containing 3 to 8 carbon atoms, more preferably 3 to 6 carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene group, cyclooctyl group, etc.; polycyclic cycloalkyl group includes spiro ring, fused ring and bridged ring cycloalkyl group, preferably cyclopropyl group, cyclobutyl group, cyclohexyl group, cyclopentyl group and cycloheptyl group.
  • spirocycloalkyl refers to a polycyclic group of 5 to 20 membered monocyclic rings sharing one carbon atom (called a spiro atom), which may contain one or more double bonds, but none of the rings has complete conjugation The ⁇ -electron system. excellent Selected as 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of spiro atoms shared between the rings, the spirocycloalkyl group can be divided into single spirocycloalkyl, double spirocycloalkyl or polyspirocycloalkyl, preferably single spirocycloalkyl and double spirocycloalkyl.
  • spirocycloalkyl groups include: wait;
  • spirocycloalkyls in which a single spirocycloalkyl shares a spiro atom with a heterocycloalkyl, non-limiting examples include: wait.
  • fused cycloalkyl refers to a 5 to 20 membered all-carbon polycyclic group in which each ring of the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more rings may contain one or Multiple double bonds, but none of the rings have a fully conjugated ⁇ -electron system.
  • it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyl groups, preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicycloalkyl groups.
  • fused cycloalkyl groups include: wait.
  • bridged cycloalkyl refers to a 5 to 20 membered, all-carbon polycyclic group having any two rings sharing two carbon atoms not directly attached, which may contain one or more double bonds, but none of the rings has a complete Conjugated ⁇ -electron systems. Preferably it is 6 to 14 yuan or 5 to 14 yuan, more preferably 7 to 10 yuan or 5 to 10 yuan. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic.
  • bridged cycloalkyl groups include:
  • the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring where the ring bonded to the parent structure is a cycloalkyl, non-limiting examples include indanyl, tetrahydronaphthalene base, benzocycloheptyl, wait.
  • Cycloalkyl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, oxo, carboxyl or carboxylate.
  • cycloalkylene refers to a divalent cycloalkyl group formed by further substitution of one hydrogen atom of the cycloalkyl group, wherein the cycloalkylene group is optionally substituted or unsubstituted, and the definition of cycloalkyl group is as above.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent comprising 3 to 20 ring atoms, wherein one or more ring atoms are selected from nitrogen, oxygen, C(O) or A heteroatom of S(O) m (where m is an integer from 0 to 2), excluding ring portions of -OO-, -OS- or -SS-, the remaining ring atoms being carbon.
  • Non-limiting examples of monocyclic heterocyclyl groups include oxetanyl, azetidinyl, thietanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl Base, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, azeptyl, 1,4-diazepanyl, pyridonyl, pyranyl, tetrahydrothiopyranyl dioxide, wait.
  • Polycyclic heterocyclic groups include spiro rings, fused rings and bridged ring heterocyclic groups; the spiro rings, condensed rings and bridged ring heterocyclic groups involved are optionally connected to other groups through single bonds, or through rings Any two or more atoms on the ring are further linked with other cycloalkyl, heterocyclyl, aryl and heteroaryl groups.
  • spiroheterocyclyl refers to a polycyclic heterocyclic group that shares one atom (called a spiro atom) between 5 to 20-membered monocyclic rings, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O ) m (wherein m is an integer from 0 to 2), the remaining ring atoms are carbon. It may contain one or more double bonds, but none of the rings has a fully conjugated pi-electron system. Preferably it is 6 to 14 yuan, more preferably 8 to 12 yuan.
  • the spiroheterocyclyl can be divided into single spiroheterocyclyl, double spiroheterocyclyl or polyspiroheterocyclyl, preferably single spiroheterocyclyl and double spiroheterocyclyl. More preferably, it is a 3-membered/5-membered, 3-membered/6-membered, 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered monospiroheterocyclic group.
  • Non-limiting examples of spiroheterocyclyls include: wait.
  • fused heterocyclyl refers to a 5 to 20 membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system, and one or more rings may contain one or more double bond, but none of the rings has a fully conjugated ⁇ -electron system, where one or more ring atoms are heteroatoms selected from nitrogen, oxygen, or S(O) m (where m is an integer from 0 to 2), and the remaining ring
  • the atom is carbon.
  • it is 6 to 14 yuan, more preferably 8 to 12 yuan.
  • bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups preferably bicyclic or tricyclic, more preferably 4-membered/5-membered, 5-membered/5-membered, 5-membered/6-membered , 6-membered/6-membered 6-membered/7-membered bicyclic condensed heterocyclic group.
  • fused heterocyclic groups include: wait.
  • bridged heterocyclyl refers to a 5 to 14 membered polycyclic heterocyclic group in which any two rings share two atoms not directly attached, which may contain one or more double bonds, but none of the rings has a complete shared bond.
  • it is 6 to 14 yuan, more preferably 7 to 10 yuan.
  • the number of constituent rings it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic.
  • bridged heterocyclyl groups include: wait.
  • the heterocyclyl ring may be fused to an aryl, heteroaryl, or cycloalkyl ring where the ring bonded to the parent structure is a heterocyclyl, non-limiting examples of which include: wait.
  • Heterocyclic groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alk Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, oxo, carboxyl or carboxylate.
  • heterocyclylalkylene refers to a heterocyclyl group linked to an alkylene group to form a “heterocyclyl-alkylene-", wherein the heterocyclyl or alkyl group can be optionally substituted or unsubstituted, Heterocyclyl and alkylene are as defined above.
  • heterocyclic group refers to a divalent heterocyclic group formed by further substituting a hydrogen atom of a cycloalkyl group, wherein the heterocyclic group can be optionally substituted or unsubstituted, and the definition of heterocyclic group is as above .
  • aryl refers to a 6 to 14 membered all-carbon monocyclic or fused polycyclic (that is, rings sharing adjacent pairs of carbon atoms) group, preferably 6 to 10 membered, having a conjugated ⁇ -electron system, such as benzene base and naphthyl. Phenyl is more preferred.
  • the aryl ring can be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, including benzo 5-10 membered heteroaryl, benzo 3-8 membered cycloalkyl and benzo 3-8 membered Heteroalkyl, preferably benzo 5-6 membered heteroaryl, benzo 3-6 membered cycloalkyl and benzo 3-6 membered heteroalkyl, wherein the heterocyclic group contains 1-3 nitrogen atoms, oxygen atoms, A heterocyclic group with a sulfur atom; or a three-membered nitrogen-containing condensed ring containing a benzene ring.
  • ring attached to the parent structure is an aryl ring, non-limiting examples of which include: wait.
  • Aryl groups may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio, carboxyl or carboxylate.
  • arylene refers to a divalent aryl group in which one hydrogen atom of a cycloalkyl group is further substituted, wherein the arylene group is optionally substituted or unsubstituted, and the definition of aryl is as described above.
  • heteroaryl refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen.
  • Heteroaryl is preferably 5-6 membered monocyclic heteroaryl or 8-12 membered bicyclic heteroaryl, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazole Base, tetrazolyl, pyridyl, pyrimidyl, thiadiazole, pyrazinyl, etc., preferably pyridyl, oxadiazolyl, triazolyl, Thienyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyrimidinyl or thiazolyl; more preferably tetrazolyl, pyridyl, ox
  • Non-limiting examples of such bicyclic heteroaryl groups include:
  • the heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring bonded to the parent structure is a heteroaryl ring, non-limiting examples of which include: wait.
  • Heteroaryl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alk Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, carboxyl or carboxylate.
  • heteroarylene refers to a divalent heteroaryl group in which one hydrogen atom of a cycloalkyl group is further substituted, wherein the heteroarylene group is optionally substituted or unsubstituted, and the definition of heteroaryl group is as described above.
  • alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
  • alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, alkoxy can is optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkane Amino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, Aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carb
  • Haloalkyl means an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
  • Non-limiting examples of such haloalkyl groups include: trifluoromethyl, -CH 2 CF 3 ,
  • Haloalkoxy means an alkoxy group substituted with one or more halogens, wherein alkoxy group is as defined above.
  • Hydroalkyl means an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.
  • alkenylcarbonyl refers to -C(O)-(alkenyl), wherein alkenyl is as defined above.
  • alkenylcarbonyl include: vinylcarbonyl, propenylcarbonyl, butenylcarbonyl.
  • Alkenylcarbonyl may be optionally substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkoxy Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , heterocycloalkylthio, carboxyl or carboxylate.
  • Aminocarbonyl refers to NH2 -C(O)-.
  • Alkylaminocarbonyl means that one or both of the two hydrogens on an aminocarbonyl group (NH 2 -C(O)-) is replaced by an alkyl group, wherein the definition of alkyl group is as above.
  • Alkylamino means that one or both of the two hydrogens on the amino group are replaced by an alkyl group, wherein the definition of alkyl group is as above.
  • Alkylcarbonyl or "acyl” means (alkyl)-C(O)-, wherein alkyl is as defined above.
  • Haldroxy means an -OH group.
  • Halogen means fluorine, chlorine, bromine or iodine.
  • Amino refers to -NH2 .
  • Cyano refers to -CN.
  • Niro refers to -NO2 .
  • Carbonyl refers to -C(O)-.
  • Carboxy refers to -C(O)OH.
  • THF tetrahydrofuran
  • Ethyl acetate means ethyl acetate.
  • MeOH means methanol
  • DMF N,N-dimethylformamide
  • DIPEA diisopropylethylamine
  • TFA trifluoroacetic acid
  • TAA triethylamine
  • MeCN refers to acetonitrile
  • DMA refers to N,N-dimethylacetamide.
  • Et2O means diethyl ether
  • DCM dichloromethane
  • DMAP refers to 4-dimethylaminopyridine.
  • DCC dicyclohexylcarbodiimide
  • DCE 1,2 dichloroethane
  • DIPEA N,N-diisopropylethylamine
  • NBS N-bromosuccinimide
  • NIS N-iodosuccinimide
  • Cbz-Cl refers to benzyl chloroformate
  • Pd 2 (dba) 3 refers to tris(dibenzylideneacetone)dipalladium.
  • Dppf refers to 1,1'-bisdiphenylphosphinoferrocene.
  • HATU refers to 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethyluronium hexafluorophosphate.
  • KHMDS refers to potassium hexamethyldisilazide
  • LiHMDS refers to lithium bistrimethylsilylamide.
  • MeLi means methyllithium
  • n-BuLi refers to n-butyllithium
  • NaBH(OAc) 3 refers to sodium triacetoxyborohydride.
  • X is selected from A, B, or C
  • X is selected from A, B, and C
  • X is A, B, or C
  • X is A, B, and C
  • the hydrogen atoms described in the present invention can be replaced by its isotope deuterium, and any hydrogen atom in the example compounds involved in the present invention can also be replaced by a deuterium atom.
  • Optional or “optionally” means that the subsequently described event or circumstance can but need not occur, and that the description includes instances where the event or circumstance occurs or does not occur.
  • a heterocyclic group optionally substituted with an alkyl group means that an alkyl group may but need not be present, and the description includes cases where the heterocycle group is substituted with an alkyl group and cases where the heterocycle group is not substituted with an alkyl group .
  • Substituted means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms are independently substituted by the corresponding number of substituents. It goes without saying that substituents are only in their possible chemical positions and that a person skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated (eg, ethylenic) bond.
  • “Pharmaceutical composition” means a mixture containing one or more compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, and other components such as a physiologically/pharmaceutically acceptable carrier and excipients.
  • the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
  • “Pharmaceutically acceptable salt” refers to the salt of the compound of the present invention, which is safe and effective when used in mammals, and has proper biological activity.
  • the structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) or/and liquid chromatography-mass chromatography (LC-MS). NMR chemical shifts ( ⁇ ) are given in parts per million (ppm).
  • the determination of NMR is to use Bruker AVANCE-400 nuclear magnetic instrument, and measuring solvent is deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated methanol (CD 3 OD), deuterated chloroform (CDCl 3 ) or deuterium water (D 2 O), and the internal standard was tetramethylsilane (TMS).
  • Agilent 1200 Infinity Series mass spectrometer was used for liquid chromatography-mass chromatography LC-MS determination.
  • the determination of HPLC used Agilent 1200DAD high pressure liquid chromatography (Sunfire C18 150 ⁇ 4.6mm column) and Waters 2695-2996 high pressure liquid chromatography (Gimini C18 150 ⁇ 4.6mm column).
  • Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates are used for thin-layer chromatography silica gel plates.
  • the specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin-layer chromatography separation and purification products are 0.4mm-0.5mm.
  • Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
  • the starting materials in the examples of the present invention are known and commercially available, or can be synthesized using or following methods known in the art.
  • the eluent system of the silica gel column chromatography and the developing agent system of the thin layer chromatography used in the intermediate and the purified compound in the examples include: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: Dichloromethane and acetone system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and it can also be adjusted by adding a small amount of basic or acidic reagents such as triethylamine and acetic acid.
  • the ratios in the mobile phase in the HPLC chiral resolution conditions and HPLC chiral analysis conditions are volume ratios.
  • reaction solution was concentrated, the residue was diluted with saturated sodium bicarbonate solution, the aqueous phase was extracted with dichloromethane (20mL ⁇ 3), the organic phases were combined, washed with saturated sodium chloride, dried, and concentrated to obtain 1-(chloromethyl-d2 )-2,4-difluorobenzene intermediate 4 (0.42 g).
  • Methyl 4-bromothiazole-2-carboxylate 5B (970 mg, 4.37 mmol) was dissolved in tetrahydrofuran (30 mL), cooled to 0°C. Methylmagnesium bromide (3M, 4.37 mL) was added dropwise to the reaction solution, returned to room temperature, and stirred for 5 hours.
  • Lithium aluminum deuteride (388 mg, 9.24 mmol) was added in portions to a solution of methyl 3,5-difluoropyridine-2-carboxylate (1.00 g, 5.78 mmol) in tetrahydrofuran (20 mL) under ice-cooling. The reaction was stirred at room temperature for 2 hours. The reaction was quenched with ice cubes, and the reaction solution was filtered. The filtrate was concentrated, and the residue was separated by silica gel column chromatography (eluent system B) to obtain the product (3,5-difluoropyridin-2-yl)methane-d2-ol 6A (345 mg), yield: 40.6%.
  • 2,2,6-Trimethyl-4H-1,3-dioxin-4-one 1-a (8.16 g, 57.40 mmol) was dissolved in tetrahydrofuran (60 mL), and cooled to -78°C. Lithium bistrimethylsilylamide (1M, 63 mL) was added dropwise to the reaction solution, and after the addition was complete, the reaction was stirred at -78°C for 1 hour. A solution of cyclopropylformyl chloride (3 g, 28.70 mmol, 2.60 mL) in tetrahydrofuran (10 mL) was added dropwise to the reaction solution, and the reaction was stirred at -78°C for 16 hours.
  • reaction solution was concentrated, and the residue was separated by silica gel column chromatography (eluent system B) to obtain the product 2'-acetyl-3-chloro-6-cyclopropyl-4-((3,5-difluoropyridine-2 -yl)methoxy)-5'-methyl-2H-[1,4'-bipyridine]-2-one 1-f (90 mg), yield: 92%.
  • intermediate 1 (50mg, 0.12mmol), intermediate 5 (50.8mg, 0.17mmol, purity: 62%), 1,1-bis(diphenylphosphine) 1,1'-bisdiphenyl Phosphinoferrocenepalladium dichloride (8.9 mg, 0.01 mmol) and cesium carbonate (79 mg, 0.24 mmol) were dissolved in a mixed solvent of 1,4-dioxane (1 mL) and water (0.3 mL). The reaction was heated to 100°C and stirred for 3 hours.
  • lithium bistrimethylsilylamide (66.1 mL, 1M solution in tetrahydrofuran) was added dropwise to 2,2,6-trimethyl-4H-1,3-dioxo-4 - In a solution of ketone 1a (9.50 g, 66.8 mmol) in tetrahydrofuran (20 mL). After the reaction was stirred at -50°C for 1 hour, 4-valeroyl chloride (4.40 g, 37.11 mmol) was added dropwise to the reaction solution, and stirring was continued for 1 hour.
  • reaction solution was quenched with formic acid, filtered, the filtrate was concentrated, and the residue was separated by silica gel column chromatography (eluent system A) to obtain the title product 2,2-dimethyl-6-(2-oxohexyl-5- En-1-yl)-4H-1,3-dioxo-4-one 1b (3.60 g), yield: 43.3%.
  • reaction solution was quenched with dilute hydrochloric acid (0.6M, 0.5mL), stirred at room temperature for 30 minutes, concentrated, and the residue was separated by reverse phase HPLC preparative separation (formic acid system) to obtain the title product 2-acetyl-11-chloro-10- ((3,5-difluoropyridin-2-yl)methanol Oxy-d2)-5,6,7,8-tetrahydro-12H-dipyrido[1,2-a:3',4'-g]azolazol-12-one 1h (132 mg), yield : 86.5%.
  • reaction solution was cooled to room temperature, filtered, and the filtrate was separated by reverse phase HPLC (formic acid system) to obtain the title product 11-chloro-10-((3,5-difluoropyridin-2-yl)methoxy-d2)- 2-(2-(2-Hydroxypropan-2-yl)pyrimidin-4-yl)-5,6,7,8-tetrahydro-12H-dipyrido[1,2-a:3',4' -g] Azolazol-12-one 1 (50 mg), yield: 54.6%.
  • Embodiment 1-1 MS m/z (ESI): 542.2[M+H] + ;
  • Embodiment 1-2 MS m/z (ESI): 542.2[M+H] + ;
  • 2-bromo-11-chloro-10-((3,5-difluoropyridin-2-yl)methoxy-d2)-5,6,7,8-tetrahydro-12H-di Pyrido[1,2-a:3',4'-g]azol-12-one 2a (50mg, 0.10mmol, the synthesis method refers to the synthesis of 1g in Example 1), intermediate 2 (20mg, 0.15 mmol), cesium carbonate (50 mg, 0.15 mmol), and cuprous iodide (10 mg, 0.05 mmol) were dissolved in 1,4-dioxane (3 mL), and the reaction was heated to 100° C. and stirred for 2 hours.
  • reaction solution was concentrated, and the residue was separated by silica gel column chromatography (eluent system A) to obtain 11-chloro-10-((3,5-difluoropyridin-2-yl)methoxy-d2)-2- (3-(2-Hydroxypropan-2-yl)-1H-pyrazol-1-yl)-5,6,7,8-tetrahydro-12H-dipyrido[1,2-a:3', 4'-g]azolazol-12-one 2 (41 mg), yield: 75.0%.
  • Embodiment 2-1 MS m/z (ESI): 530.2[M+H] + ;
  • Embodiment 2-2 MS m/z (ESI): 530.2[M+H] + ;
  • Embodiment 3-1 MS m/z (ESI): 589.2[M+H] + ;
  • Embodiment 3-2 MS m/z (ESI): 589.2[M+H] + ;
  • the target product N-(2-(4-(11-chloro-10-((3,5-difluoropyridin-2-yl)methoxy-d2)-12- Carbonyl-6,7,8,12-tetrahydro-5H-dipyrido[1,2-a:3',4'-g]azocin-2-yl)pyrimidin-2-yl)propane-2 -yl) acetamide 4.
  • Embodiment 4-1 MS m/z (ESI): 583.2[M+H] + ;
  • Embodiment 4-2 MS m/z (ESI): 583.2[M+H] + ;
  • intermediate 8 60mg, 0.13mmol
  • 5c 33mg, 0.17mmol
  • cuprous iodide 10mg, 0.05mmol
  • potassium carbonate 18mg, 0.13mmol
  • Embodiment 5-1 MS m/z (ESI): 572.2[M+H] + ;
  • Embodiment 5-2 MS m/z (ESI): 572.2[M+H] + ;
  • 6a (4g, 27.3mmol) was dissolved in anhydrous acetonitrile (60mL), and N-iodosuccinimide (7.37g, 32.8mmol) and p-toluenesulfonic acid (235mg, 1.36mmol) were added , and the reaction was heated to 80 °C and stirred for 16 hours.
  • reaction solution was cooled to room temperature, diluted with ethyl acetate (100 mL), washed successively with saturated sodium sulfite solution (80 mL), water (80 mL) and saturated sodium chloride solution (80 mL), dried, concentrated, and the residue was subjected to silica gel column chromatography Purified by method (elution system A) to obtain 2-chloro-3-fluoro-5-iodo-pyridin-4-amine 6b (6.5 g), yield: 87.4%.
  • reaction solution was cooled to room temperature, diluted with ethyl acetate (100mL), washed with water (60mL) and saturated sodium chloride solution (60mL) successively, dried, filtered, concentrated, and the residue was washed with Purification by silica gel column chromatography (elution system B) gave 2-chloro-3-fluoro-5-vinyl-pyridin-4-amine 6c (2.1 g), yield: 82.9%.
  • reaction solution was cooled to room temperature, diluted with ethyl acetate (50 mL), washed with water (50 mL) and saturated sodium chloride solution (50 mL) successively, dried, concentrated, and the residue was purified by silica gel column chromatography (elution system B) , to give 6-(but-3-en-1-yl)-2'-chloro-3'-fluoro-4-hydroxy-5'-vinyl-2H-[1,4'-bipyridine]-2- Ketone 6d (1.1 g), yield: 59.2%.
  • reaction solution was cooled to room temperature, extracted with ethyl acetate (50mL), the organic phase was washed with water (30mL ⁇ 2) and saturated sodium chloride solution (30mL) successively, dried, concentrated, and the residue was purified by silica gel column chromatography (elution System B) to give 6-(but-3-en-1-yl)-2'-chloro-4-((3,5-difluoropyridin-2-yl)methoxy-d2)-3'- Fluoro-5'-vinyl-2H-[1,4'-bipyridine]-2-one 6e (110 mg), yield: 78.4%.
  • reaction solution was cooled to room temperature, concentrated, and the residue was purified by silica gel column chromatography (elution system B) to obtain (Z)-2-chloro-10-((3,5-difluoropyridin-2-yl)methoxy yl-d2)-1-fluoro-7,8-dihydro-12H-dipyrido[1,2-a:3',4'-g]azocine-12-one 6f (95 mg), yield : 92.1%.
  • reaction solution was cooled to room temperature, washed with water (20 mL) and saturated sodium chloride solution (20 mL) successively, dried, concentrated, and the residue was purified by silica gel column chromatography (elution system B) to obtain 2,11-dichloro-10 -((3,5-Difluoropyridin-2-yl)methoxy-d2)-1-fluoro-5,6,7,8-tetrahydro-12H-dipyrido[1,2-a:3 ',4'-g] azacin-12-one 6h (90 mg), yield: 92.5%.
  • Embodiment 6-1 MS m/z (ESI): 607.2[M+H] + ;
  • Embodiment 6-2 MS m/z (ESI): 607.2[M+H] + ;
  • reaction solution was diluted with ethyl acetate (50mL), washed successively with saturated sodium bicarbonate solution (30mL) and saturated sodium chloride solution (30mL), the organic phase was dried and concentrated, and the residue was purified by silica gel column chromatography (elution System B) to give 2-acetyl-11-chloro-10-((3,5-difluoropyridin-2-yl)methoxy-d 2 )-1-fluoro-5,6,7,8- Tetrahydro-12H-dipyrido[1,2-a:3',4'-g]azocin-12-one 7a (90 mg), yield: 98.4%.
  • reaction solution was cooled to room temperature, diluted with ethyl acetate (50mL), washed with water (30mL ⁇ 2), saturated sodium chloride solution (30mL) successively, dried and concentrated to obtain 11-chloro-10-((3,5 -Difluoropyridin-2-yl)methoxy-d 2 )-2-(3-(dimethylamino)acryloyl)-1-fluoro-5,6,7,8-tetrahydro-12H-dipyridine And[1,2-a:3',4'-g]azocin-12-one 7b (110 mg), the product was directly used in the next reaction without purification.
  • Embodiment 7-1 MS m/z (ESI): 601.2[M+H] + ;
  • Embodiment 7-2 MS m/z (ESI): 601.2[M+H] + ;
  • Embodiment 8-1 MS m/z (ESI): 548.2[M+H] + ;
  • Embodiment 8-2 MS m/z (ESI): 548.2[M+H] + ;
  • Embodiment 9-1 MS m/z (ESI): 560.2[M+H] + ;
  • Embodiment 9-2 MS m/z (ESI): 560.2[M+H] + ;
  • reaction solution was cooled to room temperature, formic acid was added dropwise to the reaction solution to adjust the pH to weak acidity, the reaction solution was extracted with saturated sodium chloride solution and ethyl acetate (25mL ⁇ 2), the organic phases were combined, dried, concentrated, and the residue 3",5'-dichloro-4"-hydroxy-3-(2-hydroxypropan-2-yl)-6"-methyl-2H,2" was obtained by silica gel column chromatography (elution system B) H-[1,2':4',1"-terpyridine]-2,2"-dione 10a (147 mg), yield: 70.91%.
  • Embodiment 10-1 MS m/z (ESI): 551.1[M+H] + ;
  • Embodiment 10-2 MS m/z (ESI): 551.1[M+H] + ;
  • Embodiment 11-1 MS m/z (ESI): 531.2[M+H] + ;
  • Embodiment 13-1 MS m/z (ESI): 571.2[M+H] + ;
  • Embodiment 13-2 MS m/z (ESI): 571.2[M+H] + ;
  • Embodiment 14-1 MS m/z (ESI): 530.2[M+H] + ;
  • Embodiment 14-2 MS m/z (ESI): 530.2[M+H] + ;
  • Embodiment 15-1 MS m/z (ESI): 557.2[M+H] + ;
  • Embodiment 15-2 MS m/z (ESI): 557.2[M+H] + ;
  • Embodiment 16-1 MS m/z (ESI): 540.2[M+H] + ;
  • Embodiment 16-2 MS m/z (ESI): 540.2[M+H] + ;
  • Embodiment 17-1 MS m/z (ESI): 528.2[M+H] + ;
  • Embodiment 17-2 MS m/z (ESI): 528.2[M+H] + ;
  • the target product (Z)-N-(2-(1-(11-chloro-10-((3,5-difluoropyridin-2-yl)methoxy-d2) was synthesized )-12-carbonyl-8,12-dihydro-7H-dipyrido[1,2-a:3',4'-g]azocin-2-yl)-4-fluoro-1H-pyrazole -3-yl)propan-2-yl)acetamide 18.
  • Embodiment 18-1 MS m/z (ESI): 587.2[M+H] + ;
  • Embodiment 18-2 MS m/z (ESI): 587.2[M+H] + ;
  • Embodiment 19-1 MS m/z (ESI): 555.2[M+H] + ;
  • Embodiment 19-2 MS m/z (ESI): 555.2[M+H] + ;
  • the target product (Z)-N-(2-(1-(11-chloro-10-((3,5-difluoropyridin-2-yl)methoxy-d2) was synthesized )-1-fluoro-12-carbonyl-8,12-dihydro-7H-dipyrido[1,2-a:3',4'-g]azocin-2-yl)-4-fluoro- 1H-pyrazol-3-yl)propan-2-yl)acetamide 62.
  • Test Example 1 Determination of the Inhibitory Effect of Compounds of the Present Invention on p38 ⁇ /MK2 Enzyme Activity
  • the purpose of this test example is to measure the inhibitory ability of the compound on p38 ⁇ /MK2 enzyme activity.
  • p38/MK2 enzyme activity assay method Incubate 0.06nM p38 ⁇ (Active p38alpha Protein) in 1 ⁇ enzyme reaction buffer (50mM HEPES pH 7.5, 1mM EGTA, 10mM MgCl 2 , 2mM DTT, 0.01% Tween-20), 1.2 nM MK2 (Inactive MK2) and compound diluted in a concentration gradient for 1 hour. Add 50 nM ULight-CREBtide and 25 ⁇ M ATP (ATP Solution), and react at room temperature for 1.5 hours.
  • 1 ⁇ enzyme reaction buffer 50mM HEPES pH 7.5, 1mM EGTA, 10mM MgCl 2 , 2mM DTT, 0.01% Tween-20
  • 1.2 nM MK2 Inactive MK2
  • compound diluted in a concentration gradient for 1 hour Add 50 nM ULight-CREBtide and 25 ⁇ M ATP (ATP Solution), and react at room temperature for 1.5 hours.
  • p38 enzyme activity assay method Incubate 3nM p38 ⁇ (Active p38alpha Protein) in 1 ⁇ enzyme reaction buffer (50mM HEPES pH 7.5, 1mM EGTA, 10mM MgCl 2 , 2mM DTT, 0.01% Tween-20), and dilute the concentration gradient compound for 1 hr. Add 50nM ULight-MBP and 50 ⁇ M ATP (ATP 10mM Solution), react at room temperature for 1.5 hours. Add an equal volume of detection and termination mixture (1 ⁇ LANCE detection buffer containing 20mM EDTA and 2nM Europium-anti-P-MBP), mix well and centrifuge, attach a sealing film, and react at room temperature for 1 hour. Read the plate with the TR-FRET program of the EnVision instrument, and detect the fluorescence value of each well at 665nm/615nm.
  • 1 ⁇ enzyme reaction buffer 50mM HEPES pH 7.5, 1mM EGTA, 10mM MgCl 2 , 2mM
  • Inhibition rate% [(average value of positive control wells - value of sample wells) / (average value of positive control wells - average value of negative control wells)] ⁇ 100, where the positive control wells are the enzyme reaction wells without compound, and the negative control wells are the wells without compound. Enzyme wells.
  • Test example 2 the assay of compound of the present invention to U937 cell p-Hsp27 inhibition
  • the purpose of this test example is to test the inhibitory ability of the compound of the present invention to p-Hsp27 in U937 cells.
  • U937 was treated with 20ng/ml PMA to differentiate overnight, and fresh culture medium was changed, and U937 was rested overnight. After differentiation, U937 digestion counts, and 25,000 cells per well are seeded in a 96-well plate until the cells adhere to the wall. Configure the compound concentration gradient, pretreat the cells with the compound for 1 hour (the highest concentration of the compound final concentration is 1 ⁇ M, and the concentration gradient is 3 times) Diluted), adding 10ng/ml LPS (Lipopolysaccharides from Escherichia coli O111:B4) to stimulate for 0.5 hours. After washing the cells with PBS, the lysis solution lyses the cells. Use the Phospho-HSP27(S78/S82) DuoSet IC ELISA kit to detect p-Hsp27 in the cell lysate, and refer to the standard steps provided by the kit manufacturer for specific steps.
  • Phospho-HSP27(S78/S82) DuoSet IC ELISA kit to detect
  • Inhibition rate percentage [(average value of p-Hsp27 in positive control wells – average value of p-Hsp27 in sample wells)/(average value of p-Hsp27 in positive control wells – average value of p-Hsp27 in negative control wells) ] ⁇ 100%, wherein the positive control wells were no compound wells (DMSO-treated wells), and the negative control wells were no LPS-stimulated wells.
  • Dose-response curve fitting use log(inhibitor)vs.response--Variable slope(four parameters) in GraphPad Prism 6 to analyze the fitting equation of the compound concentration and the corresponding inhibition rate, fit the curve and obtain the compound IC 50 value.
  • Test Example 3 Determination of the inhibitory effect of the compounds of the present invention on the expression level of TNF- ⁇ in U937 cells
  • the purpose of this test example is to measure the inhibitory ability of the compound of the present invention to the expression level of TNF- ⁇ in U937 cells.
  • the standard curve of TNF- ⁇ was drawn by linear regression method, and the concentration of TNF- ⁇ in samples was converted according to the standard curve.
  • Inhibition rate percentage [(average TNF- ⁇ concentration in positive control wells-average TNF- ⁇ concentration in sample wells)/(average TNF- ⁇ concentration in positive control wells-average TNF- ⁇ concentration in negative control wells )] ⁇ 100%, where the positive control wells were no compound wells (DMSO treated wells), and the negative control wells were medium wells.
  • Dose-response curve fitting use log(inhibitor)vs.response--Variable slope(four parameters) in GraphPad Prism 6 to analyze the fitting equation of the compound concentration and the corresponding inhibition rate, fit the curve and obtain the compound IC 50 value.
  • Test example 4 SD rat pharmacokinetic determination
  • the compound of the present invention is self-made.
  • the dose is 5mg/kg or 2mg/kg, and the administration volume is 10mL/kg; i.v., the dose is 1mg/kg, and the administration volume is 5mL/kg.
  • the SD rat pharmacokinetic measurement results show that the compound of the present invention exhibits good PK properties.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及含吡啶多环类衍生物、其制备方法和应用。特别地，本发明涉及通式（I）所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为生物调节剂在制备治疗自身免疫疾病、慢性炎性疾病、急性炎症性疾病、自身炎性疾病、动脉粥样硬化、糖尿病、纤维变性疾病、代谢疾病、癌症、肿瘤、白血病和淋巴瘤的药物中的应用，其中通式(I)中的各取代基与说明书中的定义相同。

Description

含吡啶多环类衍生物、其制备方法和应用 技术领域
本发明属于生物医药领域，具体涉及一种含吡啶多环类衍生物及其制备方法和应用。
背景技术
MK2(MAPK activated protein kinase 2，MAPK激活蛋白激酶2)是一种蛋白激酶，作为经典炎症信号转导途径MAPK的重要下游分子，调控炎症因子的表达。细胞受炎性刺激后，激活的p38 MAPK蛋白磷酸化并活化MK2，导致MK2底物TTP磷酸化，促进促炎细胞因子mRNA的稳定性，从而提高炎症细胞因子的蛋白表达水平。
在小鼠关节炎模型和骨关节炎病人软骨细胞中，MK2都表现激活状态，通过遗传学或者药理学手段抑制p38-MK2通路均可以抑制炎症因子表达水平，说明MK2参与介导了关节炎的炎症调控。p38-MK2抑制剂有望治疗复发、难治、对现有疗法响应差的类风湿性关节炎病人。
目前全球仅Aclaris Therapeutics公司的p38-MK2抑制剂ATI-450进入类风湿性关节炎临床IIb，初步临床实验结果表明ATI-450在类风湿性关节炎病人中安全耐受，药效出众持续。其他在临床的MK2抑制剂还有BMS公司的CC-99677和Moerae Matrix的MMI-0100，均可直接抑制MK2的活性，与ATI-450机制不同。
现已公开的p38-MK2(或MK2)抑制剂专利申请包括：Aclaris Therapeutics专利(WO-2012078684，WO-2013086208，WO-2014197846，WO-2021022186，WO-2012078687，WO2012078673，WO2012078674)；BMS专利(WO-2020236636，WO-2018170199，WO-2016044463，WO-2018170201，WO-2018170200，WO-2018170203，US20210198276，US20210139501，US20200148701，US20200102326)；Moerae Matrix专利(WO-2016112292，WO-2016145234，US-10336788，WO-2014040074，WO-2018231722，WO-2012142320，WO-2016033432，WO-2013134636，WO-2011149964)等。
p38-MK2抑制剂作为药物在医药行业具有良好的应用前景。p38-MK2抑制剂为复发、难治、对现有疗法响应差的类风湿性关节炎病人提供了更安全更有效的治疗方法；p38-MK2抑制剂具有广谱抑炎效果(TNF/IL-6/IL-1)，理论上可以用于治疗多种炎症疾病和自身免疫疾病；p38-MK2抑制剂为小分子抑制剂，相比与大分子药物如TNF单抗具有口服便利、病人依从性好等优势，同时 p38-MK2抑制剂临床未见有JAK抑制剂毒副作用如感染、肿瘤、血栓、心脏毒性等报道。因此，研发新型的p38-MK2抑制剂有巨大的临床需求。
发明内容
本发明的目的在于提供一种通式(I)所示的化合物、其立体异构体或其药学上可接受盐，其中通式(I)所示的化合物结构如下：
其中：
环A选自环烷基、杂环基、芳基或杂芳基；
环B选自环烷基、杂环基、芳基或杂芳基；
L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)(CRaaRbb)n1-、-(CH2)nC(O)NRcc(CH2)n1-、-(CH2)n(CRaaRbb)n1-、-(CRaaRbb)nO(CH2)n1-、-(CH2)nO(CRaaRbb)n1-、-(CRaaRbb)nS(CH2)n1-、-(CH2)nS(CRaaRbb)n1-、-(CRaaRbb)n(CH2)n1NRcc-、-(CH2)nNRcc(CRaaRbb)n1-、-(CH2)nNRccC(O)-、-(CH2)nP(O)pRaa-、-(CH2)nS(O)m-、-(CH2)nS(O)mNRcc-和-(CH2)nNRccS(O)m-；
Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
或者，Raa、Rbb和Rcc中的任意两个链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基任选地可以进一步被取代；
L2和L3各自独立地选自键、取代或未取代的烯基、取代或未取代的炔基、-(CH2)n2-、-(CH2)n2C(O)(CRa1Rb1)n3-、-(CH2)n2C(O)NRc1(CH2)n3-、-(CH2)n2(CRa1Rb1)n3-、-(CRa1Rb1)n2O(CH2)n3-、-(CH2)n2O(CRa1Rb1)n3-、-(CRa1Rb1)n2S(CH2)n3-、-(CH2)n2S(CRa1Rb1)n3-、-(CRa1Rb1)n2(CH2)n3NRc1-、-(CH2)n2NRc1(CRa1Rb1)n3-、-(CH2)n2NRc1C(O)-、-(CH2)n2P(O)p1Ra1-、-(CH2)n2S(O)m1-、-(CH2)n2S(O)m1NRc1-和-(CH2)n2NRc1S(O)m1-；
Ra1、Rb1和Rc1各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
Rb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
Rc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
Rb与Rc链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、桥环烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基或-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4C(O)NRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、烷基、桥环烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-8烷基、C1-8氘代烷基、C1-8卤代烷基、C1-8羟烷基、C1-8烷氧基、C1-8氘代烷氧基、C1-8卤代烷氧基、C2-8烯基、C2-8炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
优选地，Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、 C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基；
或者Ree、Rff链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
n4为0、1、2、3或4；
优选地，
Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
或者，任意两个相邻或不相邻的Rd链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
或者，L3与Rd链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
或者，Rc与Rd链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
x为0～6的整数；
y为0～6的整数；
z为0～6的整数；
e为0～6的整数；
n为0、1、2或3；
n1为0、1、2或3；
n2为0、1、2或3；
n3为0、1、2或3；
m为0、1、2或3；
p为0、1、2或3；
m1为0、1、2或3；
p1为0、1、2或3。
在本发明优选的实施方案中，所述化合物进一步如通式(I’-1)所示：
其中：
环D选自环烷基、杂环基、芳基或杂芳基；
环E选自杂环基；
环B选自环烷基、杂环基、芳基或杂芳基；
X3选自N或者CRb1；
L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)(CRaaRbb)n1-、-(CH2)nC(O)NRcc(CH2)n1-、-(CH2)n(CRaaRbb)n1-、-(CRaaRbb)nO(CH2)n1-、-(CH2)nO(CRaaRbb)n1-、-(CRaaRbb)nS(CH2)n1-、-(CH2)nS(CRaaRbb)n1-、-(CRaaRbb)n(CH2)n1NRcc-、-(CH2)nNRcc(CRaaRbb)n1-、-(CH2)nNRccC(O)-、-(CH2)nP(O)pRaa-、-(CH2)nS(O)m-、-(CH2)nS(O)mNRcc-和-(CH2)nNRccS(O)m-；
Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
L3选自键、取代或未取代的烯基、取代或未取代的炔基、-(CH2)n2-、-(CH2)n2C(O)(CRa1Rb1)n3-、-(CH2)n2C(O)NRc1(CH2)n3-、-(CH2)n2(CRa1Rb1)n3-、-(CRa1Rb1)n2O(CH2)n3-、-(CH2)n2O(CRa1Rb1)n3-、-(CRa1Rb1)n2S(CH2)n3-、-(CH2)n2S(CRa1Rb1)n3-、-(CRa1Rb1)n2(CH2)n3NRc1-、-(CH2)n2NRc1(CRa1Rb1)n3-、-(CH2)n2NRc1C(O)-、-(CH2)n2P(O)p1Ra1-、-(CH2)n2S(O)m1-、-(CH2)n2S(O)m1NRc1-和-(CH2)n2NRc1S(O)m1-；
Ra1、Rb1和Rc1各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，任意两个相邻或不相邻的Ra链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，L1与Ra链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rb1或Rb3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷 基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rc2或Rc3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以 进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
x为0～6的整数；
e为0～6的整数；
n为0、1、2或3；
n1为0、1、2或3；
n2为0、1、2或3；
n3为0、1、2或3；
n4为0、1、2、3或4；
n6为0、1、2、3或4；
m为0、1、2或3；
p为0、1、2或3；
m1为0、1、2或3；
p1为0、1、2或3。
在本发明进一步优选的实施方案中，本发明所述的环D选自C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；优选地，环D选自C6-10芳基、5-6元单环杂芳基或7-10元双环杂芳基；更优选地，环D选自吡唑基、噻吩基、噻唑基、恶唑基、嘧啶基、吡啶基、苯基、
在本发明进一步优选的实施方案中，本发明所述的环E选自6-12元杂环基；优选地，环E选自
在本发明优选的实施方案中，所述化合物进一步如通式(XIV)所示：
其中：
M1选自C、CH、N或不存在；
M2选自C、CH、N或不存在；
M3选自C、CH、N或不存在；
X3选自N或者CRb1；
环B选自环烷基、杂环基、芳基或杂芳基；
L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)(CRaaRbb)n1-、-(CH2)nC(O)NRcc(CH2)n1-、-(CH2)n(CRaaRbb)n1-、-(CRaaRbb)nO(CH2)n1-、-(CH2)nO(CRaaRbb)n1-、-(CRaaRbb)nS(CH2)n1-、-(CH2)nS(CRaaRbb)n1-、-(CRaaRbb)n(CH2)n1NRcc-、-(CH2)nNRcc(CRaaRbb)n1-、-(CH2)nNRccC(O)-、-(CH2)nP(O)pRaa-、-(CH2)nS(O)m-、-(CH2)nS(O)mNRcc-和-(CH2)nNRccS(O)m-；
Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基， 任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
L3选自键、取代或未取代的烯基、取代或未取代的炔基、-(CH2)n2-、-(CH2)n2C(O)(CRa1Rb1)n3-、-(CH2)n2C(O)NRc1(CH2)n3-、-(CH2)n2(CRa1Rb1)n3-、-(CRa1Rb1)n2O(CH2)n3-、-(CH2)n2O(CRa1Rb1)n3-、-(CRa1Rb1)n2S(CH2)n3-、-(CH2)n2S(CRa1Rb1)n3-、-(CRa1Rb1)n2(CH2)n3NRc1-、-(CH2)n2NRc1(CRa1Rb1)n3-、-(CH2)n2NRc1C(O)-、-(CH2)n2P(O)p1Ra1-、-(CH2)n2S(O)m1-、-(CH2)n2S(O)m1NRc1-和-(CH2)n2NRc1S(O)m1-；
Ra1、Rb1和Rc1各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，任意两个相邻或不相邻的Ra链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，L1与Ra链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rb1或Rb3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rc2或Rc3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、 羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
x为0～6的整数；
e为0～6的整数；
n为0、1、2或3；
n1为0、1、2或3；
n2为0、1、2或3；
n3为0、1、2或3；
n4为0、1、2、3或4；
n6为0、1、2、3或4；
m为0、1、2或3；
p为0、1、2或3；
m1为0、1、2或3；
p1为0、1、2或3。
在本发明更优选的实施方案中，本发明所述的环A选自C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
优选地，环A选自6-12元双环杂环基、5-6元单环杂芳基或7-10元双环杂芳基；
更优选地，环A选自吡唑基、噻吩基、噻唑基、恶唑基、嘧啶基、吡啶基、苯基、四氢喹啉基、苯并环戊基、吡咯并嘧啶基、吡咯并吡啶基、吡唑并吡啶或咪唑并吡啶。
在本发明更优选的实施方案中，本发明所述的环B选自C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
优选地，环B选自3-7元单环杂环基、6-12元双环杂环基、5元单环杂芳基、6元单环杂芳基或7-14元杂芳基并环；
更优选地，环B选自5元单环含氮杂芳基、6元单环含氮杂芳基、5-6元杂芳基并5-6元环烷基、5-6元杂芳基并5-6元杂芳基或5-6元杂芳基并苯基；
进一步优选地，环B选自嘧啶、吡啶并环己基、吡啶并环戊基、吡咯并三嗪基、吡咯并嘧啶基、吡啶并环戊烯基、吡啶、噻唑、吡唑，吡啶并吡咯酮、吡啶并呋喃酮、吡啶并环丁砜、
更进一步优选地，环B选自噻唑基、噁唑基、吡唑基、咪唑基、1,2,4-噻二唑基、1,3,4-噁二唑基、嘧啶基、吡啶并环己基、吡啶并环戊基、吡咯并三嗪基、吡咯并嘧啶基、吡啶并环戊烯基、吡啶基、吡啶并吡咯酮、吡啶并呋喃酮或吡啶并环丁砜。
在本发明进一步优选的实施方案中，本发明所述的L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)(CRaaRbb)n1-、-(CH2)nC(O)NRcc(CH2)n1-、-(CH2)n(CRaaRbb)n1-、-(CRaaRbb)nO(CH2)n1-、-(CH2)nO(CRaaRbb)n1-、-(CRaaRbb)nS(CH2)n1-、-(CH2)nS(CRaaRbb)n1-、-(CRaaRbb)n(CH2)n1NRcc-、-(CH2)nNRcc(CRaaRbb)n1-、-(CH2)nNRccC(O)-、-(CH2)nP(O)pRaa-、-(CH2)nS(O)m-、-(CH2)nS(O)mNRcc-和-(CH2)nNRccS(O)m-；
优选地，L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)-、-(CRaaRbb)nO-、-O(CRaaRbb)n1-、-(CRaaRbb)nS-、-S(CRaaRbb)n1-、-(CH2)n1NRcc-、-NRcc(CRaaRbb)n1-或-NRccC(O)-；
更优选地，L1选自键、-CH2-、-OCH2-、-OCD2-、-NH-、-C(O)NH-、-OCH(CH3)-、-OC(CH3)2-、-NH-CH2-或
Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
优选地，Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代；
或者，Raa、Rbb和Rcc中的任意两个链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基和C1-6卤代烷氧基中的一个或多个取代基所取代；
优选地，Raa、Rbb和Rcc中的任意两个链接形成C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基和C1-3卤代烷氧基中的一个或多个取代基所取代。
在本发明进一步优选的实施方案中，所述化合物进一步如通式(XV)所示：
其中：
X1选自N或者CRa5；
X3选自N或者CRb1；
Ra1、Ra2、Ra3、Ra4或Ra5各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、 C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，任意两个相邻或不相邻的Ra1、Ra2、Ra3、Ra4和Ra5链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Raa或Rbb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，Raa和Rbb链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rb1、Rb2或Rb3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代 基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，Rb1和Rb2取代基链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rc1、Rc2或Rc3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，Rc1和Rc2取代基链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，Rc1和Rb2取代基链接形成3-12元杂环基或5-14元杂芳基，所述3-12元杂环基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
R1选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、 -(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
R2、R3或R4各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，任意两个相邻或不相邻的R1、R2、R3和R4链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔 基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
n4为0、1、2、3或4；且
所述的不为
在本发明进一步优选的实施方案中，所述化合物进一步如通式(XIV-A)(XIV-B)或(XIV-C)所示：
其中：
X1选自N或者CRa5；
X2选自N或者CR2；
X3选自N或者CRb1；
Ra1、Ra2、Ra3、Ra4或Ra5各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、 C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，任意两个相邻或不相邻的Ra1、Ra2、Ra3、Ra4和Ra5链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Raa或Rbb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，Raa和Rbb链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rb1或Rb3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rc2或Rc3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rda、Rdb或R’da各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，Rda和Rdb链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Rdc或Rdd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，Rdc和Rdd链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
R1选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
R2、R3或R4各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6 烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，任意两个相邻或不相邻的R1、R2、R3和R4链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
R7选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
R6或R8各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
或者，任意两个相邻或不相邻的R6、R7和R8链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
n4为0、1、2、3或4；
n5为0、1或2；
n5’为0、1或2；
n5和n5’不同时为0；
n6为0、1、2、3或4。
在本发明进一步优选的实施方案中，所述化合物进一步如通式(I’-1-1)、(I’-1-2)、(XIV-1)、(XIV-2)、(XIV-A-1)、(XIV-A-2)、(XIV-B-1)、(XIV-B-2)、(XIV-C-1)、(XIV-C-2)、(XV-1)或(XV-2)所示：


在本发明进一步优选的实施方案中，本发明所述的Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
优选地，Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代。
在本发明进一步优选的实施方案中，本发明所述的Rb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、 C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
优选地，Rb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代。
在本发明进一步优选的实施方案中，本发明所述的Rc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
优选地，Rc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷 氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代；
或者，Rb与Rc链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代。
在本发明进一步优选的实施方案中，本发明所述的Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、5-10元桥环烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基或-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4C(O)NRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、5-10元桥环烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-8烷基、C1-8氘代烷基、C1-8卤代烷基、C1-8羟烷基、C1-8烷氧基、C1-8氘代烷氧基、C1-8卤代烷氧基、C2-8烯基、C2-8炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
优选地，Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基；
或者Ree、Rff链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
n4为0、1、2、3或4。
优选地，
Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
优选地，Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代。
进一步优选地，Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基或-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4C(O)NRhhRgg或-(CReeRff)n4S(O)2NRhhRgg；
Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基；
n4为0、1、2、3或4。
在本发明进一步优选的实施方案中，本发明所述的Ra1、Ra2、Ra3、Ra4、Ra5、Rb1、Rb2、Rb3、Rc1、Rc2及Rc3各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、 C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代。
在本发明进一步优选的实施方案中，本发明所述的Rda、Rdb、R’da、Rdc及Rdd各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代。
在本发明进一步优选的实施方案中，本发明所述的R1及R7各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基或-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4C(O)NRhhRgg或-(CReeRff)n4S(O)2NRhhRgg；
Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基；
n4为0、1、2、3或4。
在本发明进一步优选的实施方案中，本发明所述的R2、R3、R4、R6及R8各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、 硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代。
在本发明进一步优选的实施方案中，本发明所述的R2选自卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
优选地，R2选自卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基或C2-6炔基；
更优选地，R2选自氟。
在本发明进一步优选的实施方案中，本发明所述的R6选自卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
优选地，R6选自卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基或C2-6炔基；
更优选地，R6选自氟。
本发明进一步提供通式(M-1)或(M-2)所示的化合物、其立体异构体或其药学上可接受的盐：
其中：
X4选自卤素，优选地选自氯或溴；
环D及环E、M1、M2、M3、n6、L1、Ra、Rb3、Rc2、Rc3、X3及x如上所述。
本发明进一步提供前述通式(I’-1)化合物或其立体异构体及其药学上可接受的盐的制备方法，包含如下步骤：
通式(M-1)所示的化合物通过反应，得到通式(I’-1)所示的目标化合物；
其中，
X4选自卤素，优选地选自氯或溴；
环D、环E、环B、L1、L3、Ra、Rb3、Rc2、Rc3、X3、Rd、x及e如上所述。
本发明进一步提供前述通式(XIV)化合物或其立体异构体及其药学上可接受的盐的制备方法，包含如下步骤：
通式(M-2)所示的化合物通过反应，得到通式(XIV)所示的目标化合物；
其中，
X4选自卤素，优选地选自氯或溴；
M1、M2、M3、L1、L3、Ra、Rb3、Rc2、Rc3、X3、Rd、x、e及n6如上所述。
本发明进一步提供前述通式(XV)化合物或其立体异构体及其药学上可接受的盐的制备方法，包含如下步骤：
通式(M-3)与通式(M-4)反应，得到通式(XV)所示的目标化合物；
其中，
X1、X3、Ra1、Ra2、Ra3、Ra4、Raa、Rbb、Rb2、Rb3、Rc1、Rc2、Rc3、R1、R2、R3及R4如上所述。
本发明进一步涉及一种药物组合物，其包括治疗有效剂量的所述化合物、其立体异构体或其药学上可接受的盐以及一种或多种药学上可接受的载体、稀释剂或赋形剂；进一步地所述化合物、其立体异构体或其药学上可接受盐，在组合物中所占的重量百分比为0.1％～95％，优选0.5％～85％，更优选1％～60％，进一步优选10％～50％，更进一步优选15-40％，更进一步优选20-30％，更进一步优选20-25％(以药物组合物总重计)。
本发明进一步涉及所述化合物、其立体异构体或其药学上可接受的盐，或所述的药物组合物在制备治疗p38激酶介导的疾病药物中的应用。
本发明进一步涉及所述的化合物、其立体异构体或其药学上可接受的盐，或其药物组合物在制备治疗自身免疫疾病、代谢疾病和肿瘤等的药物中的应用，自身免疫疾病选自慢性炎性疾病、急性炎症性疾病、自身炎性疾病及动脉粥样硬化等；代谢性疾病选自糖尿病及纤维变性疾病等；肿瘤选自白血病及淋巴瘤等。本发明还涉及一种治疗预防和/或治疗自身免疫疾病、代谢疾病和肿瘤等的方法，其包括向患者施用治疗有效剂量的本发明所述化合物其立体异构体或其药学上可接受的盐，或其药物组合物；其中自身免疫疾病选自慢性炎性疾病、急性炎症性疾病、自身炎性疾病及动脉粥样硬化等；代谢性疾病选自糖尿病及纤维变性疾病等；肿瘤选自白血病及淋巴瘤等。
本发明还提供了使用本发明的化合物或药物组合物治疗疾病状况的方法，该疾病状况包括但不限于与p38激酶介导的疾病有关的状况。
发明的详细说明
除非有相反陈述，在说明书和权利要求书中使用的术语具有下述含义。
术语“烷基”指饱和脂肪族烃基团，其为包含1至20个碳原子的直链或支链基团，优选含有1至12个碳原子的烷基，更优选含有1至8个碳原子的烷基，进一步优选1至6个碳原子的烷基，最优选1至3个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、4-庚基、1-丙基丁基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基，及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基，非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、正庚基、4-庚基、1-丙基丁基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基，本发明优选甲基、乙基、异丙基、叔丁基、卤代烷基、氘代烷基、烷氧基取代的烷基和羟基取代的烷基。
术语“亚烷基”是指烷基的一个氢原子进一步被取代形成的二价烷基，其中烷基如上所定义。例如：“亚甲基”指-CH2-、“亚乙基”指-(CH2)2-、“亚丙基”指-(CH2)3-、“亚丁基”指-(CH2)4-等。亚烷基链与分子其余部分及与基团的连接点可经由该链内的一个碳或任何两个碳。亚烷基可以是取代的或非取代的，当被取代时，取代基可以在任何可使用的连接点上被取代，所述取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基，本发明优选甲基、乙基、异丙基、叔丁基、卤代烷基、氘代烷基、烷氧基取代的烷基和羟基取代的烷基。
术语“烯基”指由至少由两个碳原子和至少一个碳-碳双键组成的如上定义的烷基，其为包含2至20个碳原子的直链或支链基团，优选含有2至12个碳原子的烯基，更优选含有2至8个碳原子的烯基，进一步优选2至6个碳原子的烯基，最优选2至4个碳原子的烯基。例如乙烯基、1-丙烯基、2-丙烯基、1-丁烯基、2-丁烯基或3-丁烯基等。烯基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“亚烯基”是指烯基的一个氢原子进一步被取代形成的二价烯基，其中烯基如上所定义例如：亚乙烯基、亚丙烯基、亚丁烯基等。亚烯基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“炔基”指至少由两个碳原子和至少一个碳-碳三键组成的如上定义的烷基，其为包含2至20个碳原子的直链或支链基团，优选含有2至12个碳原子的炔基，更优选含有2至8个碳原子的炔基，进一步优选2至6个碳原子的炔基，最优选2至4个碳原子的炔基。例如乙炔基、丙炔基、1-丁炔基、2-丁炔基或3-丁炔基等。炔基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“亚炔基”是指炔基的一个氢原子进一步被取代形成的二价炔基，其中炔基如上所定义。例如亚乙炔基、亚丙炔基、亚丁炔基等。亚炔基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基，环烷基环包含3至20个碳原子，优选包含3至12个碳原子，更优选包含3至8个碳原子，进一步优选包含3至6个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等；多环环烷基包括螺环、稠环和桥环的环烷基，优选环丙基、环丁基、环己基、环戊基和环庚基。
术语“螺环烷基”指5至20元的单环之间共用一个碳原子(称螺原子)的多环基团，其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。优 选为6至14元，更优选为7至10元。根据环与环之间共用螺原子的数目将螺环烷基分为单螺环烷基、双螺环烷基或多螺环烷基，优选为单螺环烷基和双螺环烷基。更优选为3元/6元、3元/5元、4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺环烷基。螺环烷基的非限制性实例包括：
等；
也包含单螺环烷基与杂环烷基共用螺原子的螺环烷基，非限制性实例包括：
等。
术语“稠环烷基”指5至20元，系统中的每个环与体系中的其他环共享毗邻的一对碳原子的全碳多环基团，其中一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠环烷基，优选为双环或三环，更优选为5元/5元或5元/6元双环烷基。稠环烷基的非限制性实例包括：
等。
术语“桥环烷基”指5至20元，任意两个环共用两个不直接连接的碳原子的全碳多环基团，其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。优选为6至14元或5至14元，更优选为7至10元或5至10元。根据组成环的数目可以分为双环、三环、四环或多环桥环烷基，优选为双环、三环或四环，更有选为双环或三环。桥环烷基的非限制性实例包括：
所述环烷基环可以稠合于芳基、杂芳基或杂环烷基环上，其中与母体结构连接在一起的环为环烷基，非限制性实例包括茚满基、四氢萘基、苯并环庚烷基、 等。环烷基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“亚环烷基”是指环烷基的一个氢原子进一步被取代形成的二价环烷基，其中，亚环烷基是任选取代的或非取代的，环烷基定义如上所述。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基，其包含3至20个环原子，其中一个或多个环原子选自氮、氧、C(O)或S(O)m(其中m是整数0至2)的杂原子，但不包括-O-O-、-O-S-或-S-S-的环部分，其余环原子为碳。优选包含3至12个环原子，其中1～4个是杂原子；更优选包含3至8个环原子或6至12个环原子；最优选包含3至6个环原子；进一步优选包含1-3氮原子的3-8元杂环基，任选地，被1-2个氧原子、硫原子、氧代基取代，包括单环杂环基、螺杂环基或稠杂环基。
单环杂环基的非限制性实例包括氧杂环丁基、氮杂环丁烷基、硫杂环丁基、吡咯烷基、咪唑烷基、四氢呋喃基、四氢噻吩基、四氢吡喃基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基、吖庚基、1,4-二氮杂环庚基、吡啶酮基、吡喃基、四氢噻喃二氧化物基、等。
多环杂环基包括螺环、稠环和桥环的杂环基；其中涉及到的螺环、稠环和桥环的杂环基任选与其他基团通过单键相连接，或者通过环上的任意两个或者两个以上的原子与其他环烷基、杂环基、芳基和杂芳基进一步并环连接。
术语“螺杂环基”指5至20元的单环之间共用一个原子(称螺原子)的多环杂环基团，其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子，其余环原子为碳。其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统。优选为6至14元，更优选为8至12元。根据环与环之间共用螺原子的数目将螺杂环基分为单螺杂环基、双螺杂环基或多螺杂环基，优选为单螺杂环基和双螺杂环基。更优选为3元/5元、3元/6元、4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺杂环基。螺杂环基的非限制性实例包括：
等。
术语“稠杂环基”指5至20元，系统中的每个环与体系中的其他环共享毗邻的一对原子的多环杂环基团，一个或多个环可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统，其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子，其余环原子为碳。优选为6至14元，更优选为8至12元。根据组成环的数目可以分为双环、三环、四环或多环稠杂环基，优选为双环或三环，更优选为4元/5元、5元/5元、5元/6元、6元/6元6元/7元双环稠杂环基。稠杂环基的非限制性实例包括：

等。
术语“桥杂环基”指5至14元，任意两个环共用两个不直接连接的原子的多环杂环基团，其可以含有一个或多个双键，但没有一个环具有完全共轭的π电子系统，其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子，其余环原子为碳。优选为6至14元，更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥杂环基，优选为双环、三环或四环，更有选为双环或三环。桥杂环基的非限制性实例包括：
等。
所述杂环基环可以稠合于芳基、杂芳基或环烷基环上，其中与母体结构连接在一起的环为杂环基，其非限制性实例包括：
等。
杂环基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“杂环基亚烷基”是指杂环基与亚烷基相连形成“杂环基-亚烷基-”，其中的杂环基或烷基可以是任选取代的或非取代的，杂环基和亚烷基的定义如上所述。
术语“亚杂环基”是指环烷基的一个氢原子进一步被取代形成的二价杂环基，其中，亚杂环基可以是任选取代的或非取代的，杂环基定义如上所述。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团，优选为6至10元，例如苯基和萘基。更优选苯基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上，包括苯并5-10元杂芳基、苯并3-8元环烷基和苯并3-8元杂烷基，优选苯并5-6元杂芳基、苯并3-6元环烷基和苯并3-6元杂烷基，其中杂环基为含1-3氮原子、氧原子、硫原子的杂环基；或者还包含含苯环的三元含氮稠环。
其中与母体结构连接在一起的环为芳基环，其非限制性实例包括：
等。
芳基可以是取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“亚芳基”是指环烷基的一个氢原子进一步被取代形成的二价芳基，其中，亚芳基是任选取代的或非取代的，芳基定义如上所述。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系，其中杂原子选自氧、硫和氮。杂芳基优选为5-6元单环杂芳基或8-12元双环杂芳基，例如咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、三唑基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基等，优选吡啶基、噁二唑基、三唑基、 噻吩基、咪唑基、吡唑基、噁唑基、噻唑基、嘧啶基或噻唑基；更优选四氮唑基、吡啶基、噁二唑基、吡唑基、吡咯基、噻唑基和噁唑基。
所述双环杂芳基非限制性实例包括：
所述杂芳基环可以稠合于芳基、杂环基或环烷基环上，其中与母体结构连接在一起的环为杂芳基环，其非限制性实例包括：
等。
杂芳基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“亚杂芳基”是指环烷基的一个氢原子进一步被取代形成的二价杂芳基，其中，亚杂芳基是任选取代的或非取代的，杂芳基定义如上所述。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基)，其中烷基的定义如上所述。烷氧基的非限制性实例包括：甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基，烷氧基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、 芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
“卤代烷基”指被一个或多个卤素取代的烷基，其中烷基如上所定义。所述卤代烷基非限制性实例包括：三氟甲基、-CH2CF3、
“卤代烷氧基”指被一个或多个卤素取代的烷氧基，其中烷氧基如上所定义。
“羟烷基”指被羟基取代的烷基，其中烷基如上所定义。
术语“烯基羰基”指-C(O)-(烯基)，其中烯基的定义如上所述。烯基羰基的非限制性实例包括：乙烯基羰基、丙烯基羰基、丁烯基羰基。烯基羰基可以是任选取代的或非取代的，当被取代时，取代基优选为一个或多个以下基团，其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
“氨基羰基”指NH2-C(O)-。
“烷基氨基羰基”指氨基羰基(NH2-C(O)-)上的两个氢中的一个或全部被烷基取代，其中烷基的定义如上所述。
“烷基氨基”指氨基上的两个氢中的一个或全部被烷基取代，其中烷基的定义如上所述。
“烷基羰基”或“酰基”指(烷基)-C(O)-，其中烷基的定义如上所述。
“羟基”指-OH基团。
“卤素”指氟、氯、溴或碘。
“氨基”指-NH2。
“氰基”指-CN。
“硝基”指-NO2。
“羰基”指-C(O)-。
“羧基”指-C(O)OH。
“THF”指四氢呋喃。
“乙酸乙酯”指乙酸乙酯。
“MeOH”指甲醇。
“DMF”指N,N-二甲基甲酰胺。
“DIPEA”指二异丙基乙胺。
“TFA”指三氟乙酸。
“TEA”指三乙胺。
“MeCN”指乙晴。
“DMA”指N,N-二甲基乙酰胺。
“Et2O”指乙醚。
“DCM”指二氯甲烷。
“DMAP”指4-二甲氨基吡啶。
“DCC”指二环己基碳二亚胺。
“DCE”指1,2二氯乙烷。
“DIPEA”指N,N-二异丙基乙胺。
“NBS”指N-溴代琥珀酰亚胺。
“NIS”指N-碘代丁二酰亚胺。
“Cbz-Cl”指氯甲酸苄酯。
“Pd2(dba)3”指三(二亚苄基丙酮)二钯。
“Dppf”指1,1’-双二苯基膦二茂铁。
“HATU”指2-(7-氧化苯并三氮唑)-N,N,N’,N’-四甲基脲六氟磷酸酯。
“KHMDS”指六甲基二硅基胺基钾。
“LiHMDS”指双三甲基硅基胺基锂。
“MeLi”指甲基锂。
“n-BuLi”指正丁基锂。
“NaBH(OAc)3”指三乙酰氧基硼氢化钠。
“X选自A、B、或C”、“X选自A、B和C”、“X为A、B或C”、“X为A、B和C”等不同用语均表达了相同的意义，即表示X可以是A、B、C中的任意一种或几种。
本发明所述的氢原子均可被其同位素氘所取代，本发明涉及的实施例化合物中的任一氢原子也均可被氘原子取代。
“任选”或“任选地”意味着随后所描述的事件或环境可以但不必发生，该说明包括该事件或环境发生或不发生的场合。例如，“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在，该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
“取代的”指基团中的一个或多个氢原子，优选为最多5个，更优选为1～3个氢原子彼此独立地被相应数目的取代基取代。不言而喻，取代基仅处在它们的可能的化学位置，本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如，具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
“药物组合物”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其他化学组分的混合物，以及其他组分例如生理学/可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药，利于活性成分的吸收进而发挥生物活性。
“可药用盐”是指本发明化合物的盐，这类盐用于哺乳动物体内时具有安全性和有效性，且具有应有的生物活性。
具体实施方式
以下结合实施例进一步描述本发明，但这些实施例并非限制着本发明的范围。
实施例
本发明的化合物结构是通过核磁共振(NMR)或/和液质联用色谱(LC-MS)来确定的。NMR化学位移(δ)以百万分之一(ppm)的单位给出。NMR的测定是用Bruker AVANCE-400核磁仪，测定溶剂为氘代二甲基亚砜(DMSO-d6)，氘代甲醇(CD3OD)，氘代氯仿(CDCl3)或氘水(D2O)，内标为四甲基硅烷(TMS)。
液质联用色谱LC-MS的测定用Agilent 1200Infinity Series质谱仪。HPLC的测定使用安捷伦1200DAD高压液相色谱仪(Sunfire C18 150×4.6mm色谱柱)和Waters 2695-2996高压液相色谱仪(Gimini C18 150×4.6mm色谱柱)。
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板，TLC采用的规格是0.15mm～0.20mm，薄层层析分离纯化产品采用的规格是0.4mm～0.5mm。柱层析一般使用烟台黄海硅胶200～300目硅胶为载体。
本发明实施例中的起始原料是已知的并且可以在市场上买到，或者可以采用或按照本领域已知的方法来合成。
在无特殊说明的情况下，本发明的所有反应均在连续的磁力搅拌下，在干燥氮气或氩气氛下进行，溶剂为干燥溶剂，反应温度单位为摄氏度。
中间体及实施例中纯化化合物采用的硅胶柱色谱法的洗脱剂的体系和薄层色谱法的展开剂体系包括：A：二氯甲烷和甲醇体系，B：正己烷和乙酸乙酯体系，C：二氯甲烷和丙酮体系，溶剂的体积比根据化合物的极性不同而进行调节，也可以加入少量的三乙胺和醋酸等碱性或酸性试剂进行调节。
除非特别说明，本发明实施例中，HPLC手性拆分条件和HPLC手性分析条件中的流动相中的比值为体积比。
中间体1
2',3-二氯-4-((3,5-二氟吡啶-2-基)甲氧基)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮

第一步
将2'-氯-4-羟基-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮a(200mg,0.8mmol，其合成方法参考WO2014197846A1)，2-(氯甲基)-3,5-二氟-吡啶(157mg,0.96mmol)，碳酸钾(276mg,1.99mmol)和18-冠-6(21mg,0.08mmol)溶解于N,N-二甲基甲酰胺(4mL)中。反应加热至60℃搅拌16小时。向反应液中加入水(20mL)，水相用乙酸乙酯(20mL×2)萃取，有机相合并，干燥，浓缩。残余物用硅胶柱色谱法(洗脱剂体系A)分离得到产物2'-氯-4-((3,5-二氟吡啶-2-基)甲氧基)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮b(301mg)，产率：99％。
MS m/z(ESI):378.1[M+H]+.
第二步
将2'-氯-4-((3,5-二氟吡啶-2-基)甲氧基)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮b(301mg,0.8mmol)和N-氯代丁二酰亚胺(117mg,0.88mmol)溶解于异丙醇(6mL)中，反应加热至60℃搅拌16小时。冷却至室温，反应液浓缩，残余物用硅胶柱色谱法(洗脱剂体系A)分离得到产物2',3-二氯-4-((3,5-二氟吡啶-2-基)甲氧基)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮中间体1(190mg)，产率：57.9％。
MS m/z(ESI):412.1[M+H]+.
1H NMR(400MHz,DMSO-d6)δ8.60(s,1H),8.54(s,1H),8.07-8.13(m,1H),7.69(s,1H),6.80(s,1H),5.48(s,2H),1.98(s,3H),1.96(s,3H).
中间体2
2-(1H-吡唑-3-基)丙烷-2-醇
第一步
将1H-吡唑-3-甲酸甲酯(2g,15.9mmol)溶解在四氢呋喃(50mL)中冷却至0℃。搅拌下向反应液滴加甲基氯化镁(1M,47.58mL)。滴加完成后，反应升温至室温，继续搅拌2小时。向反应液加入乙酸乙酯(100mL)，有机相用水和饱和氯化铵洗涤，干燥，浓缩，得到产物2-(1H-吡唑-3-基)丙烷-2-醇中间体2(840mg)，产率：42％。
MS m/z(ESI):127.1[M+H]+.
1H NMR(400MHz,CDCl3)δ7.51(d,1H),6.64(s,2H),6.18(d,1H),1.62(s,6H).
中间体3
2',3-二氯-4-羟基-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮
第一步
将a(10g，40mmol)溶解在二氯乙烷(600mL)和异丙醇(400mL)的混合液中。反应液加热到60℃，向反应液中分批加N-氯代丁二酰胺(6.4g，50mmol)，反应在60℃下继续搅拌2小时。反应液浓缩，向残余物中加入异丙醇(50mL)，混合液在60℃下搅拌1小时。混合液冷却，过滤，滤饼用异丙醇洗涤。滤饼干燥得到产物2',3-二氯-4-羟基-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮中间体3(8.0g)，产率：71％。
MS m/z(ESI):285.0[M+H]+；
1H NMR(400MHz,DMSO-d6)δ11.61(s,1H),8.52(s,1H),7.64(s,1H),6.17(d,1H),1.97(s,3H),1.86(s,3H).
中间体4
1-(氯甲基-d2)-2,4-二氟苯
第一步
将2,4-二氟苯甲酸甲酯4A(0.5g,2.90mmol)溶于四氢呋喃(8mL)中搅拌，冰浴下向反应液加入氘化锂铝(122mg,2.90mmol)的四氢呋喃溶液(5mL)。反应在冰浴下搅拌1小时，反应液用饱和氯化铵淬灭，水相用乙酸乙酯(20mL×3)萃取，有机相合并，用饱和氯化钠洗涤，干燥，浓缩，残余物用硅胶柱层析(洗脱体系B)得(2,4-二氟苯基)甲醇-d2-醇4B(0.4g)，产率：94％。
MS m/z(ESI):147.1[M+H]+.
第二步
将(2,4-二氟苯基)甲醇-d2-醇4B(400mg,2.74mmol)和N,N-二甲基甲酰胺(0.05mL)溶于二氯甲烷(10mL)中搅拌，冰浴下向反应液缓慢滴加氯化亚砜(749mg,6.30mmol)。反应转至室温搅拌1小时。反应液浓缩，残余物加入饱和碳酸氢钠溶液稀释，水相用二氯甲烷(20mL×3)萃取，有机向合并，用饱和氯化钠洗涤，干燥，浓缩得到1-(氯甲基-d2)-2,4-二氟苯中间体4(0.42g)。
中间体5
(2-(2-羟基丙烷-2-基)噻唑-4-基)硼酸
第一步
将4-溴噻唑-2-羧酸5A(1g,4.81mmol)溶解于甲醇(10mL)中，室温下向反应液中缓慢滴加氯化亚砜(1.72g，14.42mmol)。滴加完成后，反应加热至50℃,搅拌3.5小时。反应恢复至室温，直接浓缩，残余物用硅胶柱色谱法(洗脱剂体系A)分离得到产物4-溴噻唑-2-羧酸甲酯5B(1.02g)，产率：95.6％。
MS m/z(ESI):222.1,224.1[M+H]+.
第二步
将4-溴噻唑-2-羧酸甲酯5B(970mg,4.37mmol)溶解于四氢呋喃(30mL)中，冷却至0℃。向反应液中滴加甲基溴化镁(3M,4.37mL)，恢复至室温，继续搅拌5小时。向反应液中加入饱和氯化铵(15mL)溶液，乙酸乙酯(15mL×2)萃取，有机相合并，干燥，浓缩，残余物用用硅胶柱色谱法(洗脱剂体系A)分离得到产物2-(4-溴噻唑-2-基)丙烷-2-醇5C(805mg,)，产率：83.0％。
MS m/z(ESI):222.1,224.1[M+H]+.
第三步
将2-(4-溴噻唑-2-基)丙烷-2-醇5C(100mg,0.45mmol)，联硼酸频那醇酯(137.2mg,0.54mmol)，三(二亚苄基丙酮)二钯(20.6mg,0.02mmol)，2-二环己基膦-2’,4’,6’-三异丙基联苯(25.8mg,0.05mmol)和醋酸钾(88.4mg,0.9mmol)溶解于无水1，4-二氧六环(9mL)中，氮气置换1分钟，反应加热至110C搅拌2小时。冷却至室温，反应液过滤，滤液浓缩，残余物经反相HPLC(甲酸体系)制备得到标题产物(2-(2-羟基丙烷-2-基)噻唑-4-基)硼酸中间体5(65mg)，产率：77.2％。
MS m/z(ESI):188.1[M+H]+.
中间体6
2-(氯甲基-d2)-3,5-二氟吡啶
第一步
冰浴下将氘化锂铝(388mg，9.24mmol)分批加入到甲基3,5-二氟吡啶-2-羧酸酯(1.00g，5.78mmol)的四氢呋喃(20mL)溶液中。反应在室温下搅拌2小时。将反应使用冰块淬灭，反应液过滤。滤液浓缩，残余物用硅胶柱色谱法(洗脱剂体系B)分离得到产物(3,5-二氟吡啶-2-基)甲烷-d2-醇6A(345mg)，产率：40.6％。
MS m/z(ESI):148.0[M+H]+.
第二步
搅拌下将二氯亚砜(839mg，7.06mmol)滴加到(3,5-二氟吡啶-2-基)甲烷-d2-醇6A(346mg，2.35mmol)的二氯甲烷(5mL)和N，N-二甲基甲酰胺(0.1mL) 溶液中。反应在室温下搅拌3小时。将反应液使用乙酸乙酯(160mL)稀释，有机相用饱和碳酸氢钠和水洗涤。有机相浓缩，残余物用硅胶柱色谱法(洗脱剂体系B)分离得到产物2-(氯甲基-d2)-3,5-二氟吡啶中间体6(150mg)，产率：38.5％。
MS m/z(ESI):166.0[M+H]+.
中间体7
1-(2-溴-5-甲基-4-吡啶基)-3-氯-4-羟基-6-甲基-吡啶-2-酮
第一步
将2-溴-5-甲基-吡啶-4-胺7A(2.03g,10.86mmol)和2,2-二甲基-6-(2-羰基丙基)-4H-1,3-二噁英-4-酮(2g,10.86mmol)溶解于1，4-二氧六环(80mL)中搅拌。将反应置于预加热至90℃的反应器中搅拌3小时。向反应液中加入浓硫酸(1.8g,18.35mmol)，继续搅拌1小时。反应液冷却，移除上清液，向残余油状物加入水。混合物在室温下搅拌30分钟，过滤得到2'-溴-4-羟基-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮7B(1.7g)，产率：53％。
MS m/z(ESI):296.1[M+H]+.
第三步
将2'-溴-4-羟基-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮7B(1.7g,5.76mmol)溶解于异丙醇(40mL)和1，2-二氯乙烷(60mL)中加热至60℃搅拌。向反应液分批加入N-氯代丁二酰胺(923mg,6.91mmol)，继续搅拌2小时。反应液浓缩，向残余物加入异丙醇(20mL)，混合物加热至60℃搅拌0.5小时。反应液冷却，过滤得到1-(2-溴-5-甲基-4-吡啶基)-3-氯-4-羟基-6-甲基-吡啶-2-酮中间体7(1.71g)，产率：90.1％。
MS m/z(ESI):330.9[M+H]+.
中间体8
2'-溴-3-氯-4-((3,5-二氟吡啶-2-基)甲氧基-d2)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮
第一步
将1-(2-溴-5-甲基-4-吡啶基)-3-氯-4-羟基-6-甲基-吡啶-2-酮中间体7(550g,1.67mmol)，中间体6(387mg,2.34mmol)，碳酸钾(577mg,4.17mmol)和18-冠-6醚(662mg,2.50mmol)溶解于N,N-二甲基甲酰胺(25mL)中加热至70℃搅拌3小时。向反应液中加入乙酸乙酯(50mL)，有机相用水和饱和氯化钠洗涤，干燥，浓缩。残余物用硅胶色谱柱纯化(洗脱体系A)得到2'-溴-3-氯-4-((3,5-二氟吡啶-2-基)甲氧基-d2)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮中间体8(540mg)，产率：70.6％。
MS m/z(ESI):458.0[M+H]+.
中间体9
N-(2-(4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺
第一步
冰浴下，将4-氟-1H-吡唑-3-甲酸甲酯(600mg，4.16mmol)溶解在无水四氢呋喃(20mL)中，搅拌下向反应液中滴加甲基溴化镁的四氢呋喃溶液(3M，6.9mL，20.7mmol)，反应在室温下搅拌3小时。将反应液倒入饱和氯化铵溶液(50mL)中，水相用乙酸乙酯萃取(50mL×3)。有机相合并，依次用水(50 mL)和饱和氯化钠溶液(50mL)洗涤，干燥，浓缩，得到2-(4-氟-1H-吡唑-3-基)丙烷-2-醇9A(600mg)，产物不经纯化直接用于下步反应。
MS m/z(ESI):145.1[M+H]+.
第二步
将9A(600mg,4.17mmol)溶解在乙腈(15mL)中搅拌，0℃下向反应液中滴加浓硫酸(5mL)，反应升温至室温搅拌3小时。将反应液倒入饱和碳酸氢钠溶液(100mL)中，水相用乙酸乙酯萃取(50mL×3)。有机相合并，依次用水(50mL)和饱和氯化钠溶液(50mL)洗涤，干燥，浓缩，残余物用硅胶柱色谱法纯化(洗脱体系B)，得到N-(2-(4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺中间体9(510mg)，产率：86.8％。
MS m/z(ESI):186.1[M+H]+.
中间体10
2'-溴-3-氯-4-((2,4-二氟苯基)甲氧基-d2)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮
第一步
氮气保护下将中间体7(400mg,1.21mmol)，碳酸钾(503mg,3.64mmol)和18-冠-6(481mg,1.82mmol)溶解于无水N,N-二甲基甲酰胺(6mL)中，加热至75℃搅拌，向反应液中滴加中间体4(300mg,1.82mmol)。反应在75℃下搅拌1小时。向反应液中加入水(50mL)，水相用乙酸乙酯萃取(50mL×2)。有机相合并，依次用水(50mL)和饱和氯化钠溶液(50mL)洗涤，干燥，滤液浓缩，残余物用硅胶柱色谱法(洗脱体系B)分离得到2'-溴-3-氯-4-((2,4-二氟 苯基)甲氧基-d2)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮中间体10(480mg)，产率：86.4％。
MS m/z(ESI):457.0[M+H]+.
参考例1
3-氯-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-2'-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5'-甲基-2H-[1,4'-联吡啶]-2-酮
第一步
将2,2,6-三甲基-4H-1,3-二噁英-4-酮1-a(8.16g,57.40mmol)溶解于四氢呋喃(60mL)中，冷却至-78℃。向反应液中滴加双三甲基硅基胺基锂(1M,63mL)，滴加完成后，反应在-78℃搅拌1小时。向反应液中滴加环丙基甲酰氯(3g,28.70mmol,2.60mL)的四氢呋喃(10mL)溶液，反应在-78℃搅拌16小时。冰浴下向反应液中加入饱和氯化铵溶液(30mL)淬灭反应，并用稀盐酸调节pH至弱酸性，有机相分离，水相用乙酸乙酯(30mL×2)萃取。有机相合并，干燥，浓缩。残余物用硅胶柱色谱法(洗脱剂体系B)分离得到产物6-(2-环丙基-2-羰基乙基)-2,2-二甲基-4H-1,3-二噁英-4-酮1-b(2.93g)，产率：48％。
MS m/z(ESI):211.1[M+H]+.
第二步
将6-(2-环丙基-2-羰基乙基)-2,2-二甲基-4H-1,3-二噁英-4-酮1-b(700mg,3.33mmol)和2-氯-4-氨基-5-甲基吡啶(617mg,4.33mmol)溶解于1,4-二氧六环(10mL) 中，反应加热至90℃搅拌3.5小时。向反应液中加入浓硫酸(0.25mL)，反应在90℃搅拌1小时。向反应液中加入水(10mL)，经反相HPLC制备分离(甲酸体系)得到产物2'-氯-6-环丙基-4-羟基-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-c(318mg)，产率：34.5％。
MS m/z(ESI):277.1[M+H]+.
第三步
将2'-氯-6-环丙基-4-羟基-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-c(318mg,1.15mmol)，2-(氯甲基)-3,5-二氟-吡啶(226mg,1.38mmol)，碳酸钾(397mg,2.87mmol)和18-冠-6(30mg,0.11mmol)溶解于N,N-二甲基甲酰胺(5mL)中。反应加热至60℃搅拌3小时。向反应液中加入水(20mL)，水相用乙酸乙酯(20mL×2)萃取。有机相合并，干燥，浓缩。残余物用硅胶柱色谱法(洗脱剂体系A)分离得到产物2'-氯-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-d(380mg)，产率：81％。
MS m/z(ESI):404.1[M+H]+.
第四步
将2'-氯-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-d(150mg,0.37mmol)，三丁基(1-乙氧基乙烯基)锡烷(148mg,0.41mmol)和双三苯基膦二氯化钯(26mg,0.04mmol)溶解于1,4-二氧六环(3mL)中，氮气置换2分钟。反应用微波加热至130℃搅拌2小时。反应液过滤，滤液浓缩。残余物用四氢呋喃(3mL)溶解，并滴加稀盐酸(2M，1mL)反应至原料完全水解。向反应液中加入饱和碳酸氢钠溶液调节pH至弱碱性，水相用乙酸乙酯(20mL×2)萃取。有机相合并，干燥，浓缩，残余物用硅胶柱色谱法(洗脱剂体系A)分离得到产物2'-乙酰基-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-e(90mg)，产率：58.9％。
MS m/z(ESI):412.1[M+H]+.
第五步
将2'-乙酰基-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-e(90mg,0.22mmol)和N-氯代丁二酰亚胺(32mg,0.24mmol)溶解于异丙醇(2mL)中，反应加热至60℃搅拌3小时。反应液浓缩，残余物用硅胶柱色谱法(洗脱剂体系B)分离得到产物2'-乙酰基-3-氯-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-f(90mg)，产率：92％。
MS m/z(ESI):446.1[M+H]+.
第六步
将2'-乙酰基-3-氯-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-f(90mg,0.2mmol)和N,N-二甲基甲酰胺二甲基缩醛(72mg,0.61 mmol)溶解于N,N-二甲基甲酰胺(2mL)中，反应加热至50℃搅拌16小时。向反应液中加入水(10mL)，水相用乙酸乙酯(15mL×2)萃取，有机相合并，干燥，浓缩得到粗产品(E)-3-氯-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-2'-(3-(二甲氨基)丙烯酰)-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-g(80mg)，产品不经纯化直接用于下一步反应。
MS m/z(ESI):501.1[M+H]+.
第七步
将(E)-3-氯-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-2'-(3-(二甲氨基)丙烯酰)-5'-甲基-2H-[1,4'-联吡啶]-2-酮1-g(80mg,0.16mmol)，2-羟基-2-甲基丙脒盐酸(33mg,0.24mmol)和碳酸钾(44mg,0.32mmol)溶解于N,N-二甲基甲酰胺(2mL)中，反应加热至75℃搅拌16小时。冷却至室温，过滤，滤液经反相HPLC制备分离(甲酸体系)得到标题产物3-氯-6-环丙基-4-((3,5-二氟吡啶-2-基)甲氧基)-2'-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5'-甲基-2H-[1,4'-联吡啶]-2-酮参考例1(55mg)，产率：63.8％。
MS m/z(ESI):540.1[M+H]+.
1H NMR(400MHz,DMSO-d6)δ8.96(d,1H),8.85(s,1H),8.75(s,1H),8.62(d,1H),8.24(d,1H),8.15-8.05(m,1H),6.47(s,1H),5.53(d,2H),5.24(s,1H),2.13(s,3H),1.53(d,6H),1.36-1.23(m,1H),1.02-0.93(m,1H),0.92-0.81(m,1H),0.75-0.63(m,2H).
参考例2
3-氯-4-((3,5-二氟吡啶-2-基)甲氧基)-2'-(2-(2-羟基丙烷-2-基)噻唑-4-基)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮

第一步
氮气保护下，将中间体1(50mg,0.12mmol)，中间体5(50.8mg,0.17mmol，纯度：62％)，1,1-双(二苯基膦)1,1'-双二苯基膦二茂铁二氯化钯(8.9mg,0.01mmol)和碳酸铯(79mg,0.24mmol)溶解于1，4-二氧六环(1mL)和水(0.3mL)混合溶剂中。反应加热至100℃搅拌3小时。反应液浓缩，残余物用硅胶柱色谱法(洗脱剂体系B)分离得到标题产物3-氯-4-((3,5-二氟吡啶-2-基)甲氧基)-2'-(2-(2-羟基丙烷-2-基)噻唑-4-基)-5',6-二甲基-2H-[1,4'-联吡啶]-2-酮参考例2(32mg)，产率：50.8％。
MS m/z(ESI):519.1[M+H]+.
1H NMR(400MHz,DMSO-d6)δ8.70(s,1H),8.61(d,1H),8.18(s,1H),8.15-8.05(m,1H),7.86(s,1H),6.80(s,1H),6.06(s,1H),5.48(d,2H),2.03(s,3H),1.97(s,3H),1.55(d,6H).
实施例1
11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮

第一步
在-50℃下，搅拌下将双三甲基硅基胺基锂(66.1mL，1M的四氢呋喃溶液)滴加到2,2,6-三甲基-4H-1,3-二氧-4-酮1a(9.50g，66.8mmol)的四氢呋喃(20mL)溶液中。反应在-50℃下搅拌1小时后，将4-烯戊酰氯(4.40g，37.11mmol)滴加到反应液中，继续搅拌1小时。将反应液使用甲酸淬灭，过滤，滤液浓缩，残余物用硅胶柱色谱法(洗脱剂体系A)分离得到标题产物2,2-二甲基-6-(2-氧代己-5-烯-1-基)-4H-1,3-二氧-4-酮1b(3.60g)，产率：43.3％。
MS m/z(ESI):225.1[M+H]+.
第二步
氮气保护下，将1j(1.50g，5.89mmol)，三丁基乙烯基锡(2.43g，7.66mmol)和1,1-双(二苯基膦)二荗铁二氯化钯(431mg,0.59mmol)溶解在1，4-二氧六环(15mL)中，密封到微波管中，反应微波加热到100℃搅拌2小时。将反应液浓缩，残余物用硅胶柱色谱法(洗脱剂体系A)分离得到标题产物2-氯-4-胺基-5-乙烯基吡啶1k(460mg)，产率：50.5％。
MS m/z(ESI):155.0[M+H]+.
第三步
将1b(6.70g，29.88mmol)和1k(3.08g，19.92mmol)溶解在1，4-二氧六环(80mL)中加热至100℃搅拌1.5小时。将浓硫酸(4.88g，49.80mmol)缓慢滴加到反应液中，反应在100℃下继续搅拌2小时。将反应液浓缩，向残余物加入甲醇和水，过滤，滤液浓缩，使用反相HPLC制备分离(甲酸体系)分离得到 标题产物6-(丁-3-烯-1-基)-2'-氯-4-羟基-5'-乙烯基-2H-[1,4'-联吡啶]-2-酮1c(3.80g)，产率：63.0％。
MS m/z(ESI):303.1[M+H]+.
第四步
氮气保护下，将1c(334mg，1.11mmol)和Grubbs二代催化剂(93mg,0.11mmol)溶解在1，2-二氯乙烷(300mL)中，反应加热到60℃搅拌2小时。向反应液中加入甲醇(10mL)，浓缩，残余物用硅胶柱色谱法(洗脱剂体系A)分离得到标题产物(Z)-2-氯-10-羟基-7,8-二氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮1d(110mg)，产率：36.0％。
MS m/z(ESI):275.0[M+H]+.
第五步
在氢气氛围下，将1d(300mg，0.19mmol)和二氧化铂(25mg,0.19mmol)溶解在四氢呋喃(20mL)中，反应于25℃搅拌3小时。将反应液过滤，滤液浓缩，残余物用硅胶柱色谱法(洗脱剂体系A)分离得到标题产物2-氯-10-羟基-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮1e(200mg)，产率：66.2％。
MS m/z(ESI):277.1[M+H]+.
第六步
将1e(480mg，1.76mmol)和N-氯代丁二酰亚胺(347mg，2.61mmol)溶解在异丙醇(20mL)中，反应加热至35℃搅拌1小时。反应液浓缩，残余物用硅胶柱色谱法(洗脱剂体系A)分离得到标题产物2,11-二氯-10-羟基-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮1f(200mg)，产率：64.3％。
MS m/z(ESI):311.0[M+H]+.
第七步
将1f(168mg，0.54mmol)，碳酸钾(149mg，1.08mmol)和中间体6(119mg,0.81mmol)溶解在N,N-二甲基甲酰胺(5mL)中，反应加热至70℃搅拌16小时。将反应液浓缩，残余物用反相HPLC制备分离(甲酸体系)分离得到标题产物2,11-二氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3'，4'-g]氮唑-12-酮1g(172mg)，产率：72.4％。
MS m/z(ESI):40.1[M+H]+.
第八步
氮气保护下，将1g(150mg，0.34mmol)，三丁基(1-乙氧基乙烯基)锡烷(185mg，0.51mmol)和二(三苯基膦)二氯化钯(24mg,0.03mmol)溶解在1，4-二氧六环(5mL)溶液中，反应用微波加热至123℃搅拌2小时。将反应液使用稀盐酸(0.6M，0.5mL)淬灭，室温搅拌30分钟，浓缩，残余物用反相HPLC制备分离(甲酸体系)分离得到标题产物2-乙酰基-11-氯-10-((3,5-二氟吡啶-2-基)甲 氧基-d2)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3'，4'-g]氮唑-12-酮1h(132mg)，产率：86.5％。
MS m/z(ESI):448.1[M+H]+.
第九步
将1h(160mg，0.36mmol)的N,N-二甲基甲酰胺(2mL)和1,1-二甲氧基-N，N-二甲基甲胺(2mL)溶液升温到70℃搅拌16小时。将反应液浓缩，残余物用反相HPLC制备分离(甲酸体系)分离得到标题产物(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(二甲氨基)丙烯酰基)-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮1i(85mg)，产率：47.3％。
MS m/z(ESI):503.2[M+H]+.
第十步
将1i(85mg,0.17mmol)，2-羟基-2-甲基丙脒盐酸盐(70mg,0.51mmol)和碳酸钾(70mg,0.51mmol)溶解于N,N-二甲基甲酰胺(3mL)中，反应加热至75℃搅拌16小时。将反应液冷却至室温，过滤，滤液用反相HPLC制备分离(甲酸体系)得到标题产物11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮1(50mg)，产率：54.6％。
MS m/z(ESI):542.2[M+H]+.
1H NMR(400MHz,CD3OD)δ8.90(d,1H),8.86(s,1H),8.54(s,1H),8.46(d,1H),8.29(d,1H),7.73(m,1H),6.84(s,1H),2.90(m,2H),2.26(m,3H),2.04(m,1H),1.62(m,8H).
实施例1的拆分
(S)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮和(R)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮
实施例1(50mg，0.091mmol)经手性拆分(OD柱)得到1-1(20mg，R.T＝3.807min)，产率：40.0％；1-2(20mg，R.T＝7.060min)，产率：40.0％。
实施例1-1：MS m/z(ESI):542.2[M+H]+；
1H NMR(400MHz,CD3OD)δ8.90(d,1H),8.86(s,1H),8.54(s,1H),8.46(d,1H),8.29(d,1H),7.73(m,1H),6.84(s,1H),2.90(m,2H),2.26(m,3H),2.04(m,1H),1.62(m,8H).
实施例1-2：MS m/z(ESI):542.2[M+H]+；
1H NMR(400MHz,CD3OD)δ8.90(d,1H),8.86(s,1H),8.54(s,1H),8.46(d,1H),8.29(d,1H),7.73(m,1H),6.84(s,1H),2.90(m,2H),2.26(m,3H),2.04(m,1H),1.62(m,8H).
HPLC手性拆分条件：
HPLC手性分析条件：
实施例2
11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮

第一步
氮气保护下，将2-溴-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3'，4'-g]氮唑-12-酮2a(50mg，0.10mmol，其合成方法参照实施例1中1g的合成)，中间体2(20mg，0.15mmol)，碳酸铯(50mg，0.15mmol)，和碘化亚铜(10mg，0.05mmol)溶解在1，4-二氧六环(3mL)中，反应加热至100℃搅拌2小时。将反应液浓缩，残余物用硅胶柱色谱法(洗脱剂体系A)分离得到11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮2(41mg)，产率：75.0％。
MS m/z(ESI):530.2[M+H]+.
1H NMR(400MHz,DMSO-d6)δ8.60(m,2H),8.52(d,1H),8.10(m,1H),7.70(s,1H),6.80(s,1H),6.56(d,1H),5.13(s,1H),2.85(m,2H),2.09(m,3H),1.90(m,1H),1.47(m,8H).
实施例2的拆分
(S)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮和(R)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-5,6,7,8-四氢-12H-二吡啶并[1，2-a:3'，4'-g]氮唑-12-酮
实施例2(80mg，0.151mmol)经手性拆分(IB柱)得到2-1(35mg，R.T＝3.677min)，产率：43.7％；2-2(30mg，R.T＝6.300min)，产率：37.5％。
实施例2-1：MS m/z(ESI):530.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.60(m,2H),8.52(d,1H),8.10(m,1H),7.70(s,1H),6.80(s,1H),6.56(d,1H),5.13(s,1H),2.85(m,2H),2.09(m,3H),1.90(m,1H),1.47(m,8H).
实施例2-2：MS m/z(ESI):530.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.60(m,2H),8.52(d,1H),8.10(m,1H),7.70(s,1H),6.80(s,1H),6.56(d,1H),5.13(s,1H),2.85(m,2H),2.09(m,3H),1.90(m,1H),1.47(m,8H).
HPLC手性拆分条件：
HPLC手性分析条件：
实施例3
N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺

第一步
氮气保护下，将2a(100mg,0.206mmol)，中间体9(52mg,0.280mmol)，碘化亚铜(19.64mg,0.103mmol)，(1R，2R)-N1，N2-二甲基环己烷-1,2-二胺(23.48mg,0.165mmol)和碳酸铯(100.58mg,0.309mmol)溶解于1，4-二氧六环(2mL)中，反应液加热至100℃搅拌0.5小时。将反应液过滤，浓缩。残余物用硅胶柱色谱法纯化(洗脱体系C)得到N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺3(90mg),产率74.1％。
MS m/z(ESI):589.2[M+H]+.
实施例3的拆分
(S)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺和(R)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺
实施例3(90mg，0.152mmol)经手性拆分(OD柱)得到3-1(20.4mg，R.T＝3.403min)，产率：22.35％；3-2(21.9mg，R.T＝4.447min)，产率：23.56％。
实施例3-1：MS m/z(ESI):589.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.64–8.51(m,3H),8.15–8.04(m,2H),7.68(s,1H),6.79(s,1H),2.93–2.76(m,2H),2.15–1.89(m,4H),1.79(s,3H),1.57(d,6H),1.53–1.29(m,2H).
实施例3-2：MS m/z(ESI):589.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.64–8.54(m,3H),8.15–8.06(m,2H),7.68(s,1H),6.79(s,1H),2.93–2.76(m,2H),2.16–1.89(m,4H),1.79(s,3H),1.57(d,6H),1.50–1.29(m,2H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例4
N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺
参照实施例1的合成方法，合成得到目标产物N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺4。
MS m/z(ESI):583.2[M+H]+；
实施例4的拆分
(S)-N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺和 (R)-N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺
实施例4(26mg，0.047mmol)经手性拆分(IB柱)得到4-1(5mg，R.T＝4.387min)，产率：19.23％；4-2(5mg，R.T＝5.183min)，产率：19.23％。
实施例4-1：MS m/z(ESI):583.2[M+H]+；
实施例4-2：MS m/z(ESI):583.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.94–8.83(m,2H),8.61(d,1H),8.24(d,2H),8.16(d,1H),8.10(ddd,1H),6.81(s,1H),2.98(dd,1H),2.80(dd,1H),2.21–2.05(m,3H),1.95–1.82(m,1H),1.77(s,3H),1.60(d,6H),1.48–1.29(m,2H).
HPLC手性拆分条件：
HPLC手性分析条件：
实施例5
N-(2-(3”-氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-5',6”-二甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺
第一步
在0℃下向2-氧代-1,2-二氢-3-吡啶羧酸甲酯5a(300mg,1.96mmol)的四氢呋喃(8mL)溶液中滴加甲基溴化镁(3M,2.61mL)，反应升至室温搅拌1.5小时。将反应液冷却至0℃，向反应液中滴加饱和氯化铵溶液淬灭反应。水相用乙酸乙酯(25mL×4)萃取，有机相合并，干燥，浓缩，残余物经硅胶柱色谱法(洗脱体系B)分离得到3-(2-羟基丙烷-2-基)吡啶-2(1H)-酮5b(173mg)，产率：57.65％。
MS m/z(ESI):154.1[M+H]+；
第二步
向5b(150mg,0.98mmol)的乙腈(2mL)溶液中滴加浓硫酸(960mg,9.8mmol)，反应升至室温，搅拌3小时。0℃下向以上反应液中加入饱和碳酸氢钠溶液，调节pH至弱碱性。反应液浓缩，残余物经硅胶柱色谱法(洗脱体系B)分离得到N-(2-(2-羰基-1,2-二氢吡啶-3-基)丙烷-2-基)乙酰胺5c(168mg)，产率：88.33％。
MS m/z(ESI):195.2[M+H]+；
第三步
氮气保护下，将中间体8(60mg,0.13mmol)，5c(33mg,0.17mmol)，碘化亚铜(10mg,0.05mmol)和碳酸钾(18mg,0.13mmol)溶解于N,N二甲基乙酰胺(1mL)中，反应加热至120℃，搅拌6小时。向反应液中加入饱和氯化氨溶液，水相用乙酸乙酯(20mL×2)萃取，有机相合并，干燥，浓缩，残余物经反相HPLC制备得到N-(2-(3”-氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-5',6”-二甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺5(35mg)，产率：46.78％。
MS m/z(ESI):572.2[M+H]+；
实施例5的拆分
(S)-N-(2-(3”-氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-5',6”-二甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺和(R)-N-(2-(3”-氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-5',6”-二甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺
实施例5(33mg,0.06mmol)经手性拆分(IB柱)得到标题产物5-1(11.1mg，R.T＝5.100min)，产率：33.64％；5-2(11mg，R.T＝6.173min)，产率：33.33％。
实施例5-1，MS m/z(ESI):572.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.68(s,1H),8.60(d,1H),8.14-8.04(m,1H),7.88-7.80(m,2H),7.75(s,1H),7.39-7.30(m,1H),6.79(s,1H),6.36(t,1H),2.07(s,3H),2.00(s,3H),1.81(s,3H),1.61-1.58(m,6H).
实施例5-2，MS m/z(ESI):572.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.68(s,1H),8.60(d,1H),8.14-8.04(m,1H),7.88-7.80(m,2H),7.75(s,1H),7.39-7.30(m,1H),6.79(s,1H),6.36(t,1H),2.07(s,3H),2.00(s,3H),1.81(s,3H),1.61-1.58(m,6H).
HPLC手性拆分条件：
HPLC手性分析方法：

实施例6
N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺
第一步
氮气保护下，将6a(4g，27.3mmol)溶解在无水乙腈(60mL)中，加入N-碘代丁二酰亚胺(7.37g,32.8mmol)和对甲苯磺酸(235mg,1.36mmol)，反应加热至80℃搅拌16小时。反应液冷却至室温，用乙酸乙酯(100mL)稀释，然后依次用饱和亚硫酸钠溶液(80mL)、水(80mL)和饱和氯化钠溶液(80mL)洗涤，干燥，浓缩，残余物用硅胶柱色谱法纯化(洗脱体系A)，得到2-氯-3-氟-5-碘-吡啶-4-胺6b(6.5g)，产率：87.4％。
MS m/z(ESI):272.9[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.10(s,1H),6.69(s,2H).
第二步
氮气保护下，将6b(4g,14.7mmol)溶解在1，4-二氧六环(60mL)和水(12mL)中，加入乙烯三氟硼酸钾(2.36g,17.6mmol)，1,1-双(二苯基膦)二茂铁二氯化钯(533mg,0.734mmol)和碳酸钠(3.89g,36.7mmol)，反应加热至80℃搅拌4小时。反应液冷却至室温，用乙酸乙酯(100mL)稀释后，依次用水(60mL)和饱和氯化钠溶液(60mL)洗涤，干燥，过滤，浓缩，残余物用 硅胶柱色谱法纯化(洗脱体系B)，得到2-氯-3-氟-5-乙烯基-吡啶-4-胺6c(2.1g)，产率：82.9％。
MS m/z(ESI):173.0[M+H]+；
1H NMR(400MHz,DMSO-d6)δ7.98(s,1H),6.82(dd,1H),6.62(s,2H),5.78(dd,1H),5.33(dd,1H).
第三步
将6c(1g,5.79mmol)溶解在1，4-二氧六环(15mL)中，加入1b(1.30g,5.79mmol)，反应加热至100℃搅拌2小时。向反应液中加入浓硫酸(1.42g,0.772mL)，反应在100℃下继续搅拌0.5小时。反应液冷却至室温，用乙酸乙酯(50mL)稀释后，依次用水(50mL)、饱和氯化钠溶液(50mL)洗涤，干燥，浓缩，残余物用硅胶柱色谱法纯化(洗脱体系B)，得到6-(丁-3-烯-1-基)-2'-氯-3'-氟-4-羟基-5'-乙烯基-2H-[1,4'-联吡啶]-2-酮6d(1.1g)，产率：59.2％。
MS m/z(ESI):321.0[M+H]+；
1H NMR(400MHz,DMSO-d6)δ11.13(s,1H),8.80(s,1H),6.29–6.22(m,1H),6.08-6.00(m,2H),5.67-5.58(m,3H),4.95-4.89(m,2H),2.19-2.16(m,2H),2.13-2.09(m,2H).
第四步
将6d(100mg，0.312mmol)溶解在N,N-二甲基甲酰胺(3mL)中，加入中间体6(77mg,0.468mmol)、18-冠-6(124mg，0.468mmol)和碳酸钾(129mg,0.935mmol)，反应加热至75℃搅拌2小时。反应液冷却至室温，用乙酸乙酯萃取(50mL)，有机相依次用水(30mL×2)、饱和氯化钠溶液(30mL)洗涤，干燥，浓缩，残余物用硅胶柱色谱法纯化(洗脱体系B)，得到6-(丁-3-烯-1-基)-2'-氯-4-((3,5-二氟吡啶-2-基)甲氧基-d2)-3'-氟-5'-乙烯基-2H-[1,4'-联吡啶]-2-酮6e(110mg)，产率：78.4％。
MS m/z(ESI):450.1[M+H]+；
第五步
将6e(110mg,0.245mmol)和Grubbs二代催化剂(21mg，0.0245mmol)溶解在1，2-二氯乙烷(80mL)中，反应在氮气保护下加热至40℃搅拌1小时。反应液冷却至室温，浓缩，残余物用硅胶柱色谱法纯化(洗脱体系B)，得到(Z)-2-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮6f(95mg)，产率：92.1％。
MS m/z(ESI):422.1[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.59(d,1H),8.32(s,1H),8.10-8.05(m,1H),6.43(d,1H),6.19(d,1H),6.04(d,1H),6.03–5.98(m,1H),2.72-2.64(m,2H),2.59–2.52(m,1H),2.47-2.41(m,1H).
第六步
将6f(95mg，0.225mmol)和二氧化铂(5mg，0.0225mmol)溶解在四氢呋喃(3mL)中，反应用氢气置换3次，然后在氢气氛围下室温搅拌2小时。反应液过滤，浓缩，残余物用硅胶柱色谱法纯化(洗脱体系B)，得到2-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮6g(90mg)，产率：94.3％。
MS m/z(ESI):424.1[M+H]+；
第七步
将6g(90mg，0.212mmol)和N-氯代丁二酰亚胺(34mg，0.255mmol)溶解在1，2-二氯乙烷(9mL)和异丙醇(3mL)中，反应加热至60℃反应2小时。反应液冷却至室温，依次用水(20mL)、饱和氯化钠溶液(20mL)洗涤，干燥，浓缩，残余物用硅胶柱色谱法纯化(洗脱体系B)，得到2,11-二氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮6h(90mg)，产率：92.5％。
MS m/z(ESI):458.0[M+H]+；
1H NMR(400MHz,CDCl3)δ8.39(d,1H),8.26(s,1H),7.35-7.30(m,1H),6.43(s,1H),2.93–2.88(m,1H),2.80-2.75(m,1H),2.28-2.17(m,3H),2.05-1.95(m,1H),1.62-1.45(m,2H).
第八步
氮气保护下，将6h(100mg，0.218mmol)，中间体9(81mg，0.436mmol)，碳酸铯(213mg，0.655mmol)，碘化亚铜(62mg，0.327mmol)和反式-N,N-二甲基-1,2-环己二胺(31mg，0.218mmol)溶解在1,4-二氧六环(2mL)中，反应加热至100℃搅拌16小时。反应液冷却至室温，过滤，滤液用乙酸乙酯(50mL)稀释后，依次用水(30mL)、饱和氯化钠溶液(30mL)洗涤，干燥，浓缩，残余物用反相柱色谱法(洗脱剂体系C)纯化，得到N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺6(40mg)，产率：30.2％。
MS m/z(ESI):607.2[M+H]+；
实施例6的拆分
(R)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺和(S)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺
实施例6(40mg，0.066mmol)经手性拆分(IB柱)得到6-1(13.2mg，R.T＝4.940min)，产率：33.0％；6-2(15.8mg，R.T＝7.710min)，产率：21.3％。
实施例6-1：MS m/z(ESI):607.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.60(d,1H),8.50(s,1H),8.45(d,1H),8.13-8.07(m,2H),6.86(s,1H),3.03-2.98(m,1H),2.86-2.80(m,1H),2.18-1.99(m,4H),1.79(s,3H),1.61-1.50(m,7H),1.40-1.34(m,1H).
实施例6-2：MS m/z(ESI):607.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.60(d,1H),8.50(s,1H),8.45(d,1H),8.13-8.07(m,2H),6.86(s,1H),3.03-2.98(m,1H),2.86-2.80(m,1H),2.18-1.99(m,4H),1.79(s,3H),1.61-1.50(m,7H),1.40-1.34(m,1H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例7
N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺
第一步
氮气保护下，将6h(90mg,0.196mmol)溶解在1,4-二氧六环(2mL)中，加入三丁基(1-乙氧基乙烯)锡(75mg,0.206mmol)和双三苯基磷二氯化钯(14mg,0.019mmol)，混合液予微波反应器中在125℃下反应2小时。反应液冷却至室温，加入稀盐酸(0.2M，1mL)搅拌1小时。反应液用乙酸乙酯(50mL)稀释后，依次用饱和碳酸氢钠溶液(30mL)和饱和氯化钠溶液(30mL)洗涤，有机相干燥，浓缩，残余物用硅胶柱色谱法纯化(洗脱体系B)，得到2-乙酰基-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮7a(90mg)，产率：98.4％。
MS m/z(ESI):466.1[M+H]+.
第二步
氮气保护下，将7a(90mg,0.193mmol)溶解在N,N-二甲基甲酰胺(2mL)中，加入N,N-二甲基甲酰胺二甲基缩醛(115mg,0.966mmol)，反应加热至55℃搅拌6小时。反应液冷却至室温，用乙酸乙酯稀释(50mL)后，依次用水(30mL×2)、饱和氯化钠溶液(30mL)洗涤，干燥，浓缩，得到11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(二甲氨基)丙烯酰)-1-氟-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮7b(110mg)，产品不经纯化直接用于下步反应。
MS m/z(ESI):521.2[M+H]+.
第三步
氮气保护下，将7b(110mg,0.211mmol)溶解在N,N-二甲基甲酰胺(3mL)中，加入N-(1-氨基-1-亚氨基-2-甲基丙烷-2-基)乙酰胺醋酸盐(90mg,0.443mmol，其制备方法参考文献：Chemistry of Heterocyclic Compounds 2020,56(10),1329–1334.)和碳酸钾(146mg,1.06mmol)，反应加热至75℃搅拌16小时。反应冷却至室温，用乙酸乙酯(50mL)稀释后，依次用水(30mL×2)、饱和氯化钠溶液(30mL)洗涤，干燥，浓缩，残余物用制备HPLC(甲酸体系)分离，得到 N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺7(35mg)，产率：27.6％。
MS m/z(ESI):601.2[M+H]+；
实施例7的拆分
(R)-N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺和(S)-N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-6,7,8,12-四氢-5H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺
实施例7(35mg，0.058mmol)经手性拆分(IB柱)得到7-1(10.7mg，R.T＝4.640min)，产率：30.45％；7-2(10.4mg，R.T＝5.473min)，产率：29.54％。
实施例7-1：MS m/z(ESI):601.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.92(d,1H),8.77(s,1H),8.60(d,1H),8.22(s,1H),8.10(ddd,1H),7.93(d,1H),6.86(s,1H),3.05(dd,1H),2.84(dd,1H),2.16(q,3H),2.07–1.94(m,1H),1.76(s,3H),1.59(d,7H),1.49–1.35(m,1H).
实施例7-2：MS m/z(ESI):601.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.92(d,1H),8.77(s,1H),8.60(d,1H),8.22(s,1H),8.10(ddd,1H),7.93(d,1H),6.86(s,1H),3.05(dd,1H),2.84(dd,1H),2.16(q,3H),2.07–1.94(m,1H),1.76(s,3H),1.59(d,7H),1.49–1.35(m,1H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例8
11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
参照实施例6的合成方法，合成得到目标产物11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮8(20mg)，产率：32.1％。
MS m/z(ESI):548.2[M+H]+；
实施例8的拆分
(R)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮和(S)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
实施例8(20mg，0.036mmol)经手性拆分(IB柱)得到8-1(10mg，R.T＝4.923min)，产率：50.0％；8-2(3mg，R.T＝9.473min)，产率：15％。
实施例8-1：MS m/z(ESI):548.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.60(d,1H),8.50(s,1H),8.33(d,1H),8.10(ddd,1H),6.86(s,1H),6.57(d,1H),5.11(s,1H),3.01(dd,1H),2.83(dd,1H),2.20–1.97(m,4H),1.55(d,1H),1.46(d,6H),1.41–1.31(m,1H).
实施例8-2：MS m/z(ESI):548.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.60(d,1H),8.50(s,1H),8.33(d,1H),8.10(ddd,1H),6.86(s,1H),6.57(d,1H),5.11(s,1H),3.01(dd,1H),2.83(dd,1H),2.20–1.97(m,4H),1.55(d,1H),1.46(d,6H),1.41–1.31(m,1H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例9
11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮

第一步
氮气保护下，将7b(100mg,0.192mmol)溶解在N,N-二甲基甲酰胺(2mL)中，加入2-羟基-2-甲基丙脒盐酸盐(80mg,0.576mmol)和碳酸钾(133mg,0.960mmol)，反应加热至75℃搅拌16小时。反应冷却至室温，用乙酸乙酯(50mL)稀释后，依次用水(30mL×2)和饱和氯化钠溶液(30mL)洗涤，有机相干燥，浓缩，残余物经硅胶柱色谱法纯化(洗脱体系B)得到11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮9(50mg)，产率：46.5％。
MS m/z(ESI):560.2[M+H]+.
实施例9的拆分
(R)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮和(S)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
实施例9(50mg，0.089mmol)经手性拆分(IB柱)得到9-1(15.4mg，R.T＝4.973min)，产率：30.8％；9-2(15.8mg，R.T＝8.337min)，产率：31.6％。
实施例9-1：MS m/z(ESI):560.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ9.02(d,1H),8.79(s,1H),8.61(d,1H),8.13-8.08(m,1H),8.03(d,1H),6.87(s,1H),5.09(s,1H),3.09–3.04(m,1H),2.88–2.82(m,1H),2.22–2.11(m,3H),2.06–1.99(m,1H),1.62–1.53(m,1H),1.52(s,6H),1.46-1.39(m,1H).
实施例9-2：MS m/z(ESI):560.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ9.02(d,1H),8.79(s,1H),8.61(d,1H),8.13-8.08(m,1H),8.03(d,1H),6.87(s,1H),5.09(s,1H),3.09–3.04(m,1H),2.88–2.82(m,1H),2.22–2.13(m,3H),2.06–1.99(m,1H),1.62–1.53(m,1H),1.52(s,6H),1.46-1.39(m,1H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例10
3”,5'-二氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-6”-甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮

第一步
氮气保护下，将2',3,5'-三氯-4-羟基-6-甲基-2H-[1,4'-联吡啶]-2-酮(150mg,0.49mmol，其合成方法参照中间体3的合成)，5b(90mg,0.59mmol)和碳酸铯(400mg,1.23mmol)溶解于二甲基亚砜(2mL)中，反应加热至120℃搅拌16小时。将反应液冷却至室温，向反应液中滴加甲酸，调节pH至弱酸性，反应液用饱和氯化钠溶液和乙酸乙酯(25mL×2)萃取，有机相合并，干燥，浓缩，残余物经硅胶柱色谱法(洗脱体系B)分离得到3”,5'-二氯-4”-羟基-3-(2-羟基丙烷-2-基)-6”-甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮10a(147mg)，产率：70.91％。
MS m/z(ESI):422.1[M+H]+；
第二步
将10a(147mg,0.35mmol)，碳酸钾(96mg,0.7mmol)和18-冠-6(138mg,0.52mmol)溶解于N,N-二甲基甲酰胺(2mL)中，反应加热至65℃，搅拌10分钟。向反应液中滴加中间体6(75mg,0.45mmol)，反应在65℃下搅拌2小时。向反应液中加入饱和氯化钠溶液，水相用乙酸乙酯(25mL×2)萃取，有机相合并，干燥，浓缩，残余物经硅胶柱色谱法(洗脱体系B)分离得到3”,5'-二氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-6”-甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮10(127mg)，产率：66.17％。
MS m/z(ESI):551.1[M+H]+；
实施例10的拆分
(S)-3”,5'-二氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-6”-甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮和(R)-3”,5'-二氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-6”-甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮
实施例10(127mg,0.23mmol)经手性拆分(IB柱)得到标题产物10-1(26.2mg，R.T＝5.667min)，产率：20.63％；10-2(22.1mg，R.T＝7.113min)，产率：17.40％。
实施例10-1，MS m/z(ESI):551.1[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.97(s,1H),8.60(d,1H),8.16-8.06(m,2H),7.92-7.86(m,1H),7.75-7.68(m,1H),6.83(s,1H),6.45(t,1H),5.21(s,1H),2.03(s,3H),1.47(d,6H).
实施例10-2，MS m/z(ESI):551.1[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.97(s,1H),8.60(d,1H),8.16-8.06(m,2H),7.92-7.86(m,1H),7.75-7.68(m,1H),6.83(s,1H),6.45(t,1H),5.21(s,1H),2.03(s,3H),1.47(d,6H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例11
3”-氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-5',6”-二甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮
第一步
氮气保护下，将中间体8(85mg,0.19mmol)，3-(2-羟基丙烷-2-基)吡啶-2(1H)-酮5b(37mg,0.24mmol)，碘化亚铜(18mg,0.09mmol)和碳酸钾(26mg,0.19mmol)溶解于N,N二甲基乙酰胺(1.5mL)中，反应加热至120℃搅拌5小时。向反应液中加入饱和氯化氨溶液，水相用乙酸乙酯(20mL×2)萃取，有机相合并，干燥，浓缩，残余物经反相HPLC制备得到3”-氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-5',6”-二甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮11(23mg)，产率：23.38％。
MS m/z(ESI):531.2[M+H]+；
实施例11的拆分
(S)-3”-氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-5',6”-二甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮和(R)-3”-氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-5',6”-二甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮
实施例11(23mg,0.04mmol)经手性拆分(IB柱)得到标题产物11-1(7.4mg，R.T＝4.833min)，产率：32.17％；11-2(8.5mg，R.T＝6.753min)，产率：36.96％。
实施例11-1，MS m/z(ESI):531.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.68(s,1H),8.60(d,1H),8.14-8.05(m,1H),7.88-7.82(m,1H),7.78(s,1H),7.72-7.66(m,1H),6.80(s,1H),6.42(t,1H),5.23(s,1H),2.07(s,3H),2.00(s,3H),1.49-1.44(m,6H).
实施例11-2，MS m/z(ESI):531.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.68(s,1H),8.60(d,1H),8.14-8.05(m,1H),7.88-7.82(m,1H),7.78(s,1H),7.72-7.66(m,1H),6.80(s,1H),6.42(t,1H),5.23(s,1H),2.07(s,3H),2.00(s,3H),1.49-1.44(m,6H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例12
N-(2-(3”,5'-二氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-6”-甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺
第一步
氮气保护下，将2',3,5'-三氯-4-羟基-6-甲基-2H-[1,4'-联吡啶]-2-酮(100mg,0.33mmol)，5c(83mg,0.43mmol)和碳酸铯(320mg,0.98mmol)溶解于二甲基亚砜(2mL)中，反应加热至120℃搅拌16小时。向反应液中加入饱和氯化钠溶液，甲酸调节pH至弱酸性，乙酸乙酯(25mL×3)萃取，有机相合并，干燥，浓缩得到粗产品N-(2-(3”,5'-二氯-4”-羟基-6”-甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺12a(100mg)，不经进一步纯化，直接用于下一步反应中。
MS m/z(ESI):463.1[M+H]+；
第二步
将12a(27mg,0.06mmol)，碳酸钾(16mg,0.12mmol)和18-冠-6(23mg,0.09mmol)溶解于N,N-二甲基甲酰胺(1mL)中，65℃搅拌15分钟，向以上反应液中加入中间体6(14mg,0.09mmol)，65℃搅拌1小时。向反应液中加入饱和氯化钠溶液，乙酸乙酯(25mL×2)萃取，有机相合并，干燥，浓缩，残余物经反相HPLC制备得到N-(2-(3”,5'-二氯-4”-((3,5-二氟吡啶-2-基)甲氧基-d2)-6”-甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺12(15.8mg)，产率：45.77％。
MS m/z(ESI):592.1[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.97(s,1H),8.60(d,1H),8.15-8.06(m,2H),7.92-7.82(m,2H),7.41-7.32(m,1H),6.83(s,1H),6.39(t,1H),2.02(s,3H),1.81(s,3H),1.60(d,6H).
实施例13
N-(2-(3”-氯-4”-((2,4-二氟苯基)甲氧基-d2)-5',6”-二甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺
第一步
氮气保护下，将中间体10(85mg,0.19mmol)，N-(2-(2-羰基-1,2-二氢吡啶-3-基)丙烷-2-基)乙酰胺5c(43mg,0.22mmol)，碘化亚铜(18mg,0.09mmol)和碳酸钾(26mg,0.19mmol)溶解于N,N-二甲基乙酰胺(1.5mL)中，反应加热至120℃搅拌3小时。向反应液中加入饱和氯化钠溶液，乙酸乙酯(25mL×2)萃取，有机相合并，干燥，浓缩，残余物经反相HPLC制备得到N-(2-(3”-氯-4”-((2,4-二氟苯基)甲氧基-d2)-5',6”-二甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺13(40mg)，产率：37.72％。
MS m/z(ESI):571.2[M+H]+；
实施例13的拆分
(S)-N-(2-(3”-氯-4”-((2,4-二氟苯基)甲氧基-d2)-5',6”-二甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺和(R)-N-(2-(3”-氯-4”-((2,4-二氟苯基)甲氧基-d2)-5',6”-二甲基-2,2”-二羰基-2H,2”H-[1,2':4',1”-三联吡啶]-3-基)丙烷-2-基)乙酰胺
实施例13(40mg,0.07mmol)经手性拆分(AD柱)得到标题产物13-1(14.6mg，R.T＝5.173min)，产率：36.50％；13-2(15.6mg，R.T＝8.937min)，产率：39.00％。
实施例13-1，MS m/z(ESI):571.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.68(s,1H),7.88-7.80(m,2H),7.77-7.66(m,2H),7.42-7.31(m,2H),7.25-7.15(m,1H),6.82(s,1H),6.36(t,1H),2.07(s,3H),2.02(s,3H),1.81(s,3H),1.60(d,6H).
实施例13-2，MS m/z(ESI):571.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.68(s,1H),7.88-7.80(m,2H),7.77-7.66(m,2H),7.42-7.31(m,2H),7.25-7.15(m,1H),6.82(s,1H),6.36(t,1H),2.07(s,3H),2.02(s,3H),1.81(s,3H),1.60(d,6H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例14
3”-氯-4”-((2,4-二氟苯基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-5',6”-二甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮
第一步
氮气保护下，将中间体10(70mg,0.15mmol)，5b(28mg,0.18mmol)，碘化亚铜(15mg,0.08mmol)和碳酸钾(21mg,0.15mmol)溶解于N,N-二甲基乙酰胺(1.5mL)中，反应加热至120℃搅拌3小时。向反应液中加入饱和氯化钠溶液，乙酸乙酯(25mL×2)萃取，有机相合并，干燥，浓缩，残余物经反相HPLC制备得到3”-氯-4”-((2,4-二氟苯基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-5',6”-二甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮14(35mg)，产率：43.18％。
MS m/z(ESI):530.2[M+H]+；
实施例14的拆分
(S)-3”-氯-4”-((2,4-二氟苯基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-5',6”-二甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮和(R)-3”-氯-4”-((2,4-二氟苯基)甲氧基-d2)-3-(2-羟基丙烷-2-基)-5',6”-二甲基-2H,2”H-[1,2':4',1”-三联吡啶]-2,2”-二酮
实施例14(35mg,0.07mmol)经手性拆分(IB柱)得到标题产物14-1(12.2mg，R.T＝5.990min)，产率：34.86％；14-2(11.9mg，R.T＝9.167min)，产率：34.00％。
实施例14-1，MS m/z(ESI):530.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.69(s,1H),7.88-7.82(m,1H),7.78(s,1H),7.74-7.65(m,2H),7.43-7.32(m,1H),7.24-7.16(m,1H),6.82(s,1H),6.42(t,1H),5.23(s,1H),2.07(s,3H),2.02(s,3H),1.46(d,6H).
实施例14-2，MS m/z(ESI):530.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.69(s,1H),7.88-7.82(m,1H),7.78(s,1H),7.74-7.65(m,2H),7.43-7.32(m,1H),7.24-7.16(m,1H),6.82(s,1H),6.42(t,1H),5.23(s,1H),2.07(s,3H),2.02(s,3H),1.46(d,6H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例15
11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
第一步
氮气保护下，将2a(100mg,0.21mmol)，5b(41mg,0.27mmol)，(1S,2S)-N1,N2-二甲基环己烷-1,2-二胺(31mg,0.22mmol)，碘化亚铜(20mg,0.1mmol)和碳酸铯(134mg,0.41mmol)溶解于1,4-二氧六环(1.5mL)中，反应加热至100℃搅拌1.5小时。向反应液中加入饱和氯化铵溶液，乙酸乙酯(25mL×2)萃取，有机相合并，干燥，浓缩，残余物经硅胶柱色谱法(洗脱体系B)分离得到白色固体11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮15(105mg),产率：91.38％。
MS m/z(ESI):557.2[M+H]+；
实施例15的拆分
(S)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮和(R)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
实施例15(105mg,0.19mmol)经手性拆分(IB柱)得到标题产物15-1(36.5mg，R.T＝3.977min)，产率：34.76％；15-2(34.3mg，R.T＝5.027min)，产率：32.67％。
实施例15-1，MS m/z(ESI):557.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.75(s,1H),8.60(d,1H),8.13-8.06(m,1H),7.88-7.82(m,1H),7.74-7.67(m,2H),6.80(s,1H),6.42(t,1H),5.21(s,1H),3.02-2.90(m,1H),2.88-2.77(m,1H),2.23-2.04(m,3H),1.95-1.82(m,1H),1.58(d,1H),1.47(s,3H),1.45(s,3H),1.42-1.32(m,1H).
实施例15-2，MS m/z(ESI):557.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.75(s,1H),8.60(d,1H),8.13-8.06(m,1H),7.88-7.82(m,1H),7.74-7.67(m,2H),6.80(s,1H),6.42(t,1H),5.21(s,1H),3.02-2.90(m,1H),2.88-2.77(m,1H),2.23-2.04(m,3H),1.95-1.82(m,1H),1.58(d,1H),1.47(s,3H),1.45(s,3H),1.42-1.32(m,1H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例16
(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
参照实施例1的合成方法，合成得到目标产物(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮16。
MS m/z(ESI):540.2[M+H]+.
1H NMR(400MHz,DMSO-d6)δ8.99(d,1H),8.80(s,1H),8.66–8.57(m,2H),8.26(d,1H),8.11(ddd,1H),6.81(s,1H),6.53(dd,1H),6.03(d,1H),5.29(s,1H),2.76(d,2H),2.57(dd,1H),2.00(q,1H),1.53(d,6H).
实施例16的拆分
(S,Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮和(R,Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
实施例16(20mg,0.037mmol)经手性拆分(OD柱)得到标题产物16-1(8mg，R.T＝3.623min)，产率：40％；16-2(6mg，R.T＝7.39min)，产率：30％。
实施例16-1，MS m/z(ESI):540.2[M+H]+；
实施例16-2，MS m/z(ESI):540.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.99(d,1H),8.80(s,1H),8.66–8.57(m,2H),8.26(d,1H),8.11(ddd,1H),6.81(s,1H),6.53(dd,1H),6.03(d,1H),5.29(s,1H),2.76(d,2H),2.57(dd,1H),2.00(q,1H),1.53(d,6H).
HPLC手性拆分条件：

HPLC手性分析方法：
实施例17
(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
参照实施例2的合成方法，合成得到目标产物(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮17。
MS m/z(ESI):528.2[M+H]+.
实施例17的拆分
(S,Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮和(R,Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
实施例17(80mg,0.152mmol)经手性拆分(OD柱)得到标题产物17-1(36mg，R.T＝3.553min)，产率：45％；17-2(38mg，R.T＝5.693min)，产率：47.5％。
实施例17-1，MS m/z(ESI):528.2[M+H]+；
实施例17-2，MS m/z(ESI):528.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.60(d,1H),8.53(d,1H),8.49(s,1H),8.10(td,1H),7.72(s,1H),6.79(s,1H),6.57(d,1H),6.47–6.39(m,1H),5.99–5.88(m,1H),5.14(s,1H),2.80–2.67(m,2H),2.67–2.52(m,2H),1.47(d,6H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例18
(Z)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-8,12-二氢-7H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺
参照实施例3的合成方法，合成得到目标产物(Z)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-8,12-二氢-7H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺18。
MS m/z(ESI):587.2[M+H]+.
实施例18的拆分
(S,Z)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-8,12-二氢-7H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺和(R,Z)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-12-羰基-8,12-二氢-7H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺
实施例18(86mg,0.147mmol)经手性拆分(OD柱)得到标题产物18-1(32mg，R.T＝3.280min)，产率：37.2％；18-2(32mg，R.T＝4.387min)，产率：37.2％。
实施例18-1，MS m/z(ESI):587.2[M+H]+；
实施例18-2，MS m/z(ESI):587.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.59(dd,2H),8.48(s,1H),8.18–8.02(m,2H),7.71(s,1H),6.78(s,1H),6.44(d,1H),5.99–5.91(m,1H),2.78–2.65(m,2H),2.57(dd,2H),1.79(s,3H),1.58(d,6H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例19
(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
参照实施例15的合成方法，合成得到目标产物(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮19。
MS m/z(ESI):555.2[M+H]+.
实施例19的拆分
(S,Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮和(R,Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
实施例19(76mg,0.137mmol)经手性拆分(IB柱)得到标题产物19-1(33mg，R.T＝5.147min)，产率：43.4％；19-2(27mg，R.T＝7.360min)，产率：35.5％。
实施例19-1，MS m/z(ESI):555.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.64(s,1H),8.60(d,1H),8.09(td,1H),7.87(dd,1H),7.78(s,1H),7.70(dd,1H),6.80(s,1H),6.53–6.38(m,2H),6.06–5.94(m,1H),5.20(s,1H),2.78(d,2H),2.59–2.51(m,2H),1.46(d,6H).
实施例19-2，MS m/z(ESI):555.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.64(s,1H),8.60(d,1H),8.09(td,1H),7.87(dd,1H),7.78(s,1H),7.70(dd,1H),6.80(s,1H),6.53–6.38(m,2H),6.06–5.94(m,1H),5.20(s,1H),2.78(d,2H),2.59–2.51(m,2H),1.46(d,6H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例56
11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮

第一步
将56a(150mg,0.298mmol,其制备方法参考实施例6中6h的合成)溶解在二甲亚砜(1.5mL)中，加入5b(137mg,0.895mmol)，碳酸铯(292mg,0.895mmol)，2-环己酮甲酸乙酯(51mg,0.298mmol)和溴化亚铜(64mg,0.447mmol)，反应在氮气保护下加热至80℃搅拌16小时。反应液冷却至室温，过滤，滤液用乙酸乙酯(30mL)稀释，然后依次用水(30mL)、饱和氯化钠溶液(30mL)洗涤，干燥，浓缩，残余物用反相色谱柱(洗脱剂体系C)纯化，得到11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮56(30mg)，产率：17.5％。
MS m/z(ESI):575.1[M+H]+；
实施例56的拆分
(R)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮和(S)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-2-羰基吡啶-1(2H)-基)-5,6,7,8-四氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
实施例56(30mg，0.066mmol)经手性拆分(OD柱)得到56-1(13.5mg，R.T＝3.543min)，产率：45.0％；56-2(13.2mg，R.T＝5.707min)，产率：44.0％。
实施例56-1：MS m/z(ESI):575.1[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.63(d,1H),8.59(d,1H),8.12-8.06(m,1H),7.73(d,1H),7.69-7.65(m,1H),6.87(s,1H),6.48-6.40(m,1H),5.18(s,1H),3.09 -3.03(m,1H),2.94-2.83(m,1H),2.22-2.03(m,4H),1.61-1.54(m,1H),1.46-1.34(m,7H).
实施例56-2：MS m/z(ESI):575.1[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.63(d,1H),8.59(d,1H),8.12-8.06(m,1H),7.73(d,1H),7.69-7.65(m,1H),6.87(s,1H),6.48-6.40(m,1H),5.18(s,1H),3.09-3.03(m,1H),2.94-2.83(m,1H),2.22-2.03(m,4H),1.61-1.54(m,1H),1.46-1.34(m,7H).
HPLC手性拆分条件：
HPLC手性分析方法：
实施例59
(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
参照实施例9的合成方法，合成得到目标产物(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(2-(2-羟基丙烷-2-基)嘧啶-4-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮59。
MS m/z(ESI):558.1[M+H]+.
1H NMR(400MHz,DMSO-d6)δ9.02(d,1H),8.68(s,1H),8.60(d,1H),8.09(ddd,1H),8.03(d,1H),6.87(s,1H),6.56(d,1H),6.09(ddd,1H),5.07(s,1H),2.80(d,2H),2.72–2.52(m,2H),1.59–1.44(m,6H).
实施例60
(Z)-N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-8,12-二氢-7H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺
参照实施例7的合成方法，合成得到目标产物(Z)-N-(2-(4-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-8,12-二氢-7H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)嘧啶-2-基)丙烷-2-基)乙酰胺60。
MS m/z(ESI):599.2[M+H]+.
1H NMR(400MHz,DMSO-d6)δ8.93(d,1H),8.66(s,1H),8.60(d,1H),8.21(s,1H),8.09(ddd,1H),7.93(d,1H),6.86(s,1H),6.58–6.51(m,1H),6.14–6.02(m,1H),2.87–2.58(m,4H),1.76(s,3H),1.59(s,6H).
实施例61
(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮
参照实施例6的合成方法，合成得到目标产物(Z)-11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-2-(3-(2-羟基丙烷-2-基)-1H-吡唑-1-基)-7,8-二氢-12H-二吡啶并[1,2-a:3',4'-g]吖辛因-12-酮61。
MS m/z(ESI):546.2[M+H]+；
1H NMR(400MHz,DMSO-d6)δ8.60(d,1H),8.40(s,1H),8.35(d,1H),8.14-8.06(m,1H),6.86(s,1H),6.59(d,1H),6.50(d,1H),6.08-5.95(m,1H),5.14(s,1H),2.84-2.68(m,3H),2.57-2.52(m,1H),1.46(d,6H).
实施例62
(Z)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-8,12-二氢-7H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺
参照实施例6的合成方法，合成得到目标产物(Z)-N-(2-(1-(11-氯-10-((3,5-二氟吡啶-2-基)甲氧基-d2)-1-氟-12-羰基-8,12-二氢-7H-二吡啶并[1,2-a:3',4'-g]吖辛因-2-基)-4-氟-1H-吡唑-3-基)丙烷-2-基)乙酰胺62。
MS m/z(ESI):605.2[M+H]+；
1H NMR(400MHz,CDCl3)δ8.39(d,1H),8.24(s,1H),8.18(d,1H),7.37-7.29(m,1H),6.57(s,1H),6.46-6.36(m,2H),6.00-5.89(m,1H),2.89-2.78(m,1H),2.76-2.67(m,2H),2.57-2.42(m,1H),2.00(s,3H),1.79(s,6H).
































实施例测试评价
以下结合测试例进一步描述解释本发明，但这些实施例并非意味着限制本发明的范围。
测试例1、本发明化合物对p38α/MK2酶活抑制作用的测定
1.实验目的：该测试例的目的是测量化合物对p38α/MK2酶活的抑制能力。
2.实验仪器和试剂：
2.1仪器：
2.2试剂：

3.实验方法：
p38/MK2酶活实验方法：在1×酶反应缓冲液(50mM HEPES pH 7.5,1mM EGTA,10mM MgCl2,2mM DTT,0.01％Tween-20)中，孵育0.06nM p38α(Active p38alpha Protein)，1.2nM MK2(Inactive MK2)以及浓度梯度稀释的化合物1小时。加入50nM ULight-CREBtide和25μM ATP(ATP Solution)，室温反应1.5小时。加入等体积检测及终止混合液(含20mM EDTA以及2nM Europium-anti-phospho-CREB的1×LANCE detection buffer)，混匀离心，贴上封板膜，室温反应1小时。用EnVision仪器的TR-FRET程序进行读板，检测各孔665nm/615nm的荧光值。
p38酶活实验方法：在1×酶反应缓冲液(50mM HEPES pH 7.5,1mM EGTA,10mM MgCl2,2mM DTT,0.01％Tween-20)中，孵育3nM p38α(Active p38alpha Protein)，以及浓度梯度稀释的化合物1小时。加入50nM ULight-MBP和50μM ATP(ATP 10mM Solution)，室温反应1.5小时。加入等体积检测及终止混合液(含20mM EDTA以及2nM Europium-anti-P-MBP的1×LANCE detection buffer)，混匀离心，贴上封板膜，室温反应1小时。用EnVision仪器的TR-FRET程序进行读板，检测各孔665nm/615nm的荧光值。
4.实验数据处理方法：
将原始数据(665nm/615nm读值比率)按照以下公式进行计算，得到抑制率。抑制率％＝[(阳性对照孔平均值–样品孔值)/(阳性对照孔平均值–阴性对照孔平均值)]×100，其中阳性对照孔为无化合物酶反应孔，阴性对照孔为不加酶的反应孔。
使用GraphPad Prism 6中的log(inhibitor)vs.response--Variable slope(four parameters)对化合物浓度及对应的抑制率进行拟合方程分析，拟合曲线并得出化合物IC50值。
拟合计算方程为Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))
5.实验结果：

6.实验结论：
以上数据显示，本发明实施例化合物对p38α/MK2酶活具有较强的抑制能力，同时具有很好的选择性。
测试例2、本发明化合物对U937细胞p-Hsp27抑制作用的测定
1.实验目的：该测试例的目的是测试本发明化合物对U937细胞p-Hsp27的抑制能力。
2.实验仪器和试剂：
2.1仪器：
2.2试剂：
3.实验方法：
20ng/ml PMA处理U937分化过夜，换新鲜培养液，U937静息过夜。分化后的U937消化计数，按照每孔25,000细胞种于96孔板中至细胞贴壁。配置化合物浓度梯度，化合物预处理细胞1小时(化合物终浓度最高浓度1μM，3倍浓度梯度 稀释)，加入10ng/ml LPS(Lipopolysaccharides from Escherichia coli O111:B4)刺激0.5小时。用PBS清洗细胞后，裂解液裂解细胞。使用Phospho-HSP27(S78/S82)DuoSet IC ELISA试剂盒进行细胞裂解液中p-Hsp27检测，具体步骤参照试剂盒厂商提供的标准步骤。
4.实验数据处理方法：
计算p-Hsp27抑制率：抑制率百分比＝[(阳性对照孔p-Hsp27平均值–样品孔p-Hsp27平均值)/(阳性对照孔p-Hsp27平均值–阴性对照孔p-Hsp27平均值)]×100％，其中阳性对照孔为无化合物孔(DMSO处理孔)，阴性对照孔为无LPS刺激孔。
剂量响应曲线拟合：使用GraphPad Prism 6中的log(inhibitor)vs.response--Variable slope(four parameters)对化合物浓度及对应的抑制率进行拟合方程分析，拟合曲线并得出化合物IC50值。
拟合计算方程为Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))
5.实验结果：
6.实验结论：
以上数据显示，本发明实施例化合物对U937细胞p-Hsp27具有较强的抑制能力。
测试例3、本发明化合物对U937细胞TNF-α表达水平的抑制作用的测定
1.实验目的：该测试例的目的是测量本发明化合物对U937细胞TNF-α表达水平的抑制能力。
2.实验仪器和试剂：
2.1仪器：
2.2试剂：
3.实验方法：
20ng/ml PMA处理U937分化过夜，换新鲜培养液，U937静息过夜。分化后的U937消化计数，按照每孔50,000细胞种于96孔板中至细胞贴壁。配置化合物浓度梯度，化合物预处理细胞1小时(化合物终浓度最高浓度1μM，3倍浓度梯度稀释)，加入10ng/ml LPS(Lipopolysaccharides from Escherichia coli O111:B4)刺激4小时后离心收集培养上清，用于后续ELISA检测上清中TNF-α浓度。TNF-α浓度检测依据ELISA试剂盒厂商提供的标准步骤进行。
4.实验数据处理方法：
TNF-α标准品通过线性回归方法绘制标准曲线，依据标准曲线换算样品TNF-α浓度。
计算抑制率：抑制率百分比＝[(阳性对照孔TNF-α浓度平均值–样品孔TNF-α浓度平均值)/(阳性对照孔TNF-α浓度平均值–阴性对照孔TNF-α浓度平均值)]×100％，其中阳性对照孔为无化合物孔(DMSO处理孔)，阴性对照孔为培养基孔。
剂量响应曲线拟合：使用GraphPad Prism 6中的log(inhibitor)vs.response--Variable slope(four parameters)对化合物浓度及对应的抑制率进行拟合方程分析，拟合曲线并得出化合物IC50值。拟合计算方程为Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))。
5.实验结果：

6.实验结论：
以上数据显示，本发明实施例化合物对U937细胞TNF-α表达水平具有较强的抑制能力。
测试例4、SD大鼠药代动力学测定
1.实验目的：
以SD大鼠为受试动物，研究本发明化合物，在5mg/kg或2mg/kg剂量下口服和1mg/kg剂量下静脉注射给药在大鼠体内(血浆)的药代动力学行为。
2.实验方案
2.1试验药品：
本发明的化合物，自制。
2.2试验动物：
SD大鼠每组3只，雄性，上海杰思捷实验动物有限公司，动物生产许可证号(SCXK(沪)2013-0006 N0.311620400001794)。
2.3药物配制：
PO，10％solutol HS15，超声溶解，配制为澄清溶液或均一混悬液。
IV，5％DMSO+10％Solutol HS15+85％PBS，超声溶解，配制为澄清溶液。
2.4给药方案：
SD大鼠每组3只，雄性；禁食一夜后分别p.o.，剂量为5mg/kg或2mg/kg，给药体积10mL/kg；i.v.，剂量为1mg/kg，给药体积5mL/kg。
2.5样品采集：
大鼠口服给药后，在0.25、0.5、1、2、4、6、8和24小时；大鼠静脉注射给药后，在0.083、0.25、0.5、1、2、4、6、8和24小时；颈静脉采血0.2mL，置于EDTA-K2试管中，4℃6000rpm离心6min分离血浆，于-80℃保存。
2.6样品处理：
1)血浆样品20uL加入100uL乙腈沉淀，混合后3500×g离心5～20分钟。
2)取处理后上清溶液进行LC/MS/MS分析待测化合物的浓度，LC/MS/MS分析仪器：AB Sciex API 4000Qtrap。
2.7液相分析：
●液相条件：Shimadzu LC-20AD泵
●色谱柱：Waters Xbridge C18 5μm,4.6X 50mm移动相：A液为0.1％甲酸水溶液，B液为甲醇
●流速：1.0mL/min
●洗脱时间：0-4.0分钟，洗脱液如下：
3.试验结果及数据处理：
药代动力学主要参数用WinNonlin 6.1计算得到。
4.实验结论
SD大鼠药代动力学测定结果显示，本发明化合物呈现好较好的PK性质。

Claims (25)

  1. 一种通式(I)所示的化合物、其立体异构体或其药学上可接受盐：
    其中：
    环A选自环烷基、杂环基、芳基或杂芳基；
    环B选自环烷基、杂环基、芳基或杂芳基；
    L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)(CRaaRbb)n1-、-(CH2)nC(O)NRcc(CH2)n1-、-(CH2)n(CRaaRbb)n1-、-(CRaaRbb)nO(CH2)n1-、-(CH2)nO(CRaaRbb)n1-、-(CRaaRbb)nS(CH2)n1-、-(CH2)nS(CRaaRbb)n1-、-(CRaaRbb)n(CH2)n1NRcc-、-(CH2)nNRcc(CRaaRbb)n1-、-(CH2)nNRccC(O)-、-(CH2)nP(O)pRaa-、-(CH2)nS(O)m-、-(CH2)nS(O)mNRcc-和-(CH2)nNRccS(O)m-；
    Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    或者，Raa、Rbb和Rcc中的任意两个链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基任选地可以进一步被取代；
    L2和L3各自独立地选自键、取代或未取代的烯基、取代或未取代的炔基、-(CH2)n2-、-(CH2)n2C(O)(CRa1Rb1)n3-、-(CH2)n2C(O)NRc1(CH2)n3-、-(CH2)n2(CRa1Rb1)n3-、-(CRa1Rb1)n2O(CH2)n3-、-(CH2)n2O(CRa1Rb1)n3-、-(CRa1Rb1)n2S(CH2)n3-、-(CH2)n2S(CRa1Rb1)n3-、-(CRa1Rb1)n2(CH2)n3NRc1-、-(CH2)n2NRc1(CRa1Rb1)n3-、-(CH2)n2NRc1C(O)-、-(CH2)n2P(O)p1Ra1-、-(CH2)n2S(O)m1-、-(CH2)n2S(O)m1NRc1-和-(CH2)n2NRc1S(O)m1-；
    Ra1、Rb1和Rc1各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述 的氨基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    Rb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    Rc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    Rb与Rc链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、桥环烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基、杂芳基或-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4C(O)NRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、烷基、桥环烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-8烷基、C1-8氘代烷基、C1-8卤代烷基、C1-8羟烷基、C1-8烷氧基、C1-8氘代烷氧基、C1-8卤代烷氧基、C2-8烯基、C2-8炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
    优选地，Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基；
    或者Ree、Rff链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    n4为0、1、2、3或4；
    优选地，Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、烷基、氘代烷基、卤代烷基、羟烷基、烷氧基、氘代烷氧基、卤代烷氧基、烯基、炔基、环烷基、杂环基、芳基或杂芳基，所述的氨基、烷基、氘代烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    或者，任意两个相邻或不相邻的Rd链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    或者，L3与Rd链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    或者，Rc与Rd链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被取代；
    x为0～6的整数；
    y为0～6的整数；
    z为0～6的整数；
    e为0～6的整数；
    n为0、1、2或3；
    n1为0、1、2或3；
    n2为0、1、2或3；
    n3为0、1、2或3；
    m为0、1、2或3；
    p为0、1、2或3；
    m1为0、1、2或3；
    p1为0、1、2或3。
  2. 根据权利要求1所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，化合物进一步如通式(I’-1)所示：
    其中：
    环D选自环烷基、杂环基、芳基或杂芳基；
    环E选自杂环基；
    环B选自环烷基、杂环基、芳基或杂芳基；
    X3选自N或者CRb1；
    L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)(CRaaRbb)n1-、-(CH2)nC(O)NRcc(CH2)n1-、-(CH2)n(CRaaRbb)n1-、-(CRaaRbb)nO(CH2)n1-、-(CH2)nO(CRaaRbb)n1-、-(CRaaRbb)nS(CH2)n1-、-(CH2)nS(CRaaRbb)n1-、-(CRaaRbb)n(CH2)n1NRcc-、-(CH2)nNRcc(CRaaRbb)n1-、-(CH2)nNRccC(O)-、-(CH2)nP(O)pRaa-、-(CH2)nS(O)m-、-(CH2)nS(O)mNRcc-和-(CH2)nNRccS(O)m-；
    Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    L3选自键、取代或未取代的烯基、取代或未取代的炔基、-(CH2)n2-、-(CH2)n2C(O)(CRa1Rb1)n3-、-(CH2)n2C(O)NRc1(CH2)n3-、-(CH2)n2(CRa1Rb1)n3-、-(CRa1Rb1)n2O(CH2)n3-、-(CH2)n2O(CRa1Rb1)n3-、-(CRa1Rb1)n2S(CH2)n3-、-(CH2)n2S(CRa1Rb1)n3-、-(CRa1Rb1)n2(CH2)n3NRc1-、-(CH2)n2NRc1(CRa1Rb1)n3-、-(CH2)n2NRc1C(O)-、-(CH2)n2P(O)p1Ra1-、-(CH2)n2S(O)m1-、-(CH2)n2S(O)m1NRc1-和-(CH2)n2NRc1S(O)m1-；
    Ra1、Rb1和Rc1各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、 C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，任意两个相邻或不相邻的Ra链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，L1与Ra链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rb1或Rb3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rc2或Rc3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
    或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    x为0～6的整数；
    e为0～6的整数；
    n为0、1、2或3；
    n1为0、1、2或3；
    n2为0、1、2或3；
    n3为0、1、2或3；
    n4为0、1、2、3或4；
    n6为0、1、2、3或4；
    m为0、1、2或3；
    p为0、1、2或3；
    m1为0、1、2或3；
    p1为0、1、2或3。
  3. 根据权利要求2所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，环D选自C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；优选地，环D选自C6-10芳基、5-6元单环杂芳基或7-10元双环杂芳基；更优选地，环D选自吡唑基、噻吩基、噻唑基、恶唑基、嘧啶基、吡啶基、苯基、
  4. 根据权利要求2-3任一所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，环E选自6-12元杂环基；优选地，环E选自
  5. 根据权利要求1-4任一所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，化合物进一步如通式(XIV)所示：
    其中：
    M1选自C、CH、N或不存在；
    M2选自C、CH、N或不存在；
    M3选自C、CH、N或不存在；
    X3选自N或者CRb1；
    环B选自环烷基、杂环基、芳基或杂芳基；
    L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)(CRaaRbb)n1-、-(CH2)nC(O)NRcc(CH2)n1-、-(CH2)n(CRaaRbb)n1-、-(CRaaRbb)nO(CH2)n1-、-(CH2)nO(CRaaRbb)n1-、-(CRaaRbb)nS(CH2)n1-、-(CH2)nS(CRaaRbb)n1-、-(CRaaRbb)n(CH2)n1NRcc-、-(CH2)nNRcc(CRaaRbb)n1-、-(CH2)nNRccC(O)-、-(CH2)nP(O)pRaa-、-(CH2)nS(O)m-、-(CH2)nS(O)mNRcc-和-(CH2)nNRccS(O)m-；
    Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    L3选自键、取代或未取代的烯基、取代或未取代的炔基、-(CH2)n2-、-(CH2)n2C(O)(CRa1Rb1)n3-、-(CH2)n2C(O)NRc1(CH2)n3-、-(CH2)n2(CRa1Rb1)n3-、-(CRa1Rb1)n2O(CH2)n3-、-(CH2)n2O(CRa1Rb1)n3-、-(CRa1Rb1)n2S(CH2)n3-、 -(CH2)n2S(CRa1Rb1)n3-、-(CRa1Rb1)n2(CH2)n3NRc1-、-(CH2)n2NRc1(CRa1Rb1)n3-、-(CH2)n2NRc1C(O)-、-(CH2)n2P(O)p1Ra1-、-(CH2)n2S(O)m1-、-(CH2)n2S(O)m1NRc1-和-(CH2)n2NRc1S(O)m1-；
    Ra1、Rb1和Rc1各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，任意两个相邻或不相邻的Ra链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，L1与Ra链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rb1或Rb3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rc2或Rc3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷 氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
    或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    x为0～6的整数；
    e为0～6的整数；
    n为0、1、2或3；
    n1为0、1、2或3；
    n2为0、1、2或3；
    n3为0、1、2或3；
    n4为0、1、2、3或4；
    n6为0、1、2、3或4；
    m为0、1、2或3；
    p为0、1、2或3；
    m1为0、1、2或3；
    p1为0、1、2或3。
  6. 根据权利要求1所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，环A选自C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
    优选地，环A选自6-12元双环杂环基、5-6元单环杂芳基或7-10元双环杂芳基；
    更优选地，环A选自吡唑基、噻吩基、噻唑基、恶唑基、嘧啶基、吡啶基、苯基、四氢喹啉基、苯并环戊基、吡咯并嘧啶基、吡咯并吡啶基、吡唑并吡啶或咪唑并吡啶。
  7. 根据权利要求1-6任一项所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，环B选自C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
    优选地，环B选自3-7元单环杂环基、6-12元双环杂环基、5元单环杂芳基、6元单环杂芳基或7-14元杂芳基并环；
    更优选地，环B选自5元单环含氮杂芳基、6元单环含氮杂芳基、5-6元杂芳基并5-6元环烷基、5-6元杂芳基并5-6元杂芳基或5-6元杂芳基并苯基；
    进一步优选地，环B选自嘧啶、吡啶并环己基、吡啶并环戊基、吡咯并三嗪基、吡咯并嘧啶基、吡啶并环戊烯基、吡啶、噻唑、吡唑，吡啶并吡咯酮、吡啶并呋喃酮、吡啶并环丁砜、
    更进一步优选地，环B选自嘧啶、吡啶并环己基、吡啶并环戊基、吡咯并三嗪基、吡咯并嘧啶基、吡啶并环戊烯基、吡啶、噻唑、吡唑，吡啶并吡咯酮、吡啶并呋喃酮或吡啶并环丁砜。
  8. 根据权利要求1所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，化合物进一步如通式(XV)所示：
    其中：
    X1选自N或者CRa5；
    X3选自N或者CRb1；
    Ra1、Ra2、Ra3、Ra4或Ra5各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，任意两个相邻或不相邻的Ra1、Ra2、Ra3、Ra4和Ra5链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂 环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Raa或Rbb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，Raa和Rbb链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rb1、Rb2或Rb3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，Rb1和Rb2取代基链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6 氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rc1、Rc2或Rc3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，Rc1和Rc2取代基链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，Rc1和Rb2取代基链接形成3-12元杂环基或5-14元杂芳基，所述3-12元杂环基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    R1选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧 基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
    或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    R2、R3或R4各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，任意两个相邻或不相邻的R1、R2、R3和R4链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    n4为0、1、2、3或4；且
    所述的不为
  9. 根据权利要求1-8任一所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，化合物进一步如通式(XIV-A)、(XIV-B)或(XIV-C)所示：
    其中：
    X1选自N或者CRa5；
    X2选自N或者CR2；
    X3选自N或者CRb1；
    Ra1、Ra2、Ra3、Ra4或Ra5各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，任意两个相邻或不相邻的Ra1、Ra2、Ra3、Ra4和Ra5链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Raa或Rbb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，Raa和Rbb链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rb1或Rb3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rc2或Rc3各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷 氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rda、Rdb或R’da各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，Rda和Rdb链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Rdc或Rdd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，Rdc和Rdd链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    R1选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6 烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
    或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    R2、R3或R4各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，任意两个相邻或不相邻的R1、R2、R3和R4链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、 氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    R7选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基、5-14元杂芳基、-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4NRhhORgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4S(O)Rgg、-(CReeRff)n4SRgg、-(CReeRff)n4C(O)NRhhRgg、-(CReeRff)n4S(O)NRhhRgg、-(CReeRff)n4SNRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6桥环烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
    或者Ree、Rff链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    R6或R8各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、 C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    或者，任意两个相邻或不相邻的R6、R7和R8链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    n4为0、1、2、3或4；
    n5为0、1或2；
    n5’为0、1或2；
    n5和n5’不同时为0；
    n6为0、1、2、3或4。
  10. 根据权利要求1-9任一所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，化合物进一步如通式(I’-1-1)、(I’-1-2)(XIV-1)、(XIV-2)、(XIV-A-1)、(XIV-A-2)、(XIV-B-1)、(XIV-B-2)、(XIV-C-1)、(XIV-C-2)、(XV-1)或(XV-2)所示：


  11. 根据权利要求1-7或10任一项所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)(CRaaRbb)n1-、-(CH2)nC(O)NRcc(CH2)n1-、-(CH2)n(CRaaRbb)n1-、-(CRaaRbb)nO(CH2)n1-、-(CH2)nO(CRaaRbb)n1-、-(CRaaRbb)nS(CH2)n1-、-(CH2)nS(CRaaRbb)n1-、-(CRaaRbb)n(CH2)n1NRcc-、-(CH2)nNRcc(CRaaRbb)n1-、-(CH2)nNRccC(O)-、-(CH2)nP(O)pRaa-、-(CH2)nS(O)m-、-(CH2)nS(O)mNRcc-和-(CH2)nNRccS(O)m-；
    优选地，L1选自键、取代或未取代的亚烯基、取代或未取代的亚炔基、-(CH2)n-、-(CH2)nC(O)-、-(CRaaRbb)nO-、-O(CRaaRbb)n1-、-(CRaaRbb)nS-、-S(CRaaRbb)n1-、-(CH2)n1NRcc-、-NRcc(CRaaRbb)n1-或-NRccC(O)-；
    更优选地，L1选自键、-CH2-、-OCH2-、-OCD2-、-NH-、-C(O)NH-、-OCH(CH3)-、-OC(CH3)2-、-NH-CH2-或
    Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    优选地，Raa、Rbb和Rcc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3 烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代；
    或者，Raa、Rbb和Rcc中的任意两个链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基和C1-6卤代烷氧基中的一个或多个取代基所取代；
    优选地，Raa、Rbb和Rcc中的任意两个链接形成C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基和C1-3卤代烷氧基中的一个或多个取代基所取代。
  12. 根据权利要求1-7或10-11任一项所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    优选地，Ra各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷 氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代。
  13. 根据权利要求1、6-7或11-12任一项所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，Rb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    优选地，Rb各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代。
  14. 根据权利要求1、6-7或11-13任一项所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，Rc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    优选地，Rc各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代；
    或者，Rb与Rc链接形成C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代。
  15. 根据权利要求1-7或10-14任一项所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，
    Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、5-10元桥环烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基或-(CReeRff)n4C(O)Rgg、-(CReeRff)n4NRhhC(O)Rgg、-(CReeRff)n4S(O)2Rgg、-(CReeRff)n4C(O)NRhhRgg或-(CReeRff)n4S(O)2NRhhRgg，所述的氨基、C1-6烷基、5-10元桥环烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-8烷基、C1-8氘代烷基、C1-8卤代烷基、C1-8羟烷基、C1-8烷氧基、C1-8氘代烷氧基、C1-8卤代烷氧基、C2-8烯基、C2-8炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基；
    优选地，Ree、Rff、Rgg和Rhh各自独立的选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基；
    或者Ree、Rff链接形成环烷基、杂环基、芳基或杂芳基，所述环烷基、杂环基、芳基和杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    n4为0、1、2、3或4；
    优选地，
    Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    优选地，Rd各自独立地选自氢、氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基或5-10元杂芳基，所述的氨基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3烷氧基、C1-3卤代烷氧基、C1-3羟烷基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-3烷基、C1-3氘代烷基、C1-3卤代烷基、C1-3羟烷基、C1-3烷氧基、C1-3氘代烷氧基、C1-3卤代烷氧基、C2-4烯基、C2-4炔基、C3-8环烷基、3-8元杂环基、C6-10芳基和5-10元杂芳基中的一个或多个取代基所取代。
  16. 根据权利要求8-10任一项所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，R2选自卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧 基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    优选地，R2选自卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基或C2-6炔基；
    更优选地，R2选自氟。
  17. 根据权利要求8-10任一项所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，R6选自卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基或5-14元杂芳基，所述的氨基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6烷氧基、C1-6卤代烷氧基、C1-6羟烷基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基，任选地可以进一步被氘、卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基、C2-6炔基、C3-12环烷基、3-12元杂环基、C6-14芳基和5-14元杂芳基中的一个或多个取代基所取代；
    优选地，R6选自卤素、硝基、羟基、巯基、氰基、氨基、氧代基、硫代基、羧基、C1-6烷基、C1-6氘代烷基、C1-6卤代烷基、C1-6羟烷基、C1-6烷氧基、C1-6氘代烷氧基、C1-6卤代烷氧基、C2-6烯基或C2-6炔基；
    更优选地，R6选自氟。
  18. 根据权利要求1-17任一项所述的化合物、其立体异构体或其药学上可接受盐，其特征在于，化合物的结构如下所示：






















  19. 一种通式(M-1)或(M-2)所示的化合物、其立体异构体或其药学上可接受的盐：
    其中：
    X4选自卤素，优选地选自氯或溴；
    环D及环E如权利要求2所述；
    M1、M2、M3及n6如权利要求5所述；
    L1、Ra、Rb3、Rc2、Rc3、X3及x如权利要求2或5所述。
  20. 一种制备权利要求2所述的通式(I’-1)化合物或其立体异构体及其药学上可接受的盐的方法，其特征在于，包含如下步骤：
    通式(M-1)所示的化合物通过反应，得到通式(I’-1)所示的目标化合物；
    其中，
    X4选自卤素，优选地选自氯或溴；
    环D、环E、环B、L1、L3、Ra、Rb3、Rc2、Rc3、X3、Rd、x及e如权利要求2所述。
  21. 一种制备权利要求5所述的通式(XIV)化合物或其立体异构体及其药学上可接受的盐的方法，其特征在于，包含如下步骤：
    通式(M-2)所示的化合物通过反应，得到通式(XIV)所示的目标化合物；
    其中，
    X4选自卤素，优选地选自氯或溴；
    M1、M2、M3、L1、L3、Ra、Rb3、Rc2、Rc3、X3、Rd、x、e及n6如权利要求5所述。
  22. 一种制备权利要求8所述的通式(XV)化合物或其立体异构体及其药学上可接受的盐的方法，其特征在于，包含如下步骤：
    通式(M-3)与通式(M-4)反应，得到通式(XV)所示的目标化合物；
    其中，
    X1、X3、Ra1、Ra2、Ra3、Ra4、Raa、Rbb、Rb2、Rb3、Rc1、Rc2、Rc3、R1、R2、R3及R4如权利要求8所述。
  23. 一种药物组合物，其包括治疗有效剂量的权利要求1～17任一项所述化合物、其立体异构体或其药学上可接受的盐以及一种或多种药学上可接受的载体、稀释剂或赋形剂。
  24. 根据权利要求1～18任一项所述化合物、其立体异构体或其药学上可接受的盐，或权利要求23所述的药物组合物在制备治疗p38激酶介导的疾病药物中的应用。
  25. 根据权利要求1～18任一项所述化合物、其立体异构体或其药学上可接受的盐，或权利要求23所述的药物组合物在制备治疗自身免疫疾病、慢性炎性疾病、急性炎症性病症、自身炎性疾病、动脉粥样硬化、糖尿病、纤维变性疾病、代谢疾病、癌症、肿瘤、白血病和淋巴瘤的药物中的应用。
PCT/CN2023/072370 2022-01-14 2023-01-16 含吡啶多环类衍生物、其制备方法和应用 Ceased WO2023134764A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020247027246A KR20240134978A (ko) 2022-01-14 2023-01-16 피리딘 함유 폴리시클릭 유도체, 이의 제조 방법 및 용도
JP2024540616A JP2025503581A (ja) 2022-01-14 2023-01-16 ピリジン含有多環系誘導体、その製造方法及び応用
CA3242679A CA3242679A1 (en) 2022-01-14 2023-01-16 Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof
EP23740105.4A EP4464694A4 (en) 2022-01-14 2023-01-16 POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
US18/728,864 US20250066360A1 (en) 2022-01-14 2023-01-16 Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof
AU2023207395A AU2023207395A1 (en) 2022-01-14 2023-01-16 Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof
CN202380016406.6A CN118525005A (zh) 2022-01-14 2023-01-16 含吡啶多环类衍生物、其制备方法和应用
MX2024008704A MX2024008704A (es) 2022-01-14 2023-01-16 Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.
IL314247A IL314247A (en) 2022-01-14 2023-01-16 A pyridine-containing polycyclic derivative and a method of its preparation and use

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202210041733 2022-01-14
CN202210041733.4 2022-01-14
CN202211294865.4 2022-10-21
CN202211294865 2022-10-21
CN202211474196.9 2022-11-22
CN202211474196 2022-11-22

Publications (1)

Publication Number Publication Date
WO2023134764A1 true WO2023134764A1 (zh) 2023-07-20

Family

ID=87280137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/072370 Ceased WO2023134764A1 (zh) 2022-01-14 2023-01-16 含吡啶多环类衍生物、其制备方法和应用

Country Status (10)

Country Link
US (1) US20250066360A1 (zh)
EP (1) EP4464694A4 (zh)
JP (1) JP2025503581A (zh)
KR (1) KR20240134978A (zh)
CN (1) CN118525005A (zh)
AU (1) AU2023207395A1 (zh)
CA (1) CA3242679A1 (zh)
IL (1) IL314247A (zh)
MX (1) MX2024008704A (zh)
WO (1) WO2023134764A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024149359A1 (zh) * 2023-01-13 2024-07-18 上海美悦生物科技发展有限公司 苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149964A2 (en) 2010-05-24 2011-12-01 Moerae Matrix, Inc., Methods for treating or preventing vascular graft failure
WO2012078684A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyridinone-pyridinyl compounds
WO2012078687A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyrimidine urea compounds
WO2012078674A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
WO2012078673A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
WO2012142320A2 (en) 2011-04-12 2012-10-18 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2013086208A1 (en) 2011-12-06 2013-06-13 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
WO2014040074A2 (en) 2012-09-10 2014-03-13 Moerae Matrix, Inc. Compositions and methods for treating cutaneous scarring
WO2014197846A1 (en) 2013-06-07 2014-12-11 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
WO2016033432A1 (en) 2014-08-29 2016-03-03 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2016044463A2 (en) 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2016112292A1 (en) 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
WO2016145234A2 (en) 2015-03-12 2016-09-15 Moerae Matrix, Inc. Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
WO2018170199A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Forms and compositions of a mk2 inhibitor
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018231722A1 (en) 2017-06-12 2018-12-20 Moerae Matrix, Inc. Immunomodulatory effect of inhaled kinase inhibitor peptides in lung
US10336788B2 (en) 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2021022186A1 (en) 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Deuterated mk2 pathway inhibitors and methods of using the same
WO2023283338A1 (en) * 2021-07-09 2023-01-12 Xinthera, Inc. Pyridinone mk2 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079873A2 (en) * 2006-12-20 2008-07-03 Bristol-Myers Squibb Company Thiazolyl compounds useful as kinase inhibitors
WO2008079294A1 (en) * 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
JP5385895B2 (ja) * 2007-04-10 2014-01-08 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なチアゾリル化合物
WO2009022171A1 (en) * 2007-08-13 2009-02-19 Astrazeneca Ab Pyridinyiioxy pyridines as alk5 inhibitors
CN103508961B (zh) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
SG11202103457PA (en) * 2018-12-27 2021-05-28 Nexys Therapeutics Inc (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer
WO2022212489A1 (en) * 2021-03-31 2022-10-06 Xinthera, Inc. Mk2 inhibitors and uses thereof
WO2023001282A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 杂环取代的嘧啶衍生物
WO2023125708A1 (zh) * 2021-12-29 2023-07-06 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN116444493A (zh) * 2022-01-14 2023-07-18 上海翰森生物医药科技有限公司 含双并环类衍生物、其制备方法和应用
CN117800948A (zh) * 2022-05-12 2024-04-02 上海美悦生物科技发展有限公司 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149964A2 (en) 2010-05-24 2011-12-01 Moerae Matrix, Inc., Methods for treating or preventing vascular graft failure
WO2012078684A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyridinone-pyridinyl compounds
WO2012078687A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyrimidine urea compounds
WO2012078674A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
WO2012078673A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
WO2012142320A2 (en) 2011-04-12 2012-10-18 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2013086208A1 (en) 2011-12-06 2013-06-13 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
WO2014040074A2 (en) 2012-09-10 2014-03-13 Moerae Matrix, Inc. Compositions and methods for treating cutaneous scarring
WO2014197846A1 (en) 2013-06-07 2014-12-11 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US10336788B2 (en) 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
WO2016033432A1 (en) 2014-08-29 2016-03-03 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2016044463A2 (en) 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2016112292A1 (en) 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
WO2016145234A2 (en) 2015-03-12 2016-09-15 Moerae Matrix, Inc. Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
US20200102326A1 (en) 2017-03-16 2020-04-02 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
WO2018170199A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Forms and compositions of a mk2 inhibitor
US20200148701A1 (en) 2017-03-16 2020-05-14 Celgene Car Llc Forms and compositions of a mk2 inhibitor
US20210139501A1 (en) 2017-03-16 2021-05-13 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US20210198276A1 (en) 2017-03-16 2021-07-01 Celgene Car Llc Forms and compositions of a mk2 inhibitor
WO2018231722A1 (en) 2017-06-12 2018-12-20 Moerae Matrix, Inc. Immunomodulatory effect of inhaled kinase inhibitor peptides in lung
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2021022186A1 (en) 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Deuterated mk2 pathway inhibitors and methods of using the same
WO2023283338A1 (en) * 2021-07-09 2023-01-12 Xinthera, Inc. Pyridinone mk2 inhibitors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 56, no. 10, 2020, pages 1329 - 1334
See also references of EP4464694A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024149359A1 (zh) * 2023-01-13 2024-07-18 上海美悦生物科技发展有限公司 苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途

Also Published As

Publication number Publication date
KR20240134978A (ko) 2024-09-10
MX2024008704A (es) 2024-07-22
AU2023207395A1 (en) 2024-07-11
CN118525005A (zh) 2024-08-20
EP4464694A4 (en) 2026-04-01
US20250066360A1 (en) 2025-02-27
IL314247A (en) 2024-09-01
CA3242679A1 (en) 2023-07-20
EP4464694A1 (en) 2024-11-20
JP2025503581A (ja) 2025-02-04

Similar Documents

Publication Publication Date Title
WO2024022444A1 (zh) 稠环类化合物、其制备方法及其在医药上的应用
CN112552294B (zh) 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
CN115368383A (zh) 稠合含氮杂环类化合物、其制备方法及其在医药上的应用
CN118176198A (zh) 含氮的四环化合物、其制备方法及其在医药上的应用
WO2022268051A1 (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
CN115304623A (zh) 一种嘧啶并环衍生物及其在医药上的应用
WO2022017339A1 (zh) 稠合哒嗪类衍生物、其制备方法及其在医药上的应用
CN116194446A (zh) Sos1抑制剂、包含其的药物组合物及其用途
WO2024078620A1 (zh) 含氮杂环类衍生物抑制剂、其制备方法和应用
CN113072551B (zh) 含氮联苯类衍生物抑制剂、其制备方法和应用
WO2022247816A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
TWI823959B (zh) 吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2021249519A1 (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN114163454A (zh) 含吡啶多环类衍生物抑制剂、其制备方法和应用
WO2025007915A1 (zh) 一类含氮杂环类衍生物抑制剂、其制备方法和应用
CN107207504B (zh) 酞嗪酮衍生物、其制备方法及用途
WO2022111526A1 (zh) 一种苯环衍生物及其组合物和药学上的应用
WO2023016518A1 (zh) 一种杂环衍生物及其组合物和药学上的应用
WO2024067691A1 (zh) 含氮杂环类化合物及其医药用途
WO2023134765A1 (zh) 含五元环类衍生物、其制备方法和应用
WO2023109892A1 (zh) 一种抑制或降解brd9的化合物及其组合物和药学上的应用
WO2022017365A1 (zh) 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用
WO2025087267A1 (zh) 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
KR20240041354A (ko) 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도
WO2024094171A1 (zh) 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23740105

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023207395

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3242679

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024012636

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2024540616

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202380016406.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2024/008704

Country of ref document: MX

Ref document number: 314247

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 18728864

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2024122792

Country of ref document: RU

Ref document number: 2023740105

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023740105

Country of ref document: EP

Effective date: 20240814

ENP Entry into the national phase

Ref document number: 112024012636

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240620

WWP Wipo information: published in national office

Ref document number: 2024122792

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 18728864

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2024122792

Country of ref document: RU